Development of Dynamic, Bioorthogonal Peptide Cross-Linking Methods by Haney, Conor
Development of Dynamic, Bioorthogonal Peptide Cross-Linking Methods 
by 
Conor Michael Haney 
B. S. Chemistry, University of Pittsburgh, 2009 
Submitted to the Graduate Faculty of 
the Kenneth P. Dietrich School of Arts and Sciences in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
University of Pittsburgh 
2014 
ii 
UNIVERSITY OF PITTSBURGH 
KENNETH P. DIETRICH SCHOOL OF ARTS AND SCIENCES 
This dissertation was presented 
by 
Conor M. Haney 
It was defended on 
August 14
th
, 2014 
and approved by 
Dr. Alexander Deiters, Professor, Department of Chemistry 
Dr. Xinyu Liu, Assistant Professor, Department of Chemistry 
Dr. Ronald Wetzel, Professor, Department of Structural Biology 
 Dissertation Advisor: Dr. W. Seth Horne, Assistant Professor, Department of Chemistry 
iii 
Copyright © by Conor M. Haney 
2014 
iv 
Short peptide sequences typically lack well-defined structure when removed from the context of a 
larger protein. In order to constrain peptides into well-defined structures, nature often relies on the 
formation of disulfides between cysteine residues. Chemists have leveraged alternative chemoselective 
reactions to constrain peptides into defined folded conformations. Chemoselective cyclization strategies 
typically require extensive synthetic manipulation or the use of conditions which are incompatible with 
biological systems. 
This work encompasses the development of alternative peptide cyclization strategies that can be 
utilized under conditions compatible with biological systems. The strategies we have focused on offer the 
possibility of implementing cross-linking in a dynamic and reversible manner in aqueous solutions. We 
have chosen to take advantage of the bioorthogonal and reversible nature of oxime and hydrazone 
formation in the development of bioorthogonal and dynamic side chain cross-linking. 
We have demonstrated that an oxime formed by a cyclization reaction between aminooxy- and 
aldehyde-functionalized side chains in peptide sequences proceeds rapidly and in high yield. These cross-
links have been shown to affect peptide folding and are capable of dynamic covalent exchange. Oxime 
cross-links have been shown to stabilize a model protein-protein interaction, with a dependence upon the 
sequence context and structure of the cross-link formed. Analysis of a high-resolution structure of the 
cross-linked oligomer demonstrates that the oxime side chain cross-link is well accommodated into an α-
helical fold. We have also demonstrated that the product distribution of a cross-linking reaction in which 
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 v 
multiple cross-linked regioisomers can be generated is dependent upon the folded state of the peptide at 
the time of cross-link formation. 
An alternative strategy which employs the use of an intermolecular cyclization between a 
bifunctionalized peptide and dialdehyde functionalized small molecules has also been explored. The 
intermolecular cyclization strategy has been shown to affect peptide folded structure and be capable of 
dynamic covalent exchange. Intermolecular cyclization offers a generally applicable and convergent 
manner to synthesize multiple cross-linked species in a combinatorial manner. This strategy has then been 
employed to template formation of different cross-linked structures based on the presence of an expressed 
protein receptor. 
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1.0 INTRODUCTION 
1.1  DYNAMIC COVALENT CHEMISTRY 
 
Dynamic covalent chemistry (DCC) takes advantage of reversible covalent bond formation in order to 
obtain libraries of molecules at equilibrium under thermodynamic control.
1, 2, 3
 The use of a small number 
of chemical building blocks can generate a relatively large number of library constituents. Due to the 
equilibrium achieved under the conditions of dynamic covalent exchange, DCC is a powerful tool to 
probe thermodynamic minima. Stabilization of library members can potentially result from favorable 
intramolecular interactions and has been utilized to investigate the design of folded structures based on 
natural and non-natural backbones.
4
 Library members can also be stabilized by intermolecular 
interactions thereby providing a method to probe for structures which form stable assemblies or 
aggregates, or which participate in intermolecular binding interactions in a host-guest fashion or ligand-
receptor fashion.
4
 
 2 
 
Figure 1. Schematic representation of templated DCC. 
 
Due to the thermodynamic control of a dynamic covalent library (DCL), such systems have been 
shown to be responsive to stimuli. The use of pressure, temperature, or a molecular template can 
influence the product distribution in a DCL.
1, 2
 Molecular templating has been utilized for the selection of 
species that act as hosts or receptors, as well as for the discovery of new ligands.
1, 2, 3, 4
 Amplification is 
ideally selective for the compound with the most favorable binding to a given templating molecule, 
though there are exceptions due to the complex nature of DCLs (Figure 1). A report on the use of DCC to 
generate organic cages as receptors for positively charged polyamine guests made use of reversible 
disulfide bond formation to establish a DCL (Figure 2).
5
 Addition of polyamine species, spermine and 
spermidine, was shown to change the product distribution of the disulfide-linked architectures in the 
DCL. This type of template-driven synthesis of multi-component organic cages can lead to the discovery 
of novel hosts for guest molecules. Similar principles have been applied to the generation of receptors for 
biologically relevant guests including but not limited to trimethy lysine
6
 and dimethyl arginine.
7
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Figure 2. DCL used to generate receptors for cationic polyamine guests. 
Reproduced from Stefankiewicz, et al., Chem. Sci., 2012, 3, 2326.Permission for reproduction 
granted by The Royal Society of Chemistry, copyright 2012. 
 
 
Peptide and protein folding offers a fertile ground for dynamic covalent chemistry given the 
subtle interplay among non-covalent interactions within and between ligands and proteins. The use of 
reversible chemistry to affect folded structures has included biologically-derived molecules wherein 
intermolecular and intramolecular interactions form the basis for amplification of folded structures. Prior 
applications of this strategy include the formation of a DCL based on disulfide formation and exchange in 
palindromic peptide sequences.
8
 This library was capable of forming a number of possible products, 
including cyclic monomers, acyclic parallel and antiparallel species, cyclic trimers, and larger 
macrocyclic oligomers. The observed distribution of these products changed in response to concentration 
and solvent conditions. Further studies in biomolecule-inspired DLCs have been used to identify β-sheet 
 4 
forming oligopeptide building blocks,
9
 stable α-helical bundles resulting from metal chelation,10 and to 
estimate folded free energy in an equilibrating system based on bovine pancreatic polypeptide where an 
amide bond is replaced with an exchangeable thioester.
11
 
Proteins and nucleic acids have also served as useful templates for the selection of small molecule 
ligands from DCLs.
4, 12
 In these systems, a collection of small molecules capable of forming DCLs are 
equilibrated in the presence or absence of a protein target. The enhancement of particular library members 
in the presence of the protein receptor is inferred to be due to the enhanced interaction of those library 
members with the receptor. Subsequent analysis of the binding interaction can lead to the identification of 
small-molecule binders to protein receptors in a fashion that is complementary to high-throughput or 
fragment-based screening. A number of bioactive compounds have been identified for protein-based 
receptors through this methodology, where the receptors include carbonic anhydrase,
13
 glutathionine-S-
transferases,
14, 15
 and calmodulin.
16
 The use of a hydrazone-based library targeting γ-aminobutyric acid 
transporter 1 (GAT1) was shown to lead to the discovery of novel compounds for GAT1 inhibition 
(Figure 3).
17
 Mass spectrometry-based inhibition assays showed that the amplified library member had a 
pIC50 of 5.3, nearly identical to the natural substrate γ-aminobutyric acid. Further optimization of the lead 
compounds through synthesis of stable analogues showed maintenance of binding affinity.
17
 Additionally, 
some small peptide-like substrates have been utilized in the generation of template-selected DCLs to 
target PPIs involved in HIV viral budding.
18
 In these studies, templated selection of DCLs utilizing 
protein receptors is generally limited to relatively small library sizes, library members with high similarity 
to known binders to the target proteins, and to library members with limited size. 
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Figure 3. Strategy for DCL-based discovery of GAT1 inhibitors. 
Reproduced with permission from Sindelar, et al., J. Med. Chem., 2013, 56, 1323. Copyright 
2013 American Chemical Society. 
 
 
Given the known applicability of biomolecules in DCC, we have sought to utilize the tools of 
dynamic selection to furnish a general strategy for the development of peptide based protein-protein 
interaction inhibitors. This requires the development of peptide cross-linking technology which is both 
bioorthogonal and potentially reversible under aqueous conditions. Development of this technology 
would allow for the use of peptide based DCLs to generate potent binders to protein-based targets. 
1.2  PEPTIDES AS THERAPEUTICS 
The ubiquitous nature of protein-protein interactions (PPIs) in biological systems and their importance in 
the genesis of disease makes specific binders to protein-protein interfaces paramount in biomedical 
research.
19
 Scaffolds to inhibit protein-protein interactions include small molecules, peptides, and peptide 
mimetics.
20
 Small molecules represent the largest class of PPI inhibitors, but are limited in applicability 
 6 
due to relatively small binding surfaces.
19
 Alternatively, due to their similarity to natural protein binders, 
peptides constitute an attractive class of therapeutics.
21
 The ability of peptides to engage with extended 
binding interfaces, and their general non-immunogenicity, has led to increased interest in peptide-based 
PPI inhibitors in recent years. While naturally derived peptide based drugs, such as insulin, have been 
clinically relevant for decades, rationally designed peptide therapeutics have only been possible since the 
advent of solid phase peptide synthesis (SPPS) and biochemical tools for manipulation of protein 
sequences during or following in vivo expression.
21
  
Rationally designed peptide therapeutics include enfuvirtide, which prevents HIV infection of 
host cells through interaction with the viral envelope glycoprotein gp41.
22
 Upon recognition of 
lymphocyte receptors by viral proteins, gp41 undergoes a conformation change from an extended three-
helix bundle to a more compact six-helix bundle. This conformational change brings the viral capsid and 
the cell membrane into proximity, triggering the formation of a fusion pore and release of the viral 
material into the host cell. By binding to gp41 in its extended conformation, enfuvirtide prevents the 
formation of the compact six helix bundle and thus fusion pore formation (Figure 4). 
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Figure 4. Crystal structure of the six helix bundle of gp41 from PDB: 1AIK. 
N-terminal and C-terminal helices are shown as grey and green, respectively. 
 
 
Another known peptide drug is the 20-amino acid sequence bivalirudin which is an analogue of 
heparin that is clinically employed to slow blood clot formation as an alternative to heparin.
23
 Bivalirudin 
binds to thrombin, a serine protease that is central to the clotting process, in an extended conformation 
occupying both the proteolytic active site and the anion-binding exosite similar to other heparin analogues 
(Figure 5).
24
 Due to its high specificity and small size bivalirudin represents an ideal peptide therapeutic. 
 
 8 
 
Figure 5. Crystal structure of heparin analogue hirulog bound to thrombin from PDB: 2HGT 
  
 
Of note in both of these examples is that the peptide ligands are both principally unstructured in 
their unbound state. This represents one of the major limitations of peptide based therapeutics: due to 
their poorly structured nature, they can have lower inhibitory activity than well-structured proteins, and 
are easily degraded by proteases which typically recognize extended backbone conformations.
25
 
Additionally, peptide therapeutics are almost exclusively used to target extracellular proteins as poor cell 
permeability prevents application to intracellular targets.
26
 Addressing these limitations constitutes an 
ongoing and active area of study towards improving peptide-based therapeutics for clinical applications. 
1.3  FORMATION OF SECONDARY STRUCTURES IN PEPTIDES 
 The emergence of secondary structural elements from primary amino acid sequences remains 
challenging to predict. However, efforts toward understanding polypeptide folding tendencies have 
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yielded information about how to predict – and in some cases control –folding patterns.27 Each type of 
secondary structure is defined by a different intramolecular hydrogen bonding pattern (Figure 6).
28
 Turn 
regions are characterized by close spatial relationships between amino acids spaced 1 to 5 residues apart, 
with corresponding hydrogen bonds between the residues in the turn motif. β-Sheets are defined by 
interstrand hydrogen bonds in a parallel or antiparallel fashion. Though several types of helices are found 
in nature, -helices are the most common and are delineated by a network of intramolecular hydrogen 
bonds between backbone amide protons and carbonyl oxygens arranged in an i→i+4 pattern. Secondary 
structural elements are often (though not exclusively) involved in protein-protein interaction interfaces.
29
 
Thus understanding of the folding in polypeptide sequences allows for identification of more potent 
inhibitors of protein-protein interactions. Such structures also contribute to fundamental understandings 
of physical interactions that drive folding. 
 
 
Figure 6. Common peptide secondary structures.  
Main-chain hydrogen bonds are shown as dashed lines. 
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1.3.1  Controlling α-Helical Folding Patterns 
 Amongst secondary structural elements in proteins, one of the most common is the α-helix.28 
Helices are also the most common secondary structure found to participate in protein-protein binding 
interactions.
30
 Accordingly, significant research has been invested in understanding and controlling 
helical folding patterns. The hydrogen bonding network of α-helices results in a right-handed spiral 
conformation of the peptide backbone. The resulting 3.6 residues per helical turn leads to the display of 
amino acid side chains on the same face of the helix at an i→i+7 pattern (a heptad repeat). The side 
chains of residues at i→i+4 or i→i+3 are also spatially near each other (Figure 6). 
Research into the primary sequences of naturally occurring and de novo designed α-helices has 
revealed specific residue preferences for helical conformations.
27, 31, 32
 The naturally occurring amino 
acids alanine, arginine, leucine, and lysine have high inherent helical propensity, while glycine and 
proline strongly disfavor α-helical folds. Introduction of oppositely charged residues in close proximity in 
an α-helix can stabilize the fold through electrostatic interactions called “salt bridges.”33  Restricting the 
conformational preferences of the peptide backbone through Cα disubstitution can also be used to 
influence helical folding.
27
 
Due to the unidirectional arrangement of the backbone amides in an α-helix, helices have a large 
net molecular dipole. The net dipole moment results in positive charge towards the N-terminus and 
negative charge towards the C-terminus of an α-helix. Resulting unfavorable electrostatic interactions 
between the positively charged N-terminal amine or the negatively charged C-terminal carboxylate act to 
destabilize the helical fold.
34
 Accordingly, strategies used to ameliorate this net molecular dipole, often 
termed “capping,” have been used to stabilize helical folds. This can be achieved through the introduction 
of negatively and positively charged residues at the N-terminus and C-terminus, respectively, or through 
N-terminal acylation and C-terminal amidation.
27, 35
 Capping helps to ameliorate the helical dipole and 
thus stabilize the helical conformation. 
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1.4 COVALENT CONSTRAINTS IN PEPTIDE FOLDING 
 As discussed above, the development of well-folded peptide sequences is desirable for the 
generation of potential peptide-based therapeutics; however, short oligomers tend to be poorly structured 
under aqueous conditions. Nature often utilizes covalent bonds in the form of disulfides to constrain short 
sequences into defined folding patterns.
36
 Disulfide cyclization is found in very short natural sequences 
with defined folds including conotoxins and defensins amongst other functional peptides.
37, 38
 Taking 
inspiration from nature, chemists have sought to utilize disulfide formation and other chemoselective 
and/or biocompatible reactions to constrain short peptide sequences into defined folds. This strategy is 
generally referred to as “cross-linking” or “stapling.”39, 40 Cross-linking strategies have commonly been 
employed to constrain peptides into helical conformations, though there are examples of covalent 
constraints being used to stabilize other structural elements.
39, 41, 42
 A number of methods have been 
developed for both intramolecular side-chain to side-chain cross-linking as well as intermolecular cross-
link formation by reaction of bifunctionalized peptides with bifunctionalized small molecules (Figure 7). 
 
 
Figure 7. Chemoselective peptide cyclization strategies and types of chemical bonds employed. 
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1.4.1 On-Resin Peptide Cyclization Techniques 
Peptide cyclization requires reactions that proceed cleanly even in the presence of other side chain 
functional groups. Though disulfide formation constitutes such a chemoselective reaction, disulfides are 
not fully bioorthogonal; chemoselective formation of disulfides can only be achieved using sequences 
which lack any other cysteine residues. Several alternative strategies have been developed for selective 
cross-linking of peptides during on-resin solid phase peptide synthesis (SPPS) (Figure 8). 
 
 
Figure 8. Common on-resin peptide cross-linking methods. 
  
 
 One of the earliest peptide cross-linking methods explored was amide bond formation, resulting 
in a cyclic lactam (Figure 8).
43
 Lactam cyclization requires on-resin manipulation of side chains 
functionalized with carboxylic acids (e.g. aspartic acid, glutamic acid) and amines (e.g. lysine or lysine 
homologues). These groups must be protected orthogonally to the other functional side chains in the 
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peptide during SPPS. Both Boc- and Fmoc-based syntheses have been performed to install lactam side-
chain cross links. Generally, orthogonally protected Asp, Glu, and Lys residues are utilized, where the 
orthogonal protecting groups are selectively cleaved under appropriate conditions, leaving the other side 
chain protecting groups intact. The peptide is then cyclized on-resin through the formation of an activated 
ester of the carboxylic acid and subsequent intramolecular reaction to form the lactam. Extensive work on 
lactam cyclization has been carried out to establish synthetic strategies, the structural features of lactam-
cyclized peptides that best induce helical conformations, and how lactam cross-linked helices affect 
binding to biological receptors.
44, 45, 46
 
An alternative to lactam formation is the reaction of unnatural olefin side chains to generate a 
hydrocarbon-based macrocycle through a ring closing metathesis reaction (Figure 8).
47, 48
 This strategy 
has been widely examined to determine the structural and stereochemical factors that best induce helix 
formation,
48, 49
 and to examine how such cross-linked helices behave in ligand-receptor interactions.
50, 51, 52
 
It has been postulated that side chain hydrocarbon cross-links can improve helicity and affinity for 
biomolecules.
50, 51, 52, 53
 Additionally, some work suggests that hydrocarbon cross-links may improve 
cellular uptake
50, 53
 but this remains a point of some controversy.
54
 
Other chemoselective cross-linking methods include the formation of thioethers, which takes 
advantage of the general paucity of cysteine residues in naturally occurring sequences (Figure 8).
55
 
Although, in principle, thioether ligation can be performed on unprotected peptide substrates, most 
published examples of thioether cross-linking take advantage of on-resin manipulation of the peptide. 
This is necessary due to the difficulty in selectively installing an alkyl halide functionality on side chains 
of unprotected peptides and the inability of alkyl halides to persist through SPPS. Accordingly, one 
common strategy utilizes an orthogonally protected lysine, which can be deprotected and subsequently 
functionalized with an alkyl halide. A second orthogonal deprotection is then utilized to unmask a 
cysteine or other thiol-functionalized amino acid, which selectively reacts with the alkyl halide to form 
the thioether cross-link. Thioethers have been less well-studied than lactam or hydrocarbon cross-linking 
methods, possibly due to the synthetic difficulty in having two chemoselective deprotection/ligation steps; 
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however, there have been reports on the use of thioether-cyclized helices as ligands for protein 
receptors.
55
 
Cyclization and helix induction can also be achieved through covalent constraint of backbone 
atoms (Figure 9). Early work towards this end utilized hydrazone formation between aldehyde-
functionalized N-terminal amines on peptide substrates and a nearby hydrazide in the peptide backbone.
56
 
The resulting cyclic oligomer effectively replaces a backbone hydrogen bond with a covalent bond, 
generating a “hydrogen-bond surrogate,” (HBS) helix. More recent work employed other reactions for the 
creation of hydrogen bond surrogates, most notably ring-closing metathesis to generate hydrocarbon HBS 
helices.
57
 The HBS strategy generally requires precise mimicry of the geometry of the hydrogen bond that 
is replaced. Hydrogen bond surrogacy has proven to be a useful technique to improve both helical folding 
and affinity for biomolecules.
58, 59, 60, 61
 
 
 
Figure 9. Examples of hydrogen bond surrogate helices. 
(A) Structure of a HBS helix via hydrazone formation. (B) Structure of a HBS helix formed 
through olefin metathesis. (C) Hydrogen bond surrogate in an α-helix from PDB: 4MZL. The surrogate 
bond is highlighted by a dashed box. 
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While on-resin cyclization techniques have proven to be useful for affecting helical folding 
patterns as well as improving affinity for biological targets, the complex manipulations necessary to 
introduce the cross-links limit accessibility to a large number of cyclic oligomers in a combinatorial 
manner. 
1.4.2 Solution Phase Peptide Cyclization Techniques 
Though there are many techniques to cyclize peptides on-resin, cyclizing fully unprotected peptides in 
solution is considerably more difficult. Cyclization of unprotected peptides requires orthogonal reactivity 
of the participating functional groups to the other functional groups found in polypeptide chains. Without 
orthogonal reactivity the primary sequence space amenable to these methods is severely limited. 
Accordingly, prior research has sought to develop peptide cyclization strategies which can take place on 
fully unprotected peptide substrates. Such work seeks to expand the scope of cross-linking of polypeptide 
sequences. 
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Figure 10. Three examples of solution-phase cross-linking methods. 
 
Naturally occurring amino acid side chains have been employed for solution-phase cross-link 
formation, typically by utilizing cysteine
62, 63
 or lysine
64
 (Figure 10). Bis-lactam formation through 
reaction of peptidic amine side chains and activated diesters has been employed for selective cyclization 
in solution phase.
64
 This strategy is amenable to use in developing peptides for biological applications, but 
is limited by the necessity of removing all other amine-functionalized side chains in order to obtain 
selective cross-link formation.
65
 The unique reactivity of cysteine has been capitalized upon both in 
disulfide and thioether formation as a solution-phase cross-linking technique. Disulfide formation 
provides a ready access to cyclic peptides in aqueous solution, and has been applied to stabilize helices.
66
 
Peptides containing two cysteine residues have also been cyclized by thioether formation in solution 
phase, and applied to protein-protein interaction inhibitors.
62, 63, 67
 A recently developed strategy for 
chemoselective cyclization in solution involves the exploitation of SNAr coupling for perfluoroarylation 
of cysteine residues.
68
 This cross-linking technique is amenable to combinatorial synthesis of a wide array 
of cyclic products,
69
 and can affect folded structure and biomolecule affinity.
68
 However, these techniques 
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are limited by the necessity of performing the cyclization reaction in the presence of organic solvent or 
co-solvent. Disulfide formation and related techniques for cysteine thioether cross-linking are also limited 
by the lack of orthogonality to cysteine residues in peptide substrates.  
The use of unnatural residues offers greater selectivity in cross-link formation while limiting the 
necessity of primary sequence alteration. Azide-alkyne cycloaddition (“click chemistry”) has been widely 
employed for biomolecule labeling
70
 as well as in the construction of hybrid backbones
71, 72
 or cyclized 
biomolecules.
42, 73, 74
 The orthogonality of click chemistry has enabled it to be employed for on-resin
75
 and 
solution-phase cyclizations
76
 of fully unprotected peptide substrates (Figure 10). It has been shown that 
triazole-cyclized peptides can have improved helical folding and increased biological activity.
76
 However, 
the azide-alkyne cycloaddition reaction often requires the use of organic cosolvents and may not be 
compatible with redox-sensitive biomolecules.
42, 76
 
The formation of Schiff bases and related molecules (oximes, hydrazones) offers an alternative 
strategy for solution-phase peptide cyclization, and has been employed previously for this purpose (Figure 
11).
77, 78
 The formation of oximes and hydrazones is generally recognized as bioorthogonal due to the 
relative scarcity of aldehyde or ketone functionalities in biological systems and the near complete lack of 
hydrazine or aminooxy functionalities.  The enhanced nucleophilicity of hydrazine and aminooxy 
functionalities reportedly stems from the α-effect due to the presence of an atom with unshared electron 
pairs adjacent to the nucleophilic center.
79
 Owing to the poor hydrolytic stability of imines, they are rarely 
employed in the context of aqueous systems. Hydrazones and oximes, which are more hydrolytically 
stable than imines,
80
 have been widely utilized in biomolecule related applications.
81, 82
 Early work in the 
context of peptides employed oxime formation to form cyclic peptide backbones in solution on 
unprotected peptide substrates.
77, 78
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Figure 11. Imine (Schiff base), hydrazone, and oxime structures, formation and hydrolysis. 
(A) Imine, hydrazone, and oxime chemical structures and their hydrolytic stability. (B) 
Condensation and hydrolysis of generalized imine, hydrazone, oxime bonds. 
 
 
While there are some solution-phase cyclization techniques available for use with peptides these 
methods have generally not been developed as fully as on-resin cyclization. Expanding the scope and 
applicability of solution-phase cyclization offers the possibility of performing cross-linking chemistry 
under conditions which are fully compatible with biological systems. 
1.5  PROJECT GOALS 
The use of chemoselective cyclization techniques to control peptide folding and affect biological activity 
remains an active area of research. However, previously developed techniques are limited in a number of 
ways. First, most techniques for peptide cyclization require extensive on-resin manipulation of the 
substrate, which introduces synthetic complexity as well as limits the scope of peptide sequences which 
can be efficiently synthesized. Second, though some solution-phase cyclization techniques have been 
developed, they are not fully bioorthogonal and cannot be employed without the use of organic solvents. 
Third, nearly all previous cross-linking types are irreversible; thus, evaluation of different target 
structures requires constant redevelopment and optimization of the cross-linked position and/or structure 
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within the peptide sequence. We have sought to create cross-linking chemistry that is employable in near-
physiological conditions and which is dynamically reversible. Such technology offers distinct advantages 
over previously developed methods. First, the ability to form cross-links under benign buffered aqueous 
conditions allows for the possibility of utilizing receptor-based templating of the peptide structure during 
cross-link formation. Thus, one could employ a poorly structured peptide substrate which, when bound to 
an appropriate receptor, can be chemoselectively cyclized, effectively trapping the bioactive fold. Such 
chemistry could be used to discern the biologically active bound state of short sequences which bind to 
proteins. Second, employing dynamically reversible bonds offers the possibility of generating multiple 
different cross-linked structures, each of which has different folding tendencies, from a single peptide 
sequence. This allows the utilization of receptor templated selection of a particular cross-linked topology, 
as employed in DCC, to select for and isolate the structure which best binds to the receptor. We have 
pursued both of these goals through the use of oxime and hydrazone formation, which provides both a 
bioorthogonal and potentially reversible cross-link. 
1.5.1  Intramolecular Oxime Cross-link Formation 
In early work in the generation of oxime cross-linked peptides, as discussed in detail in Chapter 2, we 
utilized an intramolecular strategy to generate the desired cross-link oxime. The oxime cyclization 
proceeds through a mild oxidative unmasking of a side chain glyoxyl aldehyde, which then undergoes a 
condensation reaction with an appropriately poised aminooxy-functionalized residue to furnish the cyclic 
oxime product as one of two (E or Z) stereoisomers. This type of cross-link formation was found to affect 
helical folding in a short (17-residue) polypeptide model system, and to undergo dynamic covalent 
exchange. 
In a more complex quaternary structure, which provides the basis for investigating oxime side 
chain cross-links in a basic protein-protein interaction, we examined the importance of both the structure 
and sequence position of the oxime cross-links. In this system, the cross-links were found to be mildly 
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disruptive of the helical fold, though stabilizing to the protein-protein complex provided that no favorable 
intramolecular interactions are perturbed. Analysis of the structural factors important to quaternary 
structure stabilization allowed identification of an optimal residue pairing for future cross-linking studies. 
High-resolution structural data of the optimal cross-link demonstrates its compatibility with a helical fold. 
As a step towards receptor-templated cross-link formation in a bioactive fold, we utilized this model 
quaternary structure for the selective synthesis of one particular bicyclic species in a system where 
multiple possible cyclic products can result. 
1.5.2  Intermolecular Oxime and Hydrazone Cross-link Formation 
Owing to the poor reversibility observed in the intramolecular formation of oxime cross-links, we sought 
to develop alternative methods based on intermolecular cross-linking between bifunctionalized peptides 
and bifunctionalized small molecules as discussed in Chapter 3. This strategy is capable of furnishing 
multiple cross-linked products depending on the small molecule utilized in cross-link formation, thus 
allowing for a general and divergent synthesis of different cross-linked structures from a small set of 
peptide sequences. Intermolecular cross-linking was found to be capable of affecting the folding in a short 
model peptide, albeit somewhat less predictably than was found in the case of intramolecular cross-links. 
However, the use of intermolecular oxime and hydrazone formation was found to furnish a system more 
readily capable of dynamic covalent exchange as demonstrated through the ability to remove the cross-
link and regenerate the starting linear peptide and in the ability to exchange the cross-linking small 
molecule. 
1.5.3  Cross-Linking Peptide Ligands In The Presence Of A Protein Receptor 
Having established a cross-linking method which is fully biocompatible through the use of intermolecular 
oxime formation, we demonstrated that the presence or absence of a protein receptor can influence the 
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product distribution amongst cross-linked species. In this work we utilized gp41-5, a protein consisting of 
five of the six helical segments of the HIV glycoprotein gp41, as the receptor. We generated peptides 
derived from the C-terminal heptad repeat of gp41 as ligands for the gp41-5 receptor. Through the 
combination of a small set of peptides with two nucleophilic aminooxy-functionalized residues and 
several commercially available dialdehydes, we demonstrate that the receptor can affect the outcome of 
cross-linking reactions. Attempts at screening cross-linking reactions which contain two dialdehydes in 
order to selectively amplify a single collection of cross-linked isomers are described. In these 
experiments, the outcome of the reaction does not demonstrate selectivity of a particular linker, 
suggesting that the kinetics and/or thermodynamics of the system are not suitably balanced to achieve 
linker selection. Nevertheless, further development of this cross-linking technology may achieve the 
desired goal of selective cross-linked product amplification. 
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2.0 INTRAMOLECULAR OXIME CROSS-LINK FORMATION 
Work detailed in this chapter has been published as: 
1. Haney, C. M.; Loch, M. T.; Horne, W. S.; “Promoting peptide -helix formation with
dynamic covalent oxime side-chain cross-links.” Chemical Communications, 2011, 47,  10915-
10917 
2. Haney, C. M.; Horne, W. S.; “Oxime side-chain cross-links in an -helical coiled-coil protein:
Structure, thermodynamics, and folding-templated synthesis of bicyclic species.” Chemistry – A 
European Journal, 2013, 19, 11342-11351 
As detailed in Chapter 1, there is an unmet need for cross-linking methods that are bioorthogonal and 
dynamically reversible in aqueous conditions. Some cross-linking methods exist that are applicable to 
unprotected peptide substrates in solution but they are generally limited by the use of proteinogenic side 
chains (e.g. Cys, Lys) and the necessity of utilizing organic co-solvents. Owing to the bioorthogonality of 
oxime and hydrazone formation, and the ability of such linkages to undergo dynamic covalent exchange, 
we have sought to employ oximes as a side-chain to side-chain cross-linking method. We have utilized 
oxime cross-links in a model helical peptide and in an -helical coiled coil, which constitutes a basic 
protein-protein interaction. This work has demonstrated that oxime cross-links can influence helical 
folding, stabilize a protein quaternary structure, and undergo limited dynamic covalent exchange. We 
have also shown that the cross-linked products formed are sensitive to the folded state of the peptide 
when the reaction is performed. 
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2.1 PROMOTING α-HELIX FORMATION IN A SHORT PEPTIDE 
In a helical model system, we sought to investigate several factors necessary for the development of 
dynamic covalent peptide cross-linking methods. First, we established unnatural monomer inclusion able 
to chemoselectively form oxime side-chain cross-links. Second, we investigated how cross-links affect 
the helical folding pattern of the peptide and what structural factors of the cross-links are important to 
helix induction. Third, we assessed the capacity of the cross-links formed to undergo dynamic covalent 
exchange.  
2.1.1  Design Of The Peptide Model System 
As a -helix model system we utilized a 17-residue peptide, 1, of de novo design which was originally 
developed to gauge the importance of salt bridge interactions on helix formation (Figure 12).
33
 Peptide 1 
is known to be partially helical in aqueous solution at pH 7.
33
 We designed variants based on peptide 1 
containing unnatural residues U4, X4, and X5 to generate analogues 2-5 (Figure 12). Residues X4 and X5 
are isosteres of ornithine and lysine, respectively, and bear aminooxy functionalities attached on the 
peptide side chain. Residue U4 has a serine-acylated side chain, which can be unmasked by treatment with 
a mild oxidant under aqueous conditions to furnish a glyoxyl aldehyde yielding linear species 2a-5a. 
These oxidized, linear species can then undergo oxime formation to furnish the corresponding cyclized 
peptides 2b-5b (Figure 12C). Periodate oxidation of terminal serine residues has previously been used to 
generate protein aldehydes for bioconjugation
82, 83
 and in the formation of oxime-cyclized peptide 
scaffolds.
77, 78
 Peptide 6 is designed to isolate the effect of the inclusion of residue U4, which is bulky and 
cationic, and the subsequently unmasked glyoxyl aldehyde on the α-helical structure.  
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Figure 12. Sequences of peptides 1-6 and schematic representation of cross-linking. 
(A) Sequences of peptides of peptides 1-6. (B) Structure of monomers U4, X4, and X5.  (C) 
Schematic representation of cross-link formation. 
  
 
 The required Fmoc-protected aminooxy-functionalized monomers, 12a, 12b were synthesized 
according to scheme 2.1. 
 
 
Scheme 2.1. Synthesis of aminooxy-functionalized monomers 12a and 12b. 
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The monomers 12a and 12b  were synthesized by adaptation of previously published methods.
84
 
The Cbz/Bn-protected derivative of aspartic acid (7a) was reduced to its corresponding alcohol by 
conversion to a mixed anhydride followed by treatment with aqueous sodium borohydride.
85
 The alcohol 
in 8a was transformed to a mesylate, and the aminoxy functionality installed by nucleophilic addition of 
N-hydroxypthalimide to yield compound 10a. The pthalimide protecting group was then cleaved by 
addition of methyl hydrazine; subsequent treatment with 2-chlorotrityl chloride yielded compound 11a. 
Hydrogenolysis of the backbone protecting benzyl carbamate and benzyl ester followed by Fmoc 
protection of the free amine yielded protected monomer 12a. An identical sequence of reactions was used 
to obtain protected aminoxy-functionalized molecule 12b starting from the protected derivative of 
glutamic acid (7b). 
Serine-acylated monomer 16a was prepared according to previously reported procedures (Scheme 
2.2).
78
 The succinimidyl ester of Boc-Ser(tBu)-OH (13) was prepared by reaction with N-
hydroxysuccinimide and DCC to yield compound 14. Fmoc-protected diaminopropionic acid (15a) is 
then reacted with the succinimidyl ester of serine to yield the desired monomer 16a. 
 
 
Scheme 2.2. Synthesis of serine-acylated monomer 16a. 
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With protected amino acids 12a, 12b, and 16a in hand, peptides 1-6 were synthesized by standard 
Fmoc-based solid-phase peptide synthesis (SPPS) and purified by HPLC. A few observations regarding 
the synthesis of aminooxy-functionalized residues are notable. We found that cleavage of the peptides 
from resin using standard reagent cocktails (TFA/water/triisopropylsilane) yielded no isolatable product. 
The addition of ethanedithiol as a nucleophilic scavenger led to yields and crude purities of aminooxy-
functionalized peptides 2-5 similar to sequence 1 prepared by the same method. The loss of material 
during peptide cleavage from resin in the absence of ethanedithiol can be attributed to the irreversible 
attachment of the peptide to resin by alkylation of the aminooxy functionality.
86
 It was also observed that 
some C18 reverse-phase HPLC stationary phases irreversibly bound aminooxy-functionalized peptides. 
Although the cause of this phenomenon was never clear, we were able to find stationary phases free of 
this problem. 
2.1.2 Oxime Cross-Link Formation And Exchange In A Simple α-Helix 
With the desired peptides 1-6 in hand, we tested the efficiency of oxidation and cross-link formation 
under conditions which are typical for biophysical characterization of peptide folding. We prepared a 100 
µM solution of each peptide in 100 mM phosphate buffer at pH 7 and added aqueous sodium periodate to 
cleave the 1,2-aminoalcohol in the U4 residue and unmask the glyoxyl aldehyde. Cross-link formation 
then proceeds via a condensation reaction between the aminooxy functionalized side chain of X4 or X5 
and the unmasked aldehyde on U4. Each cross-linking reaction was analyzed by HPLC and MALDI-TOF 
MS of the collected HPLC eluent (Figure 13). Peptide 6, which contains the U4 residue but lacks the 
aminooxy functionality, was used in an identical series of reactions. The oxidation of peptide 6 furnished 
a single linear product, 6a, demonstrating the impact of U4 residue insertion and that lysine is incapable of 
forming a cyclic imine product under the conditions of the experiment. 
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Figure 13. Cross-link formation scheme and HPLCs. 
(A) Schematic representation of cross-link formation. (B-F) Chromatograms of peptide 2-6 with (blue) 
and without (black) 200 µM NaIO4 present.  
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In each case, we observed that the starting linear peptide was consumed in a matter of minutes to 
furnish two peaks in the HPLC chromatogram with masses that correspond to the cyclic oximes 2b-5b. 
The cross-linking reactions were found to be high yielding (~85-90%) and to have few byproducts. We 
assigned the two major products observed as arising from E- and Z-oxime isomers, the ratio of which 
varied amongst 2b-5b (Figure 13). Although the oxidized peptides are capable of establishing an 
equilibrium between linear species 2a-5a and the oxime cyclized products 2b-5b, the oxime products are 
thermodynamically favored. This accounts for the fact that linear species 2a-5a were not observed by 
HPLC. The distribution of products observed after cross-link formation was unchanged even after 24 
hours.  
The observed product distribution from cross-link formation could result either from kinetic or 
thermodynamic control. In the case of kinetic control, the product distribution is dictated by the activation 
energy associated with the formation of each product; the oxime isomer distribution would depend on 
which isomer has a lower energy barrier associated with its formation. If the reaction is under 
thermodynamic control, the product distribution is determined by the relative stability of each product. In 
the case of thermodynamic control, the product distribution indicates which oxime isomer provides a 
more stable cyclized species. However, if the activation energy barrier for the interconversion of the two 
cyclized products is sufficiently high under the experimental conditions, the product distribution initially 
observed could be “trapped,” at a non-equilibrium position. The observation that the product distribution 
observed for the cross-linking reactions do not change argues either that the thermodynamic minimum of 
the system has been attained, or that the system is kinetically trapped. Determining which of these two 
circumstances is manifested by the reactions performed here is difficult. However, we hypothesize that 
the reaction mixtures observed constitute a thermodynamic minimum due to the lack of changes in 
product distribution over extended periods of time, and that the product distribution can change when 
changing the conditions of the experiment as described below. 
In the case of peptide 2b, the E/Z isomers were assigned by 
1
H NMR spectroscopy after HPLC 
separation (Figure 14). While it is possible to completely separate the stereoisomers in this case, we found 
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that the two peaks interconvert rapidly in HPLC solvents, which contain trifluoracetic acid, even during 
the short time between collection and freezing for lyophilization. Nevertheless, samples enriched in each 
observed stereoisomer could be obtained by rapid freezing of eluted material and subsequent 
lyophilization (Figure 14). The separation yielded two samples of 2b, one composed of ~95% major 
isomer and the other composed of ~70% major isomer and ~30% minor isomer. Analysis of these samples 
by 
1
H NMR shows two singlets in the region expected for the oxime C-H bond. The oxime C-H 
resonance is dependent on the proximity of the proton to the nearby oxygen; the isomer with the proton 
closer to oxygen (E) is expected to be farther downfield, while the opposite (Z) configuration is expected 
to be farther upfield.
87
 The two observed singlets are thus assigned as the respective stereoisomers of the 
oxime bond, where the Z isomer is the major product and the E isomer is the minor product. 
 
 
Figure 14. Assignment of oxime stereoisomers of 2b. 
(A) Structures of E- and Z-oxime isomers. (B) HPLC chromatograms of the isolated isomer 
samples. (C) 
1
H NMR spectra of isolated fractions of 2b isomers used to assign as the E and Z oximes. 
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2.1.3  Dynamic Covalent Exchange In A Helical Peptide 
As an initial test of whether oxime cross-linked peptides undergo dynamic exchange, we 
examined the interconversion of the E and Z isomers of 2b (Figure 15). The proposed mechanism of 
isomerization involves the protonation of the oxime nitrogen, followed by attach by water on the carbonyl 
carbon involved in the oxime bond. This process leads to the formation of a tetrahedral intermediate (T0) 
which can undergo free rotation about the C-N bond. This intermediate can then proceed to complete 
hydrolysis, or re-form the oxime as either the E- or Z-stereoisomer. Though other mechanisms for 
isomerization have been proposed, kinetic experiments suggest that this pathway is the predominant 
mechanism of isomerization in aqueous solution.
88
 Since isomerization by this mechanism shares a 
common pathway with the hydrolysis required for dynamic covalent exchange, observation of 
isomerization indicates that the hydrolytic pathway is available for the cyclic oxime products generated, 
even if the linear species is not observed.  
Following HPLC separation, rapid freezing, and subsequent lyophilization, enriched samples of 
the E and Z isomers of 2b were obtained. Each fraction was split into two aliquots: one in pH 7 phosphate 
buffered water and one in water containing 0.1% by volume trifluoroacetic acid. It was observed that the 
isomers are capable of interconverting at pH 7, albeit slowly; this isomerization was observed to be faster 
at acidic pH. This suggests that the system is in dynamic exchange at pH 7, but is kinetically trapped at a 
non-equilibrium state. The rate determining step of oxime exchange in mildly acidic or neutral pH 
solution is known to be the protonation of the nitrogen, which is also the first step in isomerization.
89
 This 
suggests that dynamic covalent exchange of the oxime side chain cross-links may be possible under 
conditions known to favor oxime and hydrazone exchange (acidic pH, aniline catalyst).
90
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Figure 15. Mechanism and HPLC chromatograms of isomerization experiments. 
(A) Mechanism of oxime isomerization in aqueous solution proceeds through tetrahedral 
intermediate T0. (B, C) Major (B) and minor (C) oxime isomer peaks as isolated by analytical HPLC, 
following lyophilization and immediate injection after dissolving in water. (D,E) HPLC chromatograms 
of lyophilized samples dissolved in either 0.1 M pH 7 phosphate buffer or in 0.1% by volume TFA in 
water. 
 
 
In order to further examine the ability of the oxime cross-links to undergo dynamic covalent 
exchange, we tested the ability of the cyclized product 2b to undergo ring-opening to form product 2c 
(Figure 16). We prepared an equilibrating mixture of peptide 2b and added an exogenous aminooxy-
functionalized small molecule, O-methylhydroxylamine, under conditions that are known to facilitate 
oxime exchange. Under these conditions, the O-methylhydroxylamine can compete with the peptide X4 
residue for reaction with the glyoxyl aldehyde.  Thus, the above conditions set up a dynamic equilibrium 
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between species 2b and 2c. We found that treatment of cyclic product 2b under the conditions described 
above at pH 7 led to limited exchange to form product 2c to a final composition of 2c after 48 hours of 
~3% by HPLC analysis. At pH 4, the exchange was considerably faster and ~10% of the material was 
converted to product 2c after 24 hours. 
 
 
Figure 16. Dynamic covalent exchange of cyclic oxime 2b and linear oxime 2c. 
(A) Schematic representation of cross-link exchange experiments, where cyclic product 2b is in 
equilibrium with linear species 2a and 2c. (B) Representative chromatogram of peptide 2 10 minutes after 
addition of NaIO4. (C) Chromatograms of exchange experiments performed at pH 7 24 hours (solid blue 
line) and 48 hours (dashed blue line) after addition of aniline catalyst and O-methylhydroxylamine. (D) 
Chromatogram of exchange experiment performed at pH 4 24 hours after addition of aniline catalyst and 
O-methylhydroxylamine. (E) Overlay of the chromatograms in B-D illustrating the change over time of 
product 2c. 
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2.1.4  Oxime Cross-Link Effect On Folding In A Simple α-Helix 
In order to examine the ability of the oxime cross-links to influence helix formation in peptides 2-5, we 
utilized circular dichroism (CD) spectroscopy. CD spectroscopy is commonly used to gauge the folding 
of peptides and proteins, wherein an α-helix is indicated by minima at 208 and 222 nm.91 We prepared 
samples of peptides 1-6 at 100 µM concentration in 100 mM phosphate buffer at pH 7. Separate samples 
prepared with aqueous sodium periodate furnished linear product 6a and cross-linked products 2b-5b, 
allowing for direct comparison of the linear and cyclized peptides (Figure 17). 
Parent peptide 1 is approximately 40% helical under the conditions of the experiment as indicated 
by minima at 208 and 222 nm. Prior to oxidation and cyclization, peptides 2-5 exhibit almost no helical 
secondary structure (Figure 17A). We attribute this to the inclusion of the bulky, cationic U4 residue in 
place of alanine in parent sequence 1. In order to test this hypothesis directly, we examined a peptide (6) 
which lacks the aminooxy-functionalized X residue but which still contains the serine-acylated U4 
residue.  Peptide 6 also lacks strong helical minima, supporting the hypothesis that the U4 residue is 
responsible for abolishing the helical fold (Figure 17C). Upon oxidation and unmasking of the glyoxyl 
aldehyde – removing some of the steric bulk and charge of the U4 residue – peptide 6a was found to 
recover moderate helical folding. 
Following oxidation and cyclization, peptides 2b-5b were found by CD to increase in helical 
structure relative to their linear counterparts (Figure 17B). The α-helical population among 2b-5b varied 
as a function of the structure of the oxime cross-links, where an i→i+4 spacing of residues leads to more 
helical population than the corresponding i→i+3 spacing of the same monomer pair. Additionally, it was 
found that the thermal stability of the partially helical fold varies as a function of the cross-link structure. 
While very similar by CD scans, peptides 2b and 3b exhibit different thermal stability of their fold as 
judged by monitoring the helical minimum at 222 nm as a function of temperature (Figure 17D). Overall, 
these data demonstrate that oxime cross-links can be utilized to stabilize a helical fold with a strong 
dependence on the structure of the cross-link formed. 
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Figure 17. Circular dichroism data for peptides 1-6. 
(A) CD scans of peptides 1-5 without added periodate at 100 µM concentration in 0.1 M 
phosphate buffer, pH 7. (B) CD scans of peptides 2b-5b with added periodate at 100 µM concentration in 
0.1 M phosphate buffer, pH 7. (C) CD scans of peptides 1, 6, and 6a at 100 µM concentration in 0.1 M 
phosphate buffer, pH 7. (D) CD melts of peptides 1 and 2b-5b where molar elipticity at 222 nm is 
monitored as a function of temperature. 
 
2.1.5  Conclusions 
Work utilizing a 17-residue peptide demonstrates that oxime side chain cross-links provide a potential 
bioorthogonal cross-linking strategy that is readily implemented in buffered aqueous solution. The cross-
links are formed rapidly (in a matter of minutes) and cleanly in aqueous buffered solution to furnish the 
cyclic peptides as E- and Z- oxime isomers. In the case of peptide 2b, the Z-oxime isomer is determined 
to be the major product. 
 One of the motivations for developing oxime side-chain cross-links is to provide a dynamic 
covalent cross-linking method. We found that the isomer distribution can change upon isolation of the E- 
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and Z-oxime isomers and redissolving in aqueous solution at either neutral or acidic pH; however, the 
observation that isomerization occurs only slowly at pH 7 suggests that the system is kinetically trapped 
at neutral pH. Additionally, attempts to implement dynamic covalent exchange to form a linear oxime 
species demonstrate that although the cyclic oxime is capable of dynamic exchange the extent of 
exchange is limited, presumably by the thermodynamic favorability of the cyclic species. 
 We found that the oxime cross-links are capable of affecting the helical structure of the peptide, 
with a strong dependence on the connectivity and ring size of the cross-linked macrocycle. Additionally, 
it appears that the serine acylated U4 residue is detrimental to helical folding prior to cleavage of the 1,2-
aminoalcohol to furnish the corresponding glyoxyl aldehyde. Overall, the observed differences in helicity 
by CD suggest that an i→i+4 spacing of the two residues is necessary for accommodation into a helical 
fold.  
2.2 OXIME SIDE CHAIN CROSS-LINKS IN A MODEL QUATERNARY STRUCTURE 
Having established a foundation for the use of oxime side chain cross-links in an -helical peptide, we 
sought to increase the complexity of the system to include a model protein-protein interaction or 
quaternary structure. Towards that end, we chose to use the GCN4-p1 sequence 17, which is the 
dimerization domain from the yeast transcriptional activator GCN4 (Figure 18).
92
 This 33-residue 
sequence is known to form a dimeric -helical coiled coil in aqueous solution based on the formation of a 
hydrophobic interface along one face of the helix.
92
 In a helical wheel, each amino acid is assigned a letter 
code (a-g) based on its position in the sequence. In GCN4-p1, hydrophobic amino acids (Leu or Val) 
predominate at heptad repeat positions a and d (Figure 18).
92
 Packing of the hydrophobic surfaces formed 
by two such helices leads to dimerization. GCN4-p1 has offered a fertile ground for the study of the 
kinetics and thermodynamics of peptide folding with both natural and unnatural α-residue replacements.93, 
94, 95
 The GCN4-p1 model system has since been employed in detailed analyses of the thermodynamic 
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contributions of primary sequence changes in the stability of the coiled-coil fold,
96, 97
 and thus offers a 
platform for investigating the contribution of cross-linking for the thermodynamic folded stability of the 
coiled coil. 
 
 
 
Figure 18. Helical wheel, sequence, and crystal structure (PDB: 4DMD) of GCN4-p1. 
(A) Helical wheel representation of the GCN4-p1 sequence. Hydrophobic residues are found at 
positions a and d. (B) Sequence of GCN4-p1, 17; hydrophobic interface residues are in bold font. (C) 
Crystal structure of GCN4-p1 from PDB ID: 4DMD. 
  
 
 We utilized this model system to further investigate the influence of the structure and placement 
of oxime side chain cross-links within a helical sequence by examining a wide range of cross-linked 
macrocycle sizes, connectivities, and sequence positions. Having identified an optimal cross-link 
structure, we then prepared a bicyclic peptide based on the best residue pairing and demonstrated that the 
distribution of the products formed is dependent upon the folded structure of the peptide at the time of 
cross-link formation.  
 37 
2.2.1  Examination Of The Sensitivity Of Methionine To Periodate Oxidation 
The GCN4-p1 sequence (17) includes methionine at position 2. Converting the serine 1,2-aminoalcohol in 
U residues to an aldehyde requires the use of a mild oxidant, which could potentially oxidize methionine 
to the corresponding sulfoxide or sulfone. However, methionine has been reported to be stable to 
treatment with dilute sodium periodate.
98
 A more complete understanding of the competitive oxidation of 
methionine is of interest not just in the study of oxime side chain cross-links, but also broader 
applications of serine oxidation as a protein labeling tool. In order to address these general questions, and 
the specific suitability of peptide 17 as a host sequence for cross-linking U and X residues, we examined 
whether or not periodate would selectively oxidize a U residue in the presence of methionine. 
In order to quantify the oxidation sensitivity of methionine, we used a solution containing 100 
µM of 17 0.1 M phosphate buffer at pH 7 to which was added one equivalent of aqueous periodate. An 
identical analysis of the oxidation of the U4 residue in peptide 6 was also performed. Time dependent 
analysis of the mixture by HPLC and MALDI-TOF MS demonstrated that the U residue in peptide 6 is 
cleanly oxidized with a half-life of less than 0.3 minutes. The methionine residue in peptide 17 was found 
to be oxidized to the methionine sulfoxide with a half-life of 51 minutes.
99
 The relative rates apparently 
favor selective oxidation of the U residue. To test this hypothesis directly, we subjected a single sample 
containing 100 µM of both peptides 17 and 6 to a limiting single equivalent of sodium periodate in 0.1 M 
phosphate buffer at pH 7. Under these conditions, it was found that the U residue in 6 is cleanly converted 
to the corresponding glyoxyl aldehyde, with no appreciable formation of the methionine sulfoxide in 17 
observed (Figure 19). 
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Figure 19. Oxidation of methionine in the presence of serine-acylated U residue. 
(A) Sequences of peptides 6 and 17. (B) Schematic representation of the oxidation reaction of 
each peptide. (C) HPLC chromatogram of a 100 µM sample of each peptide in pH 7 phosphate buffer 
before and 10 minutes after NaIO4 addition.(D) HPLC chromatograms of peptide 17 in pH 7 phosphae 
buffer before (solid) and 60 minutes after (dashed) NaIO4 addition. 
 
2.2.2 Cross-Link Structure And Connectivity In An α-Helical Coiled-Coil 
GCN4-p1 provides a useful system to examine open questions relating to the use of oxime side chain 
cross-links for the stabilization of protein helices. GCN4-p1 has a well-folded quaternary structure and 
exhibits a two-state thermal unfolding transition. In order to rigorously exclude the possibility of 
methionine oxidation during cross-link formation, we replaced methionine at position 2 with its 
hydrocarbon isostere, norleucine, to generate sequence 18 (Figure 20). We then utilized residues X4 and 
X5, and U4 along with three additional serine acylated residues (U5-U7) as a means to construct differing 
macrocycle sizes and connectivities at a single sequence position in GCN4-p1.  Sequences 19-26 were 
used to probe different oxime cross-link structures, as a function of side chain length, and compare their 
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effect on the stabilization of a quaternary fold. Comparison of the linear sequences 19-26 to the 
corresponding cyclized species 19b-26b allow for quantification of the stabilization due to the 
introduction of oxime cross-links of varying structure and macrocycle size. Of the monomer pairs 
utilized, only two (U4 and X4 or X5; peptides 19 and 20) were examined previously in the 17-residue 
helical peptide (see section 2.1). 
 
 
Figure 20. Sequences of peptides 18-26. 
 
Fmoc-protected aminooxy monomers 12a and 12b and the serine-acylated monomer 16a were 
prepared as described in section 2.1.1. Additional serine-acylated monomers, 16b-16d were prepared by 
adaptation of the methods used for synthesis of monomer 16a (Scheme 2.3). 
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Scheme 2.3. Synthesis of serine-acylated monomers 16a-16d. 
 
With the desired monomers in hand, peptides 19-26 were prepared by solid-phase peptide 
synthesis, then cleaved from resin and purified by HPLC. We first examined the conversion of linear 
peptides 19-26 to the corresponding cross-linked counterparts, 19b-26b by treatment of 100 µM solutions 
of each peptide in 0.1 M phosphate buffer at pH 7 with 1 equivalent of aqueous sodium periodate. As 
previously observed in the simpler 17-residue model system, the starting linear peptide was consumed in 
10 minutes or less, and the majority of the material (~85-90%) observed by HPLC was identified as the 
cyclic oxime species by MALDI-TOF MS (Figure 21). We did not observe any evidence of cross-links 
occurring between two independent peptide chains, which we attributed to the favorable kinetics of 
intramolecular cyclization versus intermolecular ligation. 
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Figure 21. Example oxidation/cyclization reaction of peptide 22. 
(A) Schematic representation of oxidation and cross-link formation. (B) HPLC chromatogram of 
peptide 22 before and 10 minutes after addition of 1 equivalent of aqueous periodate. 
 
 
We employed CD spectroscopy to compare the quaternary folded structure of each cross-linked 
coiled-coil, 19b-26b, to its linear counterpart 19-26. In all cases, the CD samples contained 100 µM 
peptide in 0.1 M phosphate buffer at pH 7, with or without an added single equivalent of sodium 
periodate. In CD scans, the magnitude of the minimum observed at 222 nm informs about the helicity of 
the peptide; thus, changes in this helical signature revealed any perturbation of the helical fold either by 
inclusion of the unnatural residues (e.g. 19-26 vs. 18) or from cross-link formation (e.g. 19b-26b vs. 19-
26). We observed that the CD signature at 222 nm changes upon introduction of the unnatural residues in 
peptides 19-26, with a dependence on the unnatural residue substitutions (Figure 22, Table 1). The 
observed decrease in the amplitude of the helical minimum was most pronounced for the monomer pairs 
with the shortest (e.g. U4, X4) and longest (e.g., U7, X5) side chains. We attributed this decrease in helical 
content to fraying of the N-terminus near the site of the unnatural residue placement; however, without 
detailed solution-phase structural data, we cannot rule out other possible causes. 
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Figure 22. Helical signature by CD at 222 nm for peptides 19-26. 
All peptides are measured at 100 µM peptide in 0.1 M phosphate buffer at pH 7, with (dark grey) 
or without (light grey) 100 µM sodium periodate. Error bars represent the standard deviation from two 
independent experiments. 
 
 
The use of temperature-dependent CD spectroscopy can inform about the thermal stability of the 
coiled-coil fold. Monitoring the helical minimum at 222 nm as a function of temperature and fitting the 
resulting cooperative unfolding transition two a two-state thermal denaturation model allows for a 
quantitative measurement of the thermal melting temperature (Tm) of each peptide in its linear and cross-
linked form. Thermal melt data of peptides 19-26 shows that the inclusion of the unnatural residues is 
generally destabilizing, though mildly so, as evidenced by a decrease in Tm (Figure 23, Table 1). There is 
a general correlation between the length of the monomers and the resulting destabilization of the coiled 
coil, where shorter U and X residues are particularly unfavorable. Some monomer pairs, as in linear 
peptide 22 (U5 and X5) increase the stability of the coiled coil above that of the parent sequence, 18. 
Cyclization by treatment with periodate universally increases the melting temperature of the coiled coil, 
demonstrating that the oxime side chain cross-links can stabilize the quaternary fold. The size of the 
macrocycle has a definite impact on the stability of the coiled coil, where the smallest increase in Tm is 
observed for smallest macrocycle sizes, and the 23-membered macrocycle generated in peptide 22b is 
particularly favorable (Table 1). 
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Figure 23. CD melts of peptides 18-26 and 19b-26b. 
(A) CD melts of peptides 18, 20, 22, 24, and 26 prior to addition of NaIO4. (B) CD melts of 
peptides 18, 20b, 22b, 24b, and 26b after addition of NaIO4. (C) CD melts of peptides 18, 19, 21, 23, and 
25 prior to addition of NaIO4. (D) CD melts of peptides 18, 19b, 21b, 23b, and 25b after addition of 
NaIO4. 
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Table 1. Data from CD and thermodynamic analysis for peptides 18-26. 
Peptide 
[θ]222 (deg 
cm
2
 dmol
-1
 
res
-1
) 
Tm (°C) 
ΔΔGfold # vs. 
18 (kcal  
mol
-1
) 
Peptide 
[θ]222 (deg 
cm
2
 dmol
-1
 
res
-1
) 
Tm (°C) 
ΔΔGfold #b 
vs. # (kcal 
mol
-1
) 
18 -33.8 ± 0.4 67.0 ± 0.6      
19 -16.9 ± 0.5 57.8 ± 0.7 1.23 ± 0.14 19b -17.7 ± 0.2 61 ± 1 0.3 ± 0.2 
20 -24.6 ± 0.3 65.3 ± 0.2 0.28 ± 0.04 20b -24.2 ± 0.9 71.0 ± 0.2 0.68 ± 0.04 
21 -28.7 ± 0.6 66.5 ± 0.1 0.13 ± 0.05 21b -27.8 ± 0.1 71.1 ± 0.1 0.56 ± 0.02 
22 -27.0 ± 0.9 69.0 ± 0.6 -0.13 ±0.03 22b -28.0 ± 0.1 77.6 ± 0.6 1.0 ± 0.1 
23 -27.0 ± 0.5 63.8 ± 0.6 0.39 ± 0.05 23b -26.0 ± 0.1 69.8 ± 0.7 0.7 ± 0.1 
24 -22.7 ± 0.5 66.9 ± 0.2 0.1 ± 0.05 24b -24.1 ± 0.2 72.2 ± 0.1 0.63 ± 0.03 
25 -19 ± 1 64.0 ± 0.4 0.38 ± 0.05 25b -20 ± 1 74 ± 2 1.2 ± 0.2 
26 -20 ± 2 66.6 ± 0.1 0.11 ± 0.04 26b -21 ± 2 78 ± 1 1.4 ± 0.2 
 
 
An additional important measurement of the system is the ability of the peptide to adopt its 
original folded structure following thermal denaturation. Recovery of molar elipticity at 222 nm can be 
used as a measure of the ability of the peptide to re-fold. Following thermal denaturation experiments by 
CD, the peptides were allowed to equilibrate at 20 °C for five minutes prior to measurement of elipticity 
at 222 nm. Analysis of the restoration of elipticity values suggests that all of the linear peptides (19-26) 
recover their initial helicity and thus original folded structure (Figure 24). Following oxidation and 
cyclization, peptides 19b-26b do not fully recapitulate the observed elipticity prior to thermal 
denaturation (Figure 24). Peptide 19b only regains ~65% of its initial helical signature, which suggests 
that the small, highly constrained macrocycle does not allow the peptide to re-fold. The remaining 
peptides, 20b-26b exhibit small differences but all recover ~85-90% of their initial helicity. These data 
illustrate that the highly constrained macrocycle in 19b prevents the denatured peptide backbone from full 
recovery of helical secondary structure. Larger macrocycles, as in 20b-26b, do not greatly constrain the 
denatured backbone and allow for return of helical structure. 
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Figure 24. Percent recovery of helical minimum for peptides 19-26. 
 
Thermal melt data can additionally be used to quantify the impact of the inclusion of the 
unnatural residues X and U on the stability of the coiled-coil fold. This can be done by estimation of the 
difference in free energy of folding between two peptides (ΔΔGfold). This estimate is calculated as detailed 
in section 2.4.9.2; the calculations assume that the heat capacity change associated with unfolding is the 
same for all peptides. The calculation of ΔΔGfold provides an estimation of the overall stabilization of the 
coiled-coil. However, the origin of the difference in the free energy change may arise from the 
stabilization of the folded state or from changes in the chain entropy or enthalpy in the unfolded state. 
Thus, while ΔΔGfold used here provides a quantitative estimate of stabilization of the coiled-coil due to 
cross-link formation, the physical basis for the stabilization of the fold may not be clear. 
Comparison of the linear peptides 19-26 versus the starting sequence 18 demonstrates the 
thermodynamic consequence of the insertion of unnatural monomers (Figure 25A, Table 1). Replacement 
of natural α-residues independent of cyclization is generally destabilizing, though this effect is most 
pronounced in the shortest X and U monomer pairing in peptide 19. The analogous peptide with a single 
extra methylene unit in the X side chain (20, U4, X5) is significantly less destabilized in comparison to 
peptide 19. In general, the pairing of any U residue with the shorter aminooxy functionalized X4 residue is 
more destabilizing than the same length U residue paired with the longer aminooxy functionalized X5 
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residue (e.g. peptide 21 versus 22). This suggests that the bulky, cationic U residue is not solely 
responsible for destabilization of the linear peptide sequence in 19-26. Interestingly, the monomer pairing 
in peptide 22 is slightly stabilizing to the coiled-coil fold, suggesting that this pairing may reduce or 
eliminate unfavorable interactions and/or participate in favorable interactions with local regions of the 
folded protein. 
 
 
 
Figure 25. Thermodynamic impact of unnatural monomer insertion and cross-link formation. 
(A) Change in folding free energy (ΔΔGfold) for linear peptides 19-26 versus model sequence 18. 
(B) Change in folding free energy (ΔΔGfold) for linear peptides 19b-26b versus the corresponding linear 
peptide, 19-26. Error bars represent uncertainty from two independent experiments. 
 
 
The comparison of the oxidized, cyclized sequences 19b-26b to their linear counterparts, 19-26, 
allows for quantitative analysis of the thermodynamic impact of cross-link formation on the coiled-coil 
fold. Because a wide range of macrocycle sizes and connectivities are examined, this analysis can help to 
establish basic structural requirements for an oxime side chain cross-link to effectively stabilize the 
coiled-coil. This comparison suggests that macrocycle size is a key parameter in determining the extent of 
stabilization of the coiled-coil fold (Figure 25B, Table 1). Additionally, differing connectivity within a 
single macrocycle size (e.g. peptide 23 versus peptide 22) leads to different degrees of stabilization. Of 
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note is the stability imparted by the 23-membered macrocycle in 22b, when compared to the closely 
analogous macrocycle in 23b. Peptide 26b is also found to form a particularly stable coiled-coil fold. 
Overall, this data set suggests that certain macrocycles may participate in particularly favorable 
interactions, and/or have particularly favorable ring torsional angles, that contribute to stabilization of the 
coiled-coil. 
Overall, the CD and thermodynamic analysis suggests that certain macrocycles are particularly 
favorable to the stability of the GCN4-p1 coiled-coil. This is supported by the minimal decrease in 
helicity observed in CD scans and the considerable degree of increased resistance to thermal denaturation 
observed after cross-link formation.  
2.2.3  High-Resolution Structural Analysis Of The Optimal Oxime Cross-Link 
Among the eight macrocycle sizes and connectivities examined in peptides 19-26, the oxime side chain 
cross-link resulting from an i→i+4 spacing of U5 and X5 monomers was optimal for stabilizing the 
coiled-coil quaternary fold.  We applied X-ray crystallography to determine the high-resolution structure 
of both linear and cyclized peptides containing this monomer pairing. These experiments allowed for 
determination of what, if any, impact on the coiled-coil fold results from unnatural residue substitution in 
the linear precursor and cross-link formation in the cyclic product. 
 We obtained crystals of linear species 22 by hanging drop vapor diffusion and the structure was 
solved to 2.3 Å resolution (Figure 26A). The dimeric coiled coil is virtually identical to that of the native 
GCN4-p1 sequence from a previously published crystal structure (C RMSD = 0.30 Å compared to PDB: 
2ZTA).
92
 The U5 and X5 residues are accommodated into the helical fold without any local disruption. 
Fraying of the N-terminus past the unnatural residues is not observed in the crystal structure; however, 
this does not necessarily bear on the dynamics of the coiled-coil in solution, where N-terminal fraying 
may be responsible for the observed decrease in helical CD signature at 222 nm.  Similar to other 
conformationally flexible side chains in solvent-exposed positions in the crystal structure, the unnatural 
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side chains were not well resolved in electron density. This observation likely indicates that the U5 and X5 
residues lack defined polar contacts that constrain their conformational flexibility. 
 
 
Figure 26. Crystal structures of peptides 22 and 22b. 
(A) Crystal structure of linear peptide 22. (B) Crystal structure of cyclized peptide 22b. (C) 
Overlay of the four independent chains of 22b in the crystallographic asymmetric unit. Both E and Z 
stereoisomers are observed. (D) A polar contact between Gln4 and the glyoxyl oxime carbonyl oxygen 
observed in one of the four chains of 22b. 
 
 Given the solvent-accessible nature of the unnatural residues as well as their proximity to solvent 
channels in the crystal lattice, we hypothesized that the U5 and X5 side chains could be chemoselectively 
cyclized in the crystal. Soaking crystals of linear peptide 22 with buffer supplemented with periodate led 
to the formation of cyclized peptide 22b without disruption of the fold or crystal packing. The ability to 
generate the oxime cross-link in the fragile crystal lattice underscores the mild and chemoselective nature 
of the cross-linking chemistry. The resulting crystal structure of oligomer 22b was refined to 2.3 Å 
resolution and shows a coiled-coil fold almost identical to its linear counterpart (C RMSD = 0.25 Å) 
(Figure 26B). The crystallographic asymmetric unit, unlike that of 22, contains four independent peptide 
chains in two dimeric coiled-coils due to the loss of a crystallographic 2-fold symmetry axis. This 
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serendipitous outcome allowed for examination of the oxime cross-links in different chemical 
environments. Although the electron density of the cross-linked residues is not as well-defined as side-
chains involved in direct packing interactions, sufficient electron density is visible in the refined structure 
to allow for structural analysis of the cross-links themselves. Overlay of the oxime cross-links found in 
each of the independent chains shows several side-chain conformations, including both E and Z oxime 
stereoisomers, are accommodated into the helical fold (Figure 26C). The presence of multiple 
conformations and stereoisomers likely accounts for the modest electron density observed for the cross-
linked side chains. In one of the four chains containing the oxime cross-links, a potentially stabilizing 
polar interaction was observed between the carbonyl oxygen of the glyoxyl oxime and the side chain of 
Gln4 (Figure 25D). This finding suggests that the oxime cross-link itself can participate in stabilizing 
polar interactions with nearby side-chains. 
2.2.4  Cross-Link Structure And Sequence Position In An Α-Helical Coiled Coil 
In order to more fully investigate the structural factors of importance in the use of oxime side-chain cross 
links, we investigated additional sequences based on GCN4-p1. One subset of these sequences is 
regioisomers of previously described cross-links, and a second subset consists of a single cross-link 
moved to different sequence positions along the backbone. Each of these sets of peptides provides 
valuable information regarding the ability to stabilize a coiled-coil fold and how the stabilization depends 
on the sequence environment into which the unnatural X and U residues are substituted for natural α-
residues. 
2.2.4.1 Regioisomers Of Previously Utilized Cross-Links 
 
Peptides 27-30 are regioisomers of sequences 20, 22, 24 and 26, where the X and U residues are swapped. 
Each of these peptides has an X5 residue at position 7 (rather than position 11), and a serine-acylated 
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residue (U4-U7) at position 11 (Figure 27). Biophysical characterization of these regioisomer linear 
sequences and their cross-linked counterparts, as in peptides 19-26, provides valuable information about 
the importance of sequence position which can be applied in the design of oxime cross-links. 
 
 
Figure 27. Sequences of peptides 27-30. 
  
 Analysis of CD scans of peptides 27-30 shows that switching positions of the unnatural residues 
does not eliminate the mild disruption of the helical folding pattern observed previously (Figure 28). The 
detrimental impact on helicity is again most pronounced for the shortest side chains utilized (e.g. U4 in 27, 
U5 in 28). Interestingly, the decrease of the helical signature is diminished considerably in peptides 29 and 
30 compared to 27 and 28 or their regioisomer counterparts, 24 and 26. We hypothesized that the trend 
observed in peptides 27-30 may be due to the introduction of an unfavorable electrostatic interaction 
between the cationic U residue at position 11 and Lys15. This electrostatic interaction may be ameliorated 
in longer side chain lengths (e.g. 29 and 30) where increased flexibility and solvation of the U residue 
allows it to avoid the unfavorable repulsion between adjacent positive charges. 
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Figure 28. Helical signature by CD at 222 nm for peptides 27-30. 
All peptides are measured at 100 µM peptide in 0.1 M phosphate buffer at pH 7, with (dark grey) 
or without (light grey) 100 µM sodium periodate. Error bars represent the standard deviation of two 
independent experiments. 
 
 
Thermal melts of peptides 27-30 show that swapping the X and U residue positions decreases the 
thermal stability of the resulting coiled-coil (Figure 29). Generally, the shorter U residues at position 11 
are less well tolerated than the longer U residues, as illustrated by higher thermal melting temperatures for 
peptides 29 and 30 versus 27 and 28 (Figure 29, Table 2). This trend further supports the hypothesis that 
the introduction of the U residue at position 11 may create an unfavorable ionic interaction that is reduced 
in longer side chains. Formation of the cross-linked macrocycle is found to stabilize the coiled-coil fold, 
with a dependence on the structure of the oxime cross-link formed.  
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Figure 29. CD melts of peptides 18 and 27-30. 
(A) CD melts of peptides 18 and 27-30 prior to addition of NaIO4. (B) CD melts of peptides 18 
and 27b-30b after addition of NaIO4 
 
 
Table 2. Data from CD and thermodynamic analysis for peptides 27-30. 
Peptide 
[θ]222 (deg 
cm
2
 dmol
-1
 
res
-1
) 
Tm (°C) 
ΔΔGfold # vs. 
18 (kcal  
mol
-1
) 
Peptide 
[θ]222 (deg 
cm
2
 dmol
-1
 
res
-1
) 
Tm (°C) 
ΔΔGfold #b 
vs. # (kcal 
mol
-1
) 
18 -33.8 ± 0.4 67.0 ± 0.6      
27 -25 ± 2 60.7 ± 0.1 0.83 ± 0.04 27b -24.9 ± 0.9 65.6 ± 0.3 -0.59 ± 0.04 
28 -20 ± 1 64.8 ± 0.1 0.32 ± 0.02 28b -20.3 ± 0.1 68.6 ± 0.3 -0.45 ± 0.04 
29 -24 ± 2 66 ± 1 0.02 ± 0.01 29b -24 ± 2 74 ± 2 -0.9 ± 0.3 
30 -27.4 ± 0.3 67.9 ± 0.9 -0.09 ± 0.05 30b -28 ± 1 73.6 ± 0.0 -0.7 ± 0.1 
 
Quantitative analysis of the thermodynamic impact of unnatural residue replacement in peptides 
27-30 illustrates that insertion of the unnatural residues at position 7 for X and 11 for U is generally 
destabilizing to the coiled-coil fold. This is not observed when the longest U residue is utilized as in 
peptide 30 (Figure 30A). However, amongst this smaller data set there is a clear trend which suggests that 
the shorter monomer combinations are destabilizing to the coiled-coil fold. This effect is reduced as the 
monomer length increases. Formation of the macrocycle is stabilizing to the coiled-coil fold to a similar 
degree in all cases with the exception of peptide 29 (Figure 30B). The 24-membered macrocycle 
generated in peptide 29 is found to be most favorable. The macrocycle formed in peptide 29b is one 
methylene unit larger than the optimal size formed in peptides 19-26, where the positions of X and U 
residues are swapped. 
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Figure 30. Thermodynamic data for peptides 27-30. 
(A) Change in folding free energy (ΔΔGfold) for linear peptides 27-30 versus model sequence 18. 
(B) Change in folding free energy (ΔΔGfold) for linear peptides 27b-30b versus the corresponding linear 
peptide, 27-30. Error bars represent the standard deviation of two independent experiments. 
 
 
In total, the CD and thermodynamic data for sequences 27-30 suggest that the particular 
substitution pattern of X and U residues affect both the folding and stability of the coiled-coil. This is 
somewhat surprising, given the previous examination of multiple macrocycle sizes and connectivities in 
peptides 19-26. Switching of the X and U residues was not expected to have a significant impact on the 
stabilization of the coiled-coil fold. However, it is possible that the differences in 27-30 versus 19-26 
result primarily from the introduction of unfavorable ionic interactions between U residues at position 11 
and Lys15. This underlines the necessity for judicious choice of monomer substitution pattern in order to 
maintain the native folded state and thermodynamic stability. 
2.2.4.2 Sequence Positional Effects Of Residue Placement 
 
As an additional gauge of the structural factors that are important in the introduction of oxime side chain 
cross-links, we generated sequences (31-33) which change the position of residue insertion along the 
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backbone of GCN4-p1 (Figure 31). Each sequence thus represents the movement of the same pairing of 
unnatural residues, U5 and X5, along one heptad repeat of the sequence from the N-terminus towards the 
C-terminus. 
 
 
Figure 31. Sequences of peptides 18, 22, and 31-33. 
 
Peptides 22 and 31-33 show similar helical signatures by CD, which indicates that the inclusion 
of the U5 and X5 residues at varying backbone positions does not significantly distort the helical structure 
(Figure 32). Of particular note is that the substitution of residues U5 and X5 at positions 14 and 18, 
respectively, in peptide 31 does not significantly alter the secondary structure versus control sequence 18. 
This suggests that oxime side chain cross-links can be used in a number of sequence positions. In 
addition, the inclusion of the unnatural residues far from the termini decreases the negative impact on 
helicity attributed to fraying towards the termini. 
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Figure 32. Helical signature by CD at 222 nm for peptides 22 and 31-33. 
All peptides are measured at 100 µM peptide in 0.1 M phosphate buffer at pH 7, with (dark grey) 
or without (light grey) 100 µM sodium periodate. Error bars represent the standard deviation of two two 
independent experiments. 
 
 
Thermal melts of peptide 22 and 31-33 reveal modest differences in the thermal stability of the 
linear sequences as the position of the unnatural residues changes along the backbone (Figure 33). Upon 
cross-link formation, peptides 22b, 31b, and 33b are found to increase in thermal stability. Peptide 32b, 
in contrast to all other sequences studied, decreases in thermal stability slightly upon formation of the 
cross-link (ΔTm = -3.6 °C). Overall, the CD results show that cross-links at different positions along the 
backbone are well-accommodated into the helical fold with minimal disruption of the coiled-coil. 
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Figure 33. CD melts of peptides 18, 22 and 31-33. 
(A) CD melts of peptides 18, 22 and 31-33 prior to addition of NaIO4. (B) CD melts of peptides 
18, 22b and 31b-33b after addition of NaIO4 
 
 
Table 3. Circular dichroism data for peptides 31-33. 
Peptide 
[θ]222 (deg 
cm
2
 dmol
-1
 
res
-1
) 
Tm (°C) 
ΔΔGfold #b 
vs. 18 (kcal 
mol
-1
) 
Peptide 
[θ]222 (deg 
cm
2
 dmol
-1
 
res
-1
) 
Tm (°C) 
ΔΔGfold #b 
vs. # (kcal 
mol
-1
) 
18 -33.8 ± 0.4 67.0 ± 0.6      
31 -31.7 ± 0.6 73.3 ± 0.9 -0.71 ± 0.04 31b -32.4 ± 0.4 80.9 ± 0.6 -0.90 ± 0.04 
32 -28 ± 1 72 ± 1 -0.66 ± 0.04 32b -28 ± 2 69.4 ± 0.8 0.43 ± 0.03 
33 -26 ± 1 64.4 ± 0.9 0.65 ± 0.05 33b -26 ± 1 72.6 ± 0.8 -0.77 ± 0.07 
 
 
Comparison of the linear peptides 22 and 31-33 to peptide 18 shows that the insertion of 
unnatural residues U5 and X5 is mildly stabilizing to the coiled-coil fold in most sequence positions 
(Figure 33, Table 3). This trend does not hold for substitution very close to the C-terminus, as in peptide 
33. However, this region of the coiled-coil is known to be relatively unstructured from crystallographic 
analysis.
92
 Insertion of the unnatural residues near the C-terminus may increase the unstructured nature of 
the C-terminal region, leading to an unfavorable change in the folded structure. Analyses of peptide 22b 
along with peptides 31b-33b compared to their linear counterparts, 22 and 31-33 show that the cross-links 
stabilize the coiled coil when placed at most positions in the primary sequence. The destabilization 
observed for peptide 32b may be attributable to the loss of a favorable polar interaction. In the wild-type 
 57 
GCN4-p1 crystal structure, Arg25 is observed to have a polar contact with Glu21. Replacement of Arg25 
with the unnatural X5 residue can maintain this polar contact, as the X5 residue can act as a hydrogen 
bond donor although it is not charged at pH 7. Upon formation of the cross-link, the hydrogen bond donor 
capability of the X5 side chain is lost, and the side chain is sequestered in the cross-linked macrocycle, 
leading to the loss of the favorable polar contact.  
 
 
 
Figure 34. Thermodynamic data for peptides 22 and 31-33. 
(A) Change in folding free energy (ΔΔGfold) for linear peptides 22 and 31-33 versus model 
sequence 18. (B) Change in folding free energy (ΔΔGfold) for linear peptides 22b and 31b-33b versus the 
corresponding linear peptide, 22 or 31-33. Error bars are the uncertainty from two independent 
experiments. 
 
 
As discussed for peptides 27-30, the overall data obtained for peptides 22 and 31-33 argues for 
judicious replacement of natural residues with the unnatural residues used to form oxime side chain cross-
links. The series of peptides 19-33 suggests a few general rules for the introduction of oxime side chain 
cross-links into helical sequences. First, sequence positions should be chosen where the unnatural 
residues will not introduce unfavorable electrostatic interactions (e.g., the proposed interaction between U 
at residue 11 and Lys15). Second, cross-link formation may actually remove a favorable polar contact if 
the residues are placed in positions where side-chain to side-chain hydrogen bonds are likely. Third, the 
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unnatural residue replacement may introduce fraying at the termini of helices, and thus optimal 
positioning may be in the middle of a helical region in order to minimize disruption of the fold. 
2.2.5  Folding-Templated Synthesis Of A Multiply Cross-Linked Oligomer 
Based on the results described above, we hypothesized that chemoselective oxime cross-links could prove 
useful for the folding-templated synthesis of a more complex polycyclic species under benign buffered 
conditions. X-ray structural analysis of 22 and 22b showed that the coiled-coil fold is relatively 
unchanged upon cross-link formation. Thus, it is possible that the folded state at the time of cross-link 
formation will dictate the product distribution for a sequence where many cross-linked products are 
possible. In order to test this hypothesis, we generated peptide 34 which combines the unnatural residue 
insertions from sequences 22 and 30. Sequence 34 contains two U5 residues and two X5 residues in an i, 
i+4, i+7, i+11 arrangement (Figure 35A). 
After addition of periodate and unmasking of two aldehydes from the U5 residues in 34, the 
resulting linear species can establish an equilibrium between a range of cross-linked products (Figure 
35B). These cross-linked products can potentially include a single cross-link (34b), of which there are 
four possible regioisomers and eight total possible products accounting for E and Z isomers of the oxime. 
Two possible regioisomeric products may result with two cross-links (34c), each of which has four 
possible stereoisomers, resulting in eight total possible doubly cross-linked species. Overall, this single 
oligomer can potentially have sixteen products, accounting for stereochemistry. 
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Figure 35. Sequence of peptide 34 and potential cross-linked products. 
(A) Sequences of peptides 18, 22, 31, and 34. (B) Schematic representation of cross-link 
formation and the possible products that result as monocyclic or bicyclic species. 
 
   
Treatment of peptide 34 with a slight excess of sodium periodate in pH 7 phosphate buffer leads 
to complete consumption of the starting material in a matter of minutes, as was observed for the other 
coiled-coil peptides. The distribution of products obtained is considerably simpler than one would expect 
from a statistical mixture of all of the possible products. The majority of the material (~80-85%) observed 
by HPLC was found in two peaks and had a mass corresponding to a doubly cross-linked product by 
MALDI-TOF MS (isomers of 34c, Figure 36). The remaining material is distributed over several peaks 
with masses corresponding to singly cross-linked species (34b) or doubly cross-linked species (34c). No 
evidence was observed by MS of the mixture for products resulting from the intermolecular cross-linking 
of two or more peptide chains. 
 60 
 
 
Figure 36. HPLC chromatograms of peptide 34 with and without added NaIO4. 
 
CD measurements of peptide 34 both prior to addition of periodate and after cyclization shows a 
similar helical signature to peptide 22 on which its design is based (Figure 37, Table 1). After periodate 
addition, the collective mixture of cross-linked products shows an overall CD signature nearly identical to 
the linear precursor (Figure 37A). This observation argues against the formation of significant amounts of 
oxime cross-linked products incompatible with a helical fold. The potential products containing an i→ 
i+11 or i→ i+3 cross-links would lead to destabilization of the helix. Biophysical characterization 
suggests that the major products observed by HPLC correspond to partially resolvable stereoisomers of 
the bicyclic oligomer containing two i→ i+4 cross-links which are compatible with the coiled-coil. 
In temperature-dependent CD analysis, the linear precursor 34 showed slightly greater thermal 
stability than either 22 or 31 (Tm = 78.0 ± 0.1 °C), upon which it is based; the origin of this stabilization is 
not clear (Figure 37B). Upon formation of the cross-links, the resulting mixture (primarily composed of 
34c) does not show a complete unfolding transition up to 95 °C, the highest temperature tested in the 
experiment. The apparent Tm is greater than 90 °C, and the thermal transition is no longer cooperative, 
instead showing almost linear temperature dependence. 
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Figure 37. CD Data for peptide 34. 
All peptides are measured at 100 µM peptide in 0.1 M phosphate buffer at pH 7, with (dashed) or 
without (solid) 210 µM sodium periodate.  
 
 
The above data suggest that the product distribution of cross-linked oligomers can be influenced 
by the folded state of the peptide at the time of cross-link formation. In order to test this hypothesis 
directly, an oxidation/cyclization reaction was carried out at a temperature (80 °C) where peptide 34 is 
approximately 50% unfolded by CD analysis. Upon addition of periodate and equilibration for an 
additional 10 minutes at 80 °C, the distribution of products observed by HPLC is considerably different 
than observed during identical oxidation reactions performed at room temperature (Figure 38). The two 
major peaks previously assigned as species 34c change in ratio and several new peaks are observed with 
masses corresponding to other isomers of 34c. The sensitivity of the product distribution obtained from 
34 to its folded state prior to oxidation and cross-linking demonstrates the potential application of 
triggered oxime formation to identify cross-linked topologies best able to stabilize a particular fold. 
Though here the fold desired was known a priori, in principle this technique could be applied to a case in 
which the folded state is not known (e.g. a peptide ligand bound to its receptor). 
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Figure 38. HPLC chromatograms of oxidation reactions of peptide 34. 
Each sample contained 100 µM peptide 34 in 0.1 M phosphate buffer with 210 µM NaIO4 added 
at either 20 °C (bottom) or 80 °C (top). 
 
2.2.6  Conclusions 
In summary, oxime side chain cross-linking through chemoselective reaction between aminooxy- and 
aldehyde-functionalized amino acids can be utilized to enhance quaternary structure stability of a coiled-
coil protein. Triggered unmasking of glyoxyl aldehydes in situ and subsequent oxime cross-linking 
proceeds rapidly and cleanly in pH 7 buffered aqueous solution with a folded protein substrate. A series 
of sequence variants of the GCN4-p1 dimeric coiled coil with different oxime structures (both macrocycle 
size and connectivity) placed towards the N-terminus were examined. Additional sequence positions were 
tested where the cross-linked residues are placed along the solvent-exposed face of the coiled-coil. 
Quantitative comparison of folding thermodynamics show that oxime cross-links are consistently 
stabilizing to the quaternary structure with the caveat that residues involved in polar contacts should not 
be replaced. The extent of stabilization is sensitive to the size, structure, and sequence position of the 
resulting cross-links. Examination of eight different cross links of varying macrocycle size and 
connectivity led to the identification if an ideal 23-membered macrocycle resulting from pairing a U5 and 
X5 residue at an i→i+4 residue spacing. X-ray crystallographic analysis of this linear precursor (22) and 
its corresponding cross-linked product (22b) show how the cross-links are accommodated into the helix. 
 63 
The ability to form the cross-link in a protein crystal lattice underscores the mild and chemoselective 
nature of the cross-linking chemistry. 
A series of regioisomers in which the sequence positions of X and U residues are flipped and in 
which the residues are moved along the sequence were also analyzed. These peptides (27-33) demonstrate 
the importance of maintaining native side chain functionality where polar contacts are involved. 
Unfavorable electrostatic interactions may be introduced by substitution of the bulky, cationic U residue, 
and care must be taken in substitution choice to avoid this. Introduction of unnatural residues at sequence 
positions involved in favorable polar contacts was found to be destabilizing to the coiled-coil fold. 
Amongst the sequences bearing oxime cross-links, cyclization is almost universally stabilizing to the 
coiled-coil fold, with the exception of sequence 32. In this case, the decrease in stability may be attributed 
to loss of a favorable polar contact upon cyclization. The disruption of the helical fold by introduction of 
unnatural U and X residues near the N-terminus or C-terminus is minimized by insertion of the unnatural 
residues in the middle of the peptide sequence.  
Interpretation of the biophysical data is complicated somewhat by the fact that helix formation is 
coupled to self-assembly to form the coiled coil in GCN4-p1. Incorporation of the unnatural residues U 
and X near the termini slightly decreases helicity of linear precursor sequences, yet these peptides still 
show clear fully folded baselines in CD thermal denaturation experiments. This behavior has been 
reported previously upon mutations to the GCN4-p1 N-terminus,
100
 and may be attributed to the fraying 
of the helix in the folded coiled coil. The fact that moving the unnatural residues toward the middle of the 
sequence, as in peptide 31, ameliorates the decrease in helicity supports this hypothesis. The formation of 
oxime cross-links in GCN4-p1 is stabilizing to the coiled-coil but does not alter the helicity of the folded 
state. While surprising, this result does not inherently negate the use of oxime cross-links for the 
stabilization of bioactive helical folds. In prior applications of cross-linking towards stabilizing bioactive 
conformations, the motivation for cross-linking is not necessarily to generate maximally helical peptides 
but rather to stabilize the bound peptide-receptor complex. In many cases, these goals are aligned and the 
more helical peptide is also the most potent inhibitor; however, this is not always the case. In the GCN4-
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p1 system, the stability of the coiled-coil can be viewed as the best measure of the ability of oxime cross-
links to stabilize a helical fold in a protein-protein complex. 
Triggered oxime formation can be used to selectively form cross-links that stabilize a particular 
folded conformation in a quaternary structure context. This was demonstrated by use of an oligomer 
capable of forming bicyclic products (peptide 34). This oligomer contained unnatural residues at four 
sequence positions; triggered unmasking of glyoxyl aldehydes and subsequent oxime cyclization proceeds 
cleanly under buffered aqueous conditions. A single cross-linked topology was favored out of many 
possible, and this resulting bicyclic oligomer was highly resistant to thermal denaturation. The 
distribution of products obtained is altered by formation of the cross-links under conditions where the 
coiled-coil fold is partially disrupted. Collectively, these data suggest that triggered oxime formation can 
be utilized to trap and stabilize a particular peptide fold in its bound state. 
2.3 SUMMARY OF INTRAMOLECULAR OXIME CROSS-LINK FORMATION 
The use of oxidative unmasking of aldehydes from unnatural 1,2-aminoalcohol functionalized side chains 
and subsequent chemoselective reaction with aminooxy-functionalized residues to form oxime side chain 
cross-links in an intramolecular fashion has been investigated in two systems.  
 The first system is a short α-helix of limited sequence diversity. In this context, oxime side chain 
cross-links are formed rapidly and in high yield under benign buffered aqueous conditions. The resulting 
cross-links are formed as a mixture of E- and Z-oxime isomers, which are capable of interconverting at 
neutral pH and isomerize more rapidly under acidic conditions. The resulting cyclic oxime can undergo 
dynamic covalent exchange to form a linear oxime species, which suggests the applicability of oxime 
cross-links in peptide-based dynamic covalent chemistry. Oxime cross-links are found to be capable of 
enhancing helical folding with a strong dependence on the structure of the cross-links generated. Smaller 
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macrocycle sizes formed by oxime cyclization appear to be poorly accommodated into the helical fold, 
suggesting that an i→i+4 spacing of U and X residues is required to stabilize a helix.  
Data from the second model system, based on the α-helical coiled coil GCN4-p1, demonstrates 
the utility of oxime side chain cross-links in stabilizing a protein-protein complex. Amongst a range of 
structural variants containing a single cross-link, an optimal side chain pairing was identified and a high-
resolution structure of the oligomer in both linear and cyclized forms obtained. This structure 
demonstrates the compatibility of oxime cross-links with an α-helical fold. A further survey of 
regioisomers suggests some basic rules for the introduction of oxime cross-links into helical sequences. 
Positions for substitution with unnatural residues should be chosen which do not introduce potentially 
unfavorable ionic interactions and/or remove stabilizing polar interactions present in the natural sequence. 
Amongst the large number of oxime cross-links examined (a total of 15 different monocyclic oligomers), 
the cross-links are generally well-accomodated and stabilizing to the coiled-coil fold. The synthesis of a 
bicyclic oligomer demonstrates the potential applicability of oxime cross-links to trap a bioactive fold 
under conditions where a peptide is bound to a protein receptor. 
In summary, intramolecular peptide cross-linking via oxime formation is a viable and attractive 
method to control peptide folding in aqueous buffered solution. Intramolecular oxime cross-links can 
stabilize helical folds and protein quaternary structures. The observation that dynamic covalent exchange 
is severely limited in cases where intramolecular oxime cross-links are employed suggests that 
applications of this technology in the context of dynamic covalent chemistry are limited. The future 
implementation of this type of cross-linking strategy for applications in DCC may be possible by utilizing 
hydrazone formation rather than oxime formation, as hydrazones are more hydrolytically labile than 
oximes.  
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2.4 EXPERIMENTAL 
2.4.1  General Information 
Solvents and all other reagents were purchased from Sigma Aldrich, Baker, EMD, Fisher, Acros 
Organics, or TCI and used as received unless otherwise specified. Cbz-Asp-OBn, Cbz-Glu-OBn, 2-
chlorotrityl chloride, Boc-Ser(tBu)-OH, Fmoc-Dap-OH, Fmoc-Dab-OH, Fmoc-Orn-OH hydrochloride, 
and Fmoc-Lys-OH were purchased from Chem-Impex. 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium hexafluorophosphate (HCTU), (benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyBOP), NovaPEG Rink Amide Resin, 9-fluorenylmethyoxycarbonyl-N-
hydroxysuccinimide (Fmoc-OSu), and Fmoc-protected-amino acids were purchased from 
NovaBiochem and used as received. Flash column chromatography was performed using Silicycle 
SiliaFlash P60 (230-400 mesh) or SorbTech (60 Å, 40-63 µm) silica gel. Optical rotations were measured 
on a Perkin-Elmer 241 digital polarimeter with a sodium lamp at ambient temperature. NMR spectra were 
recorded on Bruker Avance-400 or Bruker Avance-300 spectrometers. MALDI-TOF mass spectrometry 
was carried out on a Voyager DE Pro instrument. Circular dichroism spectra were recorded on an Olis 
DSM17 Circular Dichroism Spectrometer using quartz cuvettes of 0.2 cm or 0.1 cm path length. 
Preparative and analytical HPLC were performed with Phenomenex Luna C18 columns.  
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2.4.2  Aminooxy-Functionalized Monomer Synthesis 
Fmoc-protected aminooxy monomers 12a and 12b were synthesized by adaptation of a previously 
reported procedure shown in Scheme 2.1 and as described below.
84
 
 
Standard Procedure A. Reduction of Carboxylic Acids:
85
 The carboxylic acid (Cbz-Asp-OBn, 7a or 
Cbz-Glu-OBn, 7b, 1.0 equiv) was dissolved in anhydrous tetrahydrofuran and cooled to −15 °C under 
nitrogen. Triethylamine (1.1 equiv) was added, followed by isobutylchloroformate (1.1 equiv). The 
reaction was stirred 10-15 minutes, then sodium borohydride (3.0 equiv) dissolved in water was added 
slowly. The reaction was stirred 20-30 minutes until vigorous bubbling ceased and the reaction vessel 
poured into water. The solution was then extracted three times with ethyl acetate. The organic layers were 
combined, washed with brine, dried over anhydrous magnesium sulfate, and concentrated. Silica gel 
chromatography (25%→50% ethyl acetate in hexanes) afforded the corresponding alcohols 8a and 8b. 
 
benzyl ((benzyloxy)carbonyl)-L-homoserinate (8a): Standard procedure A was 
employed using Cbz-Asp-OBn (1.99 g, 5.59 mmol) (7a) in 15 mL THF with 
triethylamine (858 µL, 6.16 mmol) and isobutyl chloroformate (798 µL, 6.16 mmol). 
Sodium borohydride (634 mg, 16.8 mmol) was used in 5.0 mL of water. Product 8a was isolated as a 
white solid (1.51 g, 4.42 mmol, 79.1% yield). [α]D = +0.6 (c = 1, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ = 
7.36 (10H, m) 5.67 (1H, d, J = 7.4 Hz), 5.16 (4H, m), 4.60 (1H, m), 3.68 (2H, m), 2.76 (1H, br s), 2.19 
(1H, m), 1.71 (1H, m); 
13
C NMR (100 MHz, CDCl3) δ = 172.47, 156.88, 136.12, 135.23, 128.74, 128.67, 
128.38, 128.25, 67.48, 67.38, 58.43, 51.45, 35.65; HRMS m/z calculated for C19H21NO5Na [M+Na]
+
: 
366.1317; found: 366.1322 
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benzyl (S)-2-(((benzyloxy)carbonyl)amino)-5-hydroxypentanoate (8b): Standard 
procedure A was employed using Cbz-Glu-OBn (1.99g, 5.53 mmol) (7a) in 15 mL THF 
with  triethylamine (847 µL, 6.08 mmol) and isobutyl chloroformate (788 μL, 6.08 
mmol). Sodium borohydride (628 mg, 16.6 mmol) was used in 5 mL of water. Product 
8b was isolated as a white solid (1.61 g, 4.49 mmol, 81.2%). [α]D = −1.9 (c = 1.0, CHCl3). 
1
H NMR (400 
MHz, CDCl3) δ = 7.35 (10H, m), 5.48 (1H, d, J = 8.0 Hz), 5.17 (2H, m), 5.10 (2H, s) 4.47 (1H, m), 3.62 
(2H, t, J = 5.7 Hz), 1.95 (1H, m), 1.78 (1H, m), 1.56 (3H, m); 
13
C NMR (100 MHz, CDCl3) δ = 172.40, 
156.17, 136.30, 135.36, 128.71, 128.61, 128.51, 128.40, 128.26, 128.18, 67.27, 67.10, 61.99, 53.77, 
29.29, 28.18; HRMS m/z calculated for C20H23NO5Na [M+Na]
+
: 380.1474; found: 380.1477. 
Standard Procedure B. Mesylation:
84
 The primary alcohol (8a or 8b, 1.0 equiv) was dissolved in 
anhydrous dichloromethane and cooled to 0 °C under nitrogen. Triethylamine (1.5 equiv) was added and 
the solution stirred 15 minutes. Methanesulfonyl chloride (1.2 equiv) was added and the reaction stirred 
for 1-1.5 hours at 0 °C. The reaction was then diluted with additional dichloromethane and washed twice 
with brine. The organic layer was dried over magnesium sulfate and concentrated. The resulting mesylate 
(isolated as a yellow oil) was used directly in the next step without further purification. 
benzyl N-((benzyloxy)carbonyl)-O-(methylsulfonyl)-L-homoserinate (9a): Standard 
procedure B was employed using compound 8a (1.41 g, 4.11 mmol) in 10 mL 
dichloromethane, triethylamine (858 µL, 6.16 mmol) and methanesulfonyl chloride (383 
µL, 4.93 mmol). Product 9a was isolated as a yellow oil (1.62 g, 3.85 mmol, 93.7%). [α]D = +3.8 (c = 1.0, 
CHCl3). 
1
H NMR (400 MHz, CDCl3) δ = 7.38 (10H, m), 5.61 (1H, d, J = 7.5 Hz), 5.20 (2H, s), 5.13 (2H, 
s), 4.57 (1H, m), 4.29 (2H, m), 2.92 (3H, s), 2.38 (1H, m), 2.19 (1H, m); 
13
C NMR (100 MHz, CDCl3) δ = 
171.34, 155.99, 136.11, 135.01, 128.76, 128.64, 128.50, 128.35, 128.19, 67.74, 67.25, 65.75, 50.97, 
45.85, 37.13, 31.79. 
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benzyl (S)-2-(((benzyloxy)carbonyl)amino)-5-((methylsulfonyl)oxy)pentanoate (9b): 
Standard procedure B was employed using compound 8b (1.55 g, 4.33 mmol) in 10 mL 
dichloromethane, triethylamine (905 µL, 6.49 mmol) and methanesulfonyl chloride (404 
µL, 5.19 mmol). Product 9b was isolated as a yellow oil with a small amount of residual 
dichloromethane and triethylamine (1.85 g, 4.24 mmol, 97.9%). [α]D = +0.6
 
(c = 1, CHCl3). 
1
H NMR 
(300MHz, CDCl3) δ = 7.36 (10H, m), 5.40 (1H, d, J = 7.7 Hz), 5.19 (2H, br s), 5.11 (2H, s), 4.46 (1H, m), 
4.20 (2H, t, J = 5.5 Hz), 2.00 (1H, m), 1.79 (3H, m). 
Standard Procedure C. Installation of Pthalimide:
84
 N-hydroxyphthalimide (2.0 equiv) was dissolved 
in anhydrous dimethylformamide and cooled to 0 °C on an ice bath under nitrogen. 1,8-
Diazabicyclo[5.4.0]undec-7-ene (DBU) (2.0 equiv) was added and the solution stirred for 20 minutes at 0 
°C. The mesylate  9a or 9b (1.0 equiv) was dissolved in anhydrous DMF and added to the reaction via 
syringe. The reaction was allowed to warm to room temperature and stirred for two days. Following this 
time, the reaction was diluted with ethyl acetate, washed twice with water, twice with saturated sodium 
carbonate, and twice with brine. The organic layer was dried over magnesium sulfate and concentrated. 
When necessary, the resulting oil was purified by silica gel chromatography (20%→25% ethyl acetate in 
hexanes). 
benzyl N-((benzyloxy)carbonyl)-O-(1,3-dioxoisoindolin-2-yl)-L-homoserinate 
(10a):  Standard procedure C was employed with N-hydroxypthalimide (1.26 g, 7.72 
mmol) in 7 mL anhydrous DMF with DBU (1.15 mL, 7.72 mmol) The mesylate 9a 
(1.62 g, 3.85 mmol) was added in 10 mL anhydrous DMF. Product 10a was isolated 
as a white solid (1.05 g, 2.16 mmol, 56.1% yield). [α]D = +1.0 (c = 1.0, CHCl3). 
1
H NMR (400 MHz, 
CDCl3) δ = 7.79 (4H, m), 7.29 (10H, m), 6.22 (1H, d, J = 8.3 Hz), 5.19 (4H, m), 4.68 (1H, m), 4.28 (2H, 
m), 2.35 (2H, q, J = 5.6 Hz); 
13
C NMR (100 MHz, CDCl3) δ = 171.49, 163.55, 156.31, 135.41, 134.72, 
128.93, 128.63, 128.58, 128.55, 128.44, 128.14, 128.09, 74.94, 67.43, 67.03, 51.68, 30.30; HRMS m/z 
calculated for C27H24N2O7Na [M+Na]
+
: 511.1481; found 511.1484. 
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benzyl       (S)-2-(((benzyloxy)carbonyl)amino)-5-((1,3-dioxoisoindolin-2-
yl)oxy)pentanoate (10b): Standard procedure C was employed with N-
hydroxypthalimide (1.38 g, 8.48 mmol) in 10 mL anhydrous DMF with DBU (1.27 mL, 
8.48 mmol) The mesylate 9b (1.85 g, 4.24 mmol) was added in 10 mL anhydrous DMF. 
Product 10b was isolated as a white solid (1.83 g, 3.65 mmol, 86.1%). [α]D = −6.8 (c = 
1.0, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ = 7.78 (4H, m), 7.34 (10H, m), 5.51 (1H, d, J = 8.2 Hz), 5.20 
(2H, s), 5.10 (2H, s), 4.49 (1H, m), 4.18 (2H, m), 2.16 (1H, m), 2.01 (1H, m), 1.80 (2H, m); 
13
C NMR 
(100 MHz, CDCl3) δ = 172.13, 163.76, 156.12, 136.39, 135.40, 134.64, 129.02, 128.74, 128.62, 128.56, 
128.40, 128.24, 128.16, 123.68, 77.58, 67.38, 67.08, 53.81, 28.96, 24.44; HRMS m/z calculated for 
C27H24N2O7Na [M+Na]
+
: 525.1638; found 525.1613. 
Standard Procedure D. Phthalimide Deprotection and Trityl Protection:
84
 The phthalimide 
compound 10a or 10b (1.0 equiv) was dissolved in anhydrous DCM and cooled to 0 °C under nitrogen. 
Methyl hydrazine (1.5 equiv) was added and the reaction stirred for 1.5 hours at 0 °C. The reaction was 
then filtered through celite, washed with dichloromethane, and concentrated. The resulting oil was used 
directly in the next step without additional purification. The intermediate (1.0 equiv) was dissolved in 
anhydrous dichloromethane under nitrogen. DIEA (2.0 equiv) was added, followed by 2-chlorotrityl 
chloride (1.5 equiv). The reaction was stirred at room temperature for 2 hours. After this time, the 
reaction was diluted with ethyl acetate, washed with water and brine, then dried over magnesium sulfate 
and concentrated. Silica gel chromatography (15%→25% ethyl acetate in hexanes) yielded the product 
11a or 11b. 
benzyl N-((benzyloxy)carbonyl)-O-(((2-chlorophenyl)diphenylmethyl)amino)-L-
homoserinate (11a): Standard procedure D was employed using 10a (871 mg, 1.78 
mmol) in 8 mL anhydrous methylene chloride with methyl hydrazine (141 μL, 2.67 
mmol). The resulting aminooxy compound (1.78 mmol) was dissolved in 8 mL 
anhydrous methylene chloride with diisopropylethylamine (620 µL, 3.56 mmol) and 2-chlorotrityl 
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chloride (836 mg, 2.67 mmol). The product was isolated as a viscous, light yellow oil (733 mg, 1.15 
mmol, 64.6% yield). [α]D = −10 (c = 1.0, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ = 7.19 (24H, m), 5.28 
(1H, d, J = 7.7 Hz), 5.09 (2H, s), 5.03 (2H, s), 4.70 (1H, s), 4.37 (1H, m), 3.81 (2H, m), 1.98 (2H, q, J = 
5.4 Hz); 
13
C NMR (100 MHz, CDCl3) δ = 171.72, 156.04, 143.11, 142.94, 140.37, 136.46, 135.56, 
133.86, 132.76, 131.64, 128.81, 128.75, 128.70, 128.59, 128.49, 128.37, 128.32, 128.24, 128.00, 127.97, 
127.18, 127.15, 126.49, 74.90, 70.46, 67.13, 66.98, 52.68, 30.51; HRMS m/z calculated for 
C38H35ClN2O5Na [M+Na]
+
: 657.2132; found: 657.2145. 
benzyl (S)-2-(((benzyloxy)carbonyl)amino)-5-((((2-
chlorophenyl)diphenylmethyl)amino)oxy)pentanoate (11b): Standard procedure 
D was employed using 10b (647 mg, 1.28 mmol) in 7 mL anhydrous methylene 
chloride with methyl hydrazine (101 μL, 1.92 mmol). The resulting aminooxy 
compound (1.28 mmol) was dissolved in 7 mL anhydrous methylene chloride with diisopropylethylamine 
(446 μL, 2.56 mmol) and 2-chlorotritylchloride (601 mg, 1.92 mmol). Product 11b was isolated as pale 
yellow oil (709 mg, 1.09 mmol, 85.2%). [α]D = +1.4 (c = 1.0, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ = 
7.29 (24H, m), 5.19 (1H, d, J = 6.2 Hz), 5.12 (2H, s), 5.09 (2H, s), 4.30 (1H, m), 3.20 (2H, t, J = 5.4 Hz), 
1.69 (1H, m), 1.48 (3H, m); 
13
C NMR (100 MHz, DMSO-d6) δ = 172.18, 156.12, 142.09, 141.05, 138.86, 
135.92, 133.36, 131.75, 131.04, 128.81, 128.38, 128.32, 128.00, 127.81, 127.73, 127.39, 126.65, 126.49, 
73.89, 71.87, 65.84, 65.47, 59.73, 53.76, 27.25, 24.50, 20.73, 14.06; HRMS m/z calculated for 
C39H37ClN2O5Na [M+Na]
+
: 671.2288; found: 671.2299. 
Standard Procedure E. Hydrogenolysis and Fmoc Protection:
84
 The fully protected compound 11a or 
11b (1.0 equiv) was dissolved in anhydrous methanol. The vessel was thoroughly flushed with nitrogen, 
and Pd/C (20 wt%) was added. The headspace of the reaction vessel was purged, and the vessel was fitted 
with a hydrogen filled balloon and stirred overnight. After this time, the reaction was filtered through 
celite, washed with methanol, and concentrated. The resulting white solid was dissolved in anhydrous 
DCM and placed under nitrogen atmosphere. DIEA (4.0 equiv) was added, followed by addition of 
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trimethylsilyl chloride (2.0 equiv). The reaction was stirred at room temperature for 15 minutes, then 
Fmoc-OSu (1.1 equiv) was added and the reaction stirred overnight under nitrogen. Following this time, 
the reaction was diluted with ethyl acetate and washed twice with brine. The resulting organic layer was 
dried over magnesium sulfate and concentrated. Silica gel chromatography (33%→100% ethyl acetate in 
hexanes) yielded product 12a or 12b. 
N-(((9H-fluoren-9-yl)methoxy)carbonyl)-O-(((2-
chlorophenyl)diphenylmethyl)amino)-L-homoserine (12a): Standard procedure E 
was used starting from compound 11a (643 mg, 1.01 mmol) in 8 mL anhydrous 
methanol with Pd/C, 20 wt% (50 mg, 8% w/w). The resulting white solid was dissolved 
in 8 mL anhydrous DCM with DIEA (703 μL, 4.04 mmol), trimethylsilyl chloride (256 µL, 2.02 mmol) 
and Fmoc-OSu (408 mg, 1.21 mmol). Product 12a was isolated as a white solid (489 mg 0.773 mmol, 
76.5%). [α]D = −2.7° (c = 1.0, CHCl3). 
1
H NMR (400 MHz, DMSO-d6) δ = 12.31 (1H, s), 7.90 (1H, d, J = 
7.5 Hz), 7.73 (1H, m), 7.58 (1H, s), 7.52 (2H, m), 7.42 (2H, m), 7.29 (17H, m), 5.03 (1H, s), 4.25 (2H, 
m), 3.90 (1H, m), 3.61 (2H, m), 1.84 (1H, m), 1.70 (1H, m); 
13
C NMR (100 MHz, DMSO-d6) δ = 173.76, 
156.01, 143.83, 142.07, 140.97, 140.72, 136.97, 133.36, 131.79, 131.09, 128.86, 128.33, 127.77, 127.47, 
127.45, 127.07, 126.74, 126.59, 125.30, 120.11, 79.18, 73.94, 69.47, 65.61, 65.40, 51.02, 46.63, 29.69; 
HRMS m/z calculated for C38H33ClN2O5Na [M+Na]
+
: 655.1976; found: 655.1963. 
(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-((((2-
chlorophenyl)diphenylmethyl)amino)oxy)pentanoic acid (12b): Standard 
procedure E was used starting from compound 11b (640 mg, 0.990 mmol) in 8 mL 
anhydrous methanol with Pd/C, 20 wt% (50 mg, 8% w/w). The resulting white solid 
was dissolved in 8 mL anhydrous DCM with DIEA (696 μL, 3.99 mmol), trimethylsilyl chloride (251 µL, 
1.98 mmol) and Fmoc-OSu (367 mg, 1.09 mmol). Product 12b was isolated as a white solid (428 mg, 
0.663 mmol, 67.0%). [α]D = +9.5° (c = 1.0, CHCl3). 
1
H NMR (400 MHz, DMSO-d6) δ = 12.16 (1H, s), 
7.90 (1H, d, J = 7.5 Hz), 7.72 (1H, d, J = 7.5 Hz), 7.54 (3H, m), 7.42 (2H, t, J = 7.4 Hz), 7.30 (17H, m), 
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5.03 (1H, s), 4.27 (2H, m), 3.85 (1H, m), 3.53 (2H, m), 1.53 (1H, m), 1.42 (3H, m); 
13
C NMR (100 MHz, 
DMSO-d6) δ = 173.84, 156.07, 143.84, 143.77, 142.16, 141.09, 140.69, 137.00, 133.39, 131.08, 128.84, 
128.31, 127.62, 127.43, 126.04, 126.69, 126.54, 125.27, 120.08, 114.15, 79.18, 73.92, 72.13, 65.56, 
65.35, 53.64, 46.65, 27.41, 24.72; HRMS m/z calculated for C39H35ClN2O5Na [M+Na]
+
: 669.2132; found: 
669.2129. 
2.4.3  Serine-Acylated Monomer Synthesis. 
Serine-acylated monomers 16a-16d were synthesized by adaptation of previously published methods as 
shown in Schemes 2.2 and 2.3 and described below.
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(S)-tert-butyl (1-(tert-butoxy)-4-(2,5-dioxopyrrolidin-1-yl)-3-oxobutan-2-
yl)carbamate (14):
78
 Boc-Ser(tBu)-OH (500 mg, 1.91 mmol, 1.0 equiv) was dissolved 
in 7.5 mL water and 7.5 mL dioxane under nitrogen. N-hydroxysuccinimide (242 mg, 
2.10 mmol, 1.1 equiv) was added and the reaction was cooled to 0 °C. N,N′-dicyclohexylcarbodiimide 
(433 mg, 2.10 mmol, 1.1 equiv) was added to the reaction vessel. The reaction was allowed to warm to 
room temperature and stirred for 3 hours. Following this time, the mixture was filtered through celite, 
washed with ethyl acetate and concentrated. The resulting oil was dissolved in 75 mL ethyl acetate and 
washed twice each with 30 mL saturated aqueous NaHCO3, water, and brine. The organic layer was dried 
over anhydrous sodium sulfate and concentrated to afford  compound 14 isolated as a white solid (606 
mg, 1.69 mmol, 88.5%). 
1
H NMR (400 MHz, CDCl3) δ = 5.40 (1H, d, J = 9.0 Hz), 4.75 (1H, m), 3.89 
(1H, m), 3.64 (1H, m), 2.80 (4H, s), 1.43 (9H, s), 1.18 (9H, s); 
13
C NMR (100 MHz, CDCl3) δ = 168.59, 
166.96, 155.13, 80.43, 73.94, 61.81, 53.07, 28.34, 27.22, 25.64; HRMS m/z calculated for C16H26N2O7Na 
[M+Na]
+
: 381.1638; found: 381.1645. 
Standard Procedure G. Coupline of Serine to Amine Side-Chain Compounds:
78
 The Fmoc-protected 
amino acid 15a-d (1.0 equiv) was suspended in anhydrous dimethylformamide under nitrogen. N-methyl-
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N-(trimethylsilyl) trifluoracetamide (MSTFA) (2.1 equiv) was added and the reaction stirred 4 hours at 
room temperature. Following this time, Boc-Ser(tBu)-NHS (14) (1.2 equiv) was added and the reaction 
was stirred for 2-3 days. The reaction was then diluted with ethyl acetate and washed twice with brine. 
Silica gel chromatography (33%→100% ethyl acetate in hexanes) afforded products 16a-d. 
(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((S)-3-(tert-butoxy)-2-
((tert-butoxycarbonyl)amino)propanamido)propanoic acid (16a): Standard 
procedure G was employed starting with Fmoc-diaminopropionic acid (Fmoc-
Dap-OH, 15a) (1.06 g, 3.05 mmol) in 20 mL anhydrous dimethyl formamide with 
N-methyl-N-(trimethylsilyl) trifluoroacetamide (1.19 mL, 6.42 mmol) and Boc-Ser(tBu)-NHS (1.31 g, 
3.67 mmol). Product 16a was isolated as a white solid (1.17 g, 2.05 mmol, 67%). [α]D = +11 (c = 1.0, 
CHCl3). 
1
H NMR (400 MHz, DMSO-d6) δ = 12.84 (1H, s), 7.95 (1H, m), 7.90 (2H, d, J = 7.53), 7.70 (2H, 
d, J = 7.53), 7.49 (1H, d, J = 8.0), 7.43 (2H, t, J = 7.28), 7.35 (2H, m), 6.57 (1H, d, J = 8.3), 4.32 (1H, m), 
4.24 (2H, m), 4.09 (1H, m), 4.03 (1H, m), 3.62 (1H, m), 3.46 (1H, m), 3.40 (1H, m), 3.26 (1H, m), 1.38 
(9H, s), 1.09 (9H, s); 
13
C NMR (100 MHz, DMSO-d6) δ = 171.98, 156.01, 155.16, 143.80, 143.75, 
140.74, 127.66, 127.12, 125.24, 120.15, 79.20, 78.18, 72.78, 65.78, 61.95, 55.05, 53.99, 46.61, 28.17, 
26.17, 25.25; HRMS m/z calculated for C30H39N3O8Na [M+Na]
+
: 592.2635; found: 592.2648. 
(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-((S)-3-(tert-butoxy)-2-
((tert-butoxycarbonyl)amino)propanamido)butanoic acid (16b): Standard 
procedure G was employed starting from Fmoc-diaminobutyric acid (Fmoc-Dab-
OH, 15b) (499 mg, 1.46 mmol) in 10 mL anhydrous DMF with N-methyl-N-
(trimethylsilyl)trifluoroacetamide (568 μL, 3.07 mmol) and Boc-Ser(tBu)-NHS (624 mg, 1.75 mmol). 
Product 16b was isolated as a white solid with residual DMF present (540 mg, 0.93 mmol, 63%). [α]D = 
+4.7 (c = 1.0, CHCl3). 
1
H NMR (400 MHz, DMSO-d6) δ = 12.63 (1H, s), 7.90 (2H, m), 7.74 (2H, d, J = 
7.40), 7.69 (1H, d, J = 8.03 Hz), 7.42 (2H, t, J = 7.40 Hz), 7.34 (2H, t, J = 7.40 Hz), 6.51 (1H, d, J = 8.53 
Hz), 4.27 (2H, m), 3.99 (2H, m), 3.42 (2H, m), 3.18 (1H, m), 3.07 (1H, m), 1.92 (1H, m), 1.71 (1H, m), 
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1.37 (9H, s), 1.09 (9H, s); 
13
C NMR (100 MHz, DMSO-d6)  δ = 173.71, 173.04, 170.08, 162.30, 156.12, 
155.06, 143.81, 140.71, 127.64, 127.09, 125.29, 120.12, 78.15, 72.68, 65.65, 62.03, 55.01, 51.63, 46.64, 
35.78, 30.76, 28.15, 27.19; HRMS m/z calculated for C31H41N3O8 [M+H]
+
: 584.2972; found: 584.2983.  
(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-((S)-3-(tert-butoxy)-2-
((tert-butoxycarbonyl)amino)propanamido)pentanoic acid (14c): Standard 
procedure G was employed with a slight modification. Fmoc-ornithine 
hydrochloride 15c (494 mg, 1.26 mmol) was suspended in 5 mL anhydrous 
dimethyl formamide under nitrogen with DIEA (225 μL, 1.26 mmol) and stirred 
for 5 min. Following this time, N-methyl-N-(trimethylsilyl) trifluoroacetamide (492 µL, 2.65 mmol) and 
Boc-Ser(tBu)-NHS (541 mg, 1.52 mmol) were added. Product 16c was isolated as a white solid with 
residual DMF present (614 mg, 1.02 mmol, 80.9%). [α]D = +20 (c = 1.0, CHCl3). 
1
H NMR (400 MHz, 
DMSO-d6) δ = 12.56 (1H, s), 7.89 (2H, d, J = 7.40 Hz), 7.82 (1H, t, J = 5.02 Hz), 7.72 (2H, d, J = 7.40 
Hz), 7.64 (1H, d, J = 8.03 Hz), 7.42 (2H, t, J = 7.34 Hz), 7.32 (2H, m), 6.48 (1H, d, J = 8.41 Hz), 4.26 
(3H, m), 3.94 (2H, m), 3.41 (2H, m), 3.06 (2H, m), 1.72 (1H, m), 1.55 (1H, m), 1.48 (3H, m), 1.37 (9H, 
s), 1.08 (9H, s); 
13
C NMR (100 MHz, DMSO-d6)  δ = 173.86, 169.95, 156.15, 155.06, 143.85, 143.80, 
140.73, 127.65, 127.09, 125.31, 120.12, 78.15, 72.66, 65.63, 62.05, 55.03, 53.67, 46.66, 38.18, 28.16, 
27.21, 25.89; HRMS m/z calculated for C32H43N3O8 [M+H]
+
: 598.3128; found: 598.3154. 
(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-6-((S)-3-(tert-butoxy)-2-
((tert-butoxycarbonyl)amino)propanamido)hexanoic acid (16d): Standard 
procedure G was employed starting from Fmoc-Lys-OH 15d (502 mg, 1.36 mmol) 
in 10 mL anhydrous DMF with N-methyl-N-(trimethylsilyl) trifluoroacetamide 
(528 μL, 2.85 mmol) and Boc-Ser(tBu)-NHS (581 mg, 1.63 mmol). Product 16d 
was isolated as a viscous colorless oil with a small amount of residual DMF present (576 mg, 0.942 
mmol, 69%). [α]D = −6.5 (c = 1.0, CHCl3). 
1
H NMR (400 MHz, DMSO-d6) δ = 12.55 (1H, s), 7.88 (2H, d, 
J = 7.53 Hz), 7.81 (1H, t, J = 5.02 Hz), 7.74 (2H, d, J = 7.40 Hz), 7.62 (1H, d, J = 7.91 Hz), 7.42 (2H, t, J 
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= 7.28 Hz), 7.34 (2H, t, J = 7.40 Hz), 6.48 (1H, d, J  = 8.41 Hz), 4.27 (3H, m), 3.97 (1H, m), 3.91 (1H, 
m), 3.42 (2H, m), 3.10 (1H, m), 3.01 (1H, m), 1.69 (1H, m), 1.61 (1H, m), 1.37 (12H, m), 1.08 (9H, s); 
13
C NMR (100 MHz, DMSO-d6) δ = 174. 03, 169.86, 156.16, 155.05, 143.80, 140.73, 127.64, 127.07, 
125.30, 120.12, 78.13, 72.63, 65.60, 62.03, 54.97, 53.77, 46.66, 30.38, 28.59, 28.14, 27.20, 25.23, 22.94;  
HRMS m/z calculated for C33H44N3O8 [M+H]
+
: 612.3285; found: 612.3271. 
2.4.4  Peptide Synthesis And Purification 
Peptides 1-34 were synthesized on NovaPEG Rink Amide Resin either manually with microwave heating 
(MARS microwave reactor, CEM) or in an automated fashion on a Tribute synthesizer (Protein 
Technologies, Inc.)  
 In a typical microwave procedure, the desired amino acid (4.0 equiv to resin) was preactivated 
with HCTU (4.0 equiv to resin) and DIEA (6.0 equiv to resin) in NMP for 2-3 minutes. The preactivated 
amino acid was then added to the resin in a reaction vessel fit with a stir bar. The solution was subjected 
to a microwave coupling program run consisting of a 2 minute ramp to 70 °C and a 4 minute hold at 70 
°C. After the coupling program completed, the resin was washed three times with DMF. Following 
washing, the resin was treated with 20% 4-methylpiperidine in DMF with a microwave deprotection 
program consisting of a 2 minute ramp to 80 °C and a 2 minute hold at 80 °C. Following completion of 
the deprotection program, the resin was washed three times with DMF, and the previous steps repeated 
until the peptide chain was completed on resin. 
In a typical automated synthesis, Fmoc-protected amino acids (5.0 equiv to resin) were coupled 
with HCTU (5.0 equiv to resin) and DIEA (7.5 equiv to resin) for 45 minutes at room temperature. The 
N-terminus was deprotected by treatment with 20% 4-methylpiperidine in DMF, twice for 4 minutes at 
room temperature. Following each coupling or deprotection step, the resin was washed with DMF three 
times. The previous steps were repeated until the peptide chain was completed on resin. 
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Unnatural aminooxy-functionalized monomers 12a and 12b were coupled identically to the 
procedure described above for natural Fmoc-amino acids except that PyBOP was used in place of HCTU. 
This was required by the observation of guanidinium-capped peptide impurities when HCTU was utilized 
with monomers 12a and 12b. 
Following completion of the peptide chain on resin and removal of the N-terminal Fmoc group, 
the N-terminus was acetylated by treatment with 8:2:1 v:v:v DMF:DIEA:Ac2O for 10-15 minutes at room 
temperature. Following acetylation, the resin was washed three times each with DMF, DCM, and 
methanol, then dried in a vacuum dessicator. Cleavage of the peptide from resin was accomplished by 
treatment with 92.5% trifluoroacetic acid, 3% water, 3% ethanedithiol, and 1.5% triisopropylsilane for 2-
5 hours. The crude peptide was then precipitated in cold diethyl ether and centrifuged, the ether decanted, 
and the crude material dissolved in 0.1% TFA in water and 0.1% TFA in methanol for purification. 
Peptides were purified by HPLC on a Luna C18 preparative column using gradients between 0.1% 
TFA in water and 0.1% TFA in acetonitrile. Identities of the purified peptides were confirmed by 
MALDI-TOF MS. All peptides used for biophysical characterization were ≥ 95% pure by analytical 
HPLC.  
A few observations regarding peptide synthesis and purification are of note. We found that 
cleavage of the peptides containing aminooxy functionalized X residues necessitated the use of 
ethanedithiol or other strong nucleophilic scavengers to avoid alkylation of the aminooxy functionality by 
the resin, leading to little or no isolatable product.
86
 Additionally, peptides containing aminooxy-
functionalized X residues were allowed to sit in acetonitrile for extended periods (>2 hours), significant 
amounts of unidentified byproduct were formed.
101
 We attribute this formation to the reaction of the 
nucleophilic aminooxy residue with contaminants in acetonitrile. Finally, it was observed that some 
reverse-phase C18 HPLC stationary phases irreversibly bind aminooxy-functionalized peptides. Although 
the cause of this phenomena was never clear, we were able to find stationary phases free of this problem 
(Phenomenex Luna C18). 
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Table 4. MALDI-TOF data for peptides 1-6 and reaction products. 
 [M+H]
+
 (m/z) 
Peptide Calculated Observed 
1 1704.9 1704.6 
2 1851.9 1851.5 
3 1865.9 1865.8 
4 1851.9 1851.8 
5 1865.9 1866.1 
6 1863.9 1864.0 
2b 1802.9 1802.5 
2c 1849.9 1850.1 
3b 1816.9 1816.8 
4b 1802.9 1802.3 
5b 1816.9 1817.1 
6a 1854.9* 1854.6* 
*Calculated and observed for [M+Na]
+ 
 
Table 5. MALDI-TOF data for peptides 17-34 and cyclized products. 
 [M+H]
+
 (m/z)  [M+H]
+
 (m/z) 
Peptide Calculated Observed Peptide Calculated Observed 
17 4036.2 4036.5 17-ox 4052.2 4052.4 
18 4018.3 4018.2    
19 4063.3 4063.1 19b 4014.3 4014.0 
20 4077.3 4077.3 20b 4028.3 4028.3 
21 4077.3 4077.6 21b 4028.3 4028.6 
22 4091.4 4091.6 22b 4042.3 4042.5 
23 4091.4 4091.4 23b 4042.3 4042.3 
24 4105.4 4104.4 24b 4056.3 4055.9 
25 4105.4 4105.1 25b 4056.3 4056.6 
26 4119.4 4119.0 26b 4070.3 4070.1 
27 4077.3 4077.4 27b 4028.3 4028.6 
28 4091.4 4091.4 28b 4042.3 4041.9 
29 4105.4 4105.8 29b 4056.3 4056.5 
30 4119.4 4119.1 30b 4070.3 4070.4 
31 4111.3 4111.7 31b 4062.2 4062.5 
32 4065.3 4065.1 32b 4016.2 4016.1 
33 4078.3 4078.5 33b 4029.2 4028.9 
34 4184.4 4184.6 34b 4104.4 4104.0 
   34c 4086.2 4086.8 
 
 79 
2.4.5  Peptide Oxidation And HPLC Analysis 
2.4.5.1 Helical Peptide Model System 
 
Stock solutions of peptides 1-6 were prepared in 100 mM phosphate buffered aqueous solution at pH 7 
and the concentration of each peptide determined by UV-Vis spectroscopy based on tyrosine absorbance 
at 276 nm (ԑ276 = 1450 M
-1
 cm
-1
).
102
 Oxidation and cross-linking reactions were performed by dilution of 
the peptide stock with 100 mM phosphate buffer to a final peptide concentration of 100 µM and 
subsequent addition of 2 equivalents of aqueous sodium periodate, which oxidizes the serine-acylated U 
residue to the corresponding glyoxyl aldehyde.
77, 78, 98
 Following addition of periodate, aliquots were 
removed from the oxidized solutions and diluted by 10% with 0.1% TFA in water for analysis by HPLC. 
Complete consumption of the starting peptide was observed within 10 minutes in all cases. The identity of 
the observed chromatographic peaks was determined by collection of the eluent from analytical HPLC 
and analysis by MALDI-TOF MS. 
2.4.5.2 Coiled-Coil Model System 
 
Stock solutions of peptides 17-34 were prepared in water and the concentration of each peptide 
determined by UV-Vis spectroscopy based on tyrosine absorbance and 276 nm (ԑ276 = 1450 M
-1
 cm
-1
).
102
 
A stock of sodium periodate in water was made and the concentration of periodate determined by UV-Vis 
spectroscopy (ԑ280 = 317 M
-1
 cm
-1
).
103
 Oxidation and cross-linking reactions were performed by dilution of 
the peptide stock with phosphate buffer, water, and aqueous sodium periodate to yield samples comprised 
of 100 µM peptide and 100 µM NaIO4 in 0.1 M phosphate buffer at pH 7.  
 The cyclization of peptide 34, to form a bicyclic oligomer, was carried out identically except that 
2.1 equiv of periodate relative to peptide were used to a final concentration of 210 µM NaIO4. For 
experiments performed at 80 °C, peptide 34 at 100 µM concentration in 0.1 M phosphate buffet at pH 7 
 80 
was heated to 80 °C in a water bath. After 5-10 minutes, sodium periodate was added as described above. 
The sample was maintained at 80 °C for an additional 10 minutes, and then analyzed.  
 Following addition of periodate, aliquots were removed from the peptide solutions and analyzed 
by HPLC. Complete consumption of the starting material was observed in 10 minutes or less in all cases. 
The identity of observed chromatographic peaks was determined by collection of analytical HPLC eluent 
and MALDI-TOF MS. 
2.4.6  NMR Assignment Of Oxime Isomers 
An oxidation reaction of peptide 2 was performed as described in section 2.4.5.1 with a total volume of 2 
mL. After 15 minutes, the oxidized peptide was diluted by 10% with 0.1% TFA solution and injected on 
to preparative-scale HPLC. Two fractions, corresponding to the two observed oxime isomers of species 
2b were collected, frozen immediately, and lyophilized. Though the isomers were fully separated by 
HPLC, it was observed that the minor observed isomer of 2b partially equilibrates to the major isomer of 
2b in the short period of time required to freeze the collected fraction for lyophilization. Two fractions 
were thus obtained, one composed of primarily (~95%) the major isomer of 2b and one composed of a 
mixture (~70% major, ~30% minor) of the two isomers of 2b. The lyophilized powder from each fraction 
was taken up in D2O containing 100 mM phosphate buffet at pH 7 uncorrected for the presence of D2O 
and 20 µM DSS as an internal standard. The sample was allowed to stand for 1 hour to fully exchange 
amide protons with deuterium, then analyzed by 
1
H NMR at 700 MHz using excitation sculpting to 
suppress the residual H2O signal. 
2.4.7  Oxime Isomerization Experiments 
For the isomerization experiments described in Section 2.1.2, an oxidation reaction of peptide 2 was 
carried out as described in section 2.1.2 with a total volume of 200 µL. Peaks corresponding to the two 
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isomers were collected from analytical HPLC eluent. Approximately one-third of the eluent was frozen 
until completion of the previous HPLC run from which the eluent was collected, then thawed and injected 
immediately to ascertain the composition of the isolated material. Partial conversion of the E- and Z-
oxime isomers of 2b was observed even in the short time between isolation and freezing. The remaining 
frozen eluent of each fraction was lyophilized and the lyophilized powder used directly in the experiments 
detailed below. 
 Following lyophilization, samples of each isomer were dissolved in either (1) 200 µL of 0.1 M 
phosphate buffer at pH 7.0 or (2) 200 µL of 0.1% TFA in water. Aliquots were then removed from each 
sample and analyzed by HPLC after 24 and 48 hours. It was observed that the sample in 0.1% TFA in 
water rapidly converts to a product ratio composed primarily of the Z-oxime isomer of 2b, while at 
neutral pH the system does not reach equilibrium up to 48 hours after redissolving. 
2.4.8  Oxime Exchange Experiments 
Stock solutions of O-methylhydroxylamine hydrochloride were prepared at 1 M concentration in either 
0.1 M phosphate buffer at pH 7 or pH 1. An aniline stock solution was prepared at 0.1 M in 0.1 M pH 7 
phosphate buffer. An oxidation and cross-linking reaction of peptide 2 was carried out by addition of 
sodium periodate to yield a sample comprised of 125 µM peptide, 250 µM sodium periodate in 0.1 M 
phosphate buffer at pH 7. The oxidized sample was then split into two aliquots and diluted with a 
combination of O-methylhydroxylamine stock, aniline stock, and phosphate buffer to yield two samples 
of the following compositions: (1) 100 µM peptide, 100 mM O-methylhydroxylamine (from pH 7 stock), 
10 mM aniline in 0.1 M phosphate at pH 7 or (2) : (1) 100 µM peptide, 100 mM O-methylhydroxylamine 
(from pH 7 stock), 10 mM aniline in 0.1 M phosphate at pH 4. The reactions were monitored by 
analytical HPLC, collection of the eluent, and MALDI-TOF MS to monitor the formation of linear oxime 
2c. 
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2.4.9  Circular Dichroism (CD) Spectroscopy 
2.4.9.1 CD Of The Helical Peptide Model System 
 
Circular dichroism samples were prepared by dilution of stock solutions of peptides 1-6 in water with 
phosphate buffer and water to a final concentration of 100 µM peptide in 0.1 M phosphate buffer at pH 7. 
For cyclized peptides 2b-5b and oxidized peptide 6a, identical samples were prepared except with the 
addition of aqueous sodium periodate to a final concentration of 200 µM periodate. CD scans were 
carried out from 200 to 260 nm with 1 nm step size, 2 nm bandwidth, and 5 second integration times at 
each wavelength. Spectra were corrected for buffer blanks of identical composition lacking peptide and 
for baseline molar elipticity from 255-260 nm. Variable temperature CD data were obtained by 
monitoring elipticity at 222 nm from 2-95 °C in 3 °C intervals with a dead band of 0.5 °C and a 2 minute 
equilibration at each temperature. Circular dichroism scan data was smoothed by the Savitsky-Golay 
method as implemented in GraphPad Prism. The fraction helical content for each peptide was calculated 
as previously described in the literature using equation 1 below.
91
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Equation 1 
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In the above equation, [θ]222 is the observed molar elipticity at 222 nm, [θ]helix is the molar 
elipticity at 222 nm for a fully folded α-helix, and [θ]coil is the molar elipticity at 222 nm for a random 
coil. Values of [θ]coil for each peptide were determined from the high-temperature baseline from thermal 
unfolding experiments. The value of [θ]helix was calculated as -29,800 deg cm
2
 dmol
-1
 res
-1
 according to 
equation 2 below.  
Equation 2 
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In the above equation, T is temperature in °C, n is the number of residues in the peptide, and k is a 
constant (4.0 ) taken from literature precedent.
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2.4.9.2 CD Of α-Helical Coiled Coils 
 
Measurements were performed at 100 μM peptide concentration in 100 mM phosphate buffer at pH 7, 
with and without 1 equivalent (peptides 19-33) or 2.1 equivalents (peptide 34) of aqueous sodium 
periodate. Samples for circular dichroism were prepared by an identical method as that described for 
analysis by HPLC. CD scans were carried out from 260 to 200 nm with 5 second averaging times, 1 nm 
step size, and 2 nm bandwidth at 20 °C. Spectra were corrected for a buffer blank and baseline molar 
elipticity at 260 nm. Variable temperature CD data was obtained by monitoring molar elipticity at 222 nm 
from 2-95 °C at 3 °C intervals with a dead band of 0.5 °C, 2 minute equilibration time between 
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measurements, and 5 second averaging times. Acquisition of molar elipticity at 222 nm following thermal 
melts was obtained by cooling of the sample and equilibration for 5 minutes at 20 °C. 
Melt data was processed utilizing GraphPad Prism, and fit to a two-state thermal denaturation 
model to obtain melting temperatures (Tm).
104
 The percentage of unfolded peptide at each temperature 
was calculated as in equation 3. Additional parameters used in the calculation of ΔΔG were obtained as 
described below.  
Equation 3 
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1[% 


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unfoldfoldfold
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MT
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

   
  
In the above equation, [θ]T is the molar elipticity at 222 nm at the temperature of the 
measurement, [θ]unfold is the molar elipticity at 222 nm of the fully unfolded peptide obtained from the 
two-state denaturation fit, [θ]fold is the molar elipticity at 222 nm of the fully folded peptide obtained from 
the two-state denaturation fit, T is the temperature in degrees Celsius, and Mfold is the slope of the fully 
folded measurements at low temperature from the two-state denaturation fit.
104
 The analysis of the 
percentage of unfolded peptide at a given temperature is utilized to more easily visualize the change in the 
shape of the two-state denaturation sigmoidal curve. Analysis of the percentage of unfolded peptide from 
thermal melt data does not change the measured Tm value.   
Estimation of the change in folded stability upon cyclization was obtained by calculating ΔΔGfold 
as detailed below from equation 4.
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Equation 4 
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In the above equation, ΔHTM is the enthalpy obtained for the wild-type peptide (18) from thermal 
melt analysis, TM,w.t. is the melting temperature of peptide 18 from thermal melt analysis in Kelvin (K), 
and ΔTm is calculated as in equation 5. 
Equation 5 
.,.., mutmtwmm TTT        
 
Error propagation in the calculation of ΔΔGfold is obtained from equation 6 below, where 
δ{ΔHTM}, and δ{Tm,w.t.} are values obtained as standard error of the two-state thermal denaturation curve 
fit.
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Equation 6 
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The value of δ{ΔTm} is obtained from equation 7 below, where values of δ{Tm,mut.} and δ{Tm,w.t.} 
are obtained from the two-state thermal denaturation curve fit. 
Equation 7 
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 This analysis allows us to calculate ΔΔGfold values for comparison of peptides with unnatural 
residues inserted in comparison to the wild type peptide. A comparison can also be made between the 
cross-linked peptide and the linear peptide of the same type prior to oxidation and cross-linking by 
changing parameters in the above equations to be Tm,lin. and δ{Tm,lin.} in place of  Tm,w.t. and δ{Tm,w.t.}, 
respectively. Accordingly, in comparison of the linear peptide to its oxidized, cross-linked counterpart, 
ΔHTM is taken to be the change in enthalpy for the linear peptide rather than the wild type peptide. 
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2.4.10 Methionine Oxidation Stability Studies 
A stock solution of sodium periodate in water was prepared and the concentration of periodate quantified 
by UV-Vis spectroscopy (ԑ280 = 317 M
-1
 cm
-1
).
103
 Peptide stocks of 6 and 17 were prepared in water and 
the concentration of peptide determined by UV-Vis spectroscopy as discussed previously (Section 2.3.5). 
Three parallel reactions were prepared in 0.1 M phosphate buffer at pH 7. First, a 100 µM solution of 
peptide 6 and 100 µM periodate; second, a 100 µM solution of peptide 17 and 100 µM periodate; third, 
solution containing 100 µM peptide 6, 100 µM peptide 17, and 100 µM periodate. After addition of 
periodate, each sample was analyzed by HPLC at varying time points between 2 minutes (the fastest 
possible time between periodate addition and automated injection by HPLC) and 60 minutes on a C18 
column. MALDI-TOF MS was utilized to identify the products following collection of the HPLC eluent. 
2.4.11 Crystallization, Data Collection, And Structure Determination 
Crystals of peptide 22 were grown by hanging drop vapor diffusion in 24-well plates (Hampton). 1 µL of 
peptide stock with a peptide concentration of 10-15 mg/mL in water was mixed with 1 µL of 
crystallization buffer comprised of 0.1 M sodium acetate pH 4.6, 1.6 M NaCl, and 5% v/v PEG-1500 and 
equilibrated against 1 mL of crystallization buffer at room temperature. Crystals of 22b were obtained by 
formation of the oxime cross-links in the crystal lattice of crystals of 22. Crystals of 22 were grown as 
described above, and a solution of sodium periodate in crystallization buffer (1.5 equivalents to peptide) 
was added to the drop and allowed to equilibrate over crystallization buffer. Confirmation of the 
formation of 22b was obtained by diluting crystal-containing drops 1:100 with water and analysis by 
MALDI-TOF MS. Time-dependent analysis of replicate drops treated with periodate showed complete 
cyclization within 48 hours after addition of periodate. The optimized conditions were used to generate 
crystals of 22b for diffraction analysis. Crystals of 22 and 22b were flash frozen in liquid nitrogen after 
cryoprotection in well buffer supplemented with 25% v/v glycerol. Diffraction data were collected using 
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CuKα radiation on a Rigaku/MSC diffractometer (FR-E generator, VariMax optics, AFC-Kappa 
goniometer, Saturn 944 CCD detector) equipped with an X-stream 2000 low temperature system operated 
at 100 K. The linear peptide 22 crystallized in a C2 lattice with one dimeric coiled coil in the asymmetric 
unit. In the oxime cross-linked structure of 22b, the crystallographic 2-fold symmetry axis was lost 
resulting in a lower-symmetry P1 cell with two coiled coils in the asymmetric unit (four independent 
peptide chains) related by non-crystallographic symmetry. Coordinates and structure factors for 22 and 
22b are deposited in the Protein Data Bank under accession codes 4HU5 and 4HU6, respectively. 
 
Table 6. Crystallographic data collection and refinement statistics for 22 and 22b. 
 Peptide 22 Peptide 22b 
Data Collection   
Unit cell dimensions (Å, °) 
a = 76.7, b = 30.9, c = 
33.3  
β = 97.7 
a = 30.9, b = 33.1,  
c = 41.1  
α = 93.9, β = 112.0,  
γ = 98.7 
Space group C2 P1 
Resolution (Å) 
50.00-2.30 
(2.38-2.30) 
28.52-2.30 
(2.38-2.30) 
Total observations 16,894 11,907 
Unique observations 3,576 6,255 
Redundancy 4.7 (4.7) 1.90 (1.91) 
Completeness (%) 99.7 (100) 95.2 (91.7) 
I/σ 20.2 (6.5) 9.2 (2.1) 
Rmerge (%) 10.6 (30.7) 5.0 (22.3) 
Refinement   
Resolution (Å) 25.00-2.30 28.52-2.30 
R (%) 20.6 26.0 
Rfree (%) 26.8 29.2 
Avg. B factor (Å
2
) 30.2 38.8 
RMSD   
Bonds (Å) 0.012 0.009 
Angles (°) 1.26 1.48 
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3.0 INTERMOLECULAR OXIME AND HYDRAZONE CROSS-LINKS 
Work detailed in this chapter has been published as: 
 1. Haney, C. M.; Horne, W. S.; “Dynamic covalent side-chain cross links via intermolecular 
 oxime or hydrazone formation from bifunctional peptides and simple organic linkers.” Journal of 
 Peptide Science, 2014, 20, 108-114 
 
In addition to the intramolecular cross-link strategy outlined in Chapter 2, intermolecular cross-links 
formed by reaction of a linear peptide chain bearing two identical side chains and a bifunctionalized small 
molecule have also been examined. After such a reaction sequence, the small molecule becomes an 
integral part of the macrocycle, offering variability of the cross-link connectivity and size in a divergent 
manner from a single peptide sequence. Previous applications of intermolecular cross-linking include 
reactions between peptide thiols and alkyl or aryl dihalides to form thioethers,
62, 63, 67, 68, 69, 106
 peptide 
amines and dicarboxylic acids to form lactams,
64, 65
 and peptide azides and dialkynyl linkers to form 
ditriazole-cyclized products.
107
 As with intramolecular cross-linking methods, intermolecular cross-link 
formation has been utilized to modulate peptide folding, affinity for biomolecules, and cellular uptake.
107
 
We sought to adapt the strategy for oxime cross-linkinking described in the previous chapter to an 
intermolecular system in which peptides bearing two nucleophilic side chains react with dialdehyde-
functionalized small molecules. This approach offers an alternate methodology to the intramolecular 
cross-link formation outlined in Chapter 2 without the need for oxidative conditions. Though the 
previously utilized strategy was capable of eliciting helical folding and stabilizing a protein quaternary 
assembly, the cross-links generated showed only limited dynamic covalent exchange. We hypothesized 
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that the intermolecular formation of oxime and hydrazone cross-links could allow for more facile 
exchange of the cross-linking moiety. 
3.1 MODEL SYSTEM FOR INTERMOLECULAR CROSS-LINK FORMATION 
In order to establish methods for intermolecular cross-link formation, we utilized sequence 1, described in 
Chapter 2. We replaced selected residues with either aminooxy-functionalized residue X5 or a new, 
hydrazide-functionalized residue Z5 to generate derivatives 35-37 (Figure 39). The hydrazide-
functionalized Z5 residue leads to a hydrazone cross-link. We hypothesized that the hydrazone cross-links 
would offer more facile exchange given the known difference in hydrolytic lability of hydrazones versus 
oximes.
81
 Sequences 35 and 36 were designed to test the effect of residue spacing (i→i+4, 35 or i→i+11, 
36) or the stability of the bis-oxime cross-link formed, as in peptide 37,  an analogue of 35 but containing 
hydrazides at an i→i+4 spacing to generate a bis-hydrazone cross-link. 
We reacted peptides 35-37 with four different commercially available dialdehyde small 
molecules (a-d) to form cyclic products (35a-35d, 36a, 36d, and 37a-37d), wherein the peptide number 
and letter combination indicate the cross-linked product formed (e.g. peptide 35 with linker a becomes 
35a) (Figure 39). We examined the formation of the cross-linked species, the effect of cross-link 
formation upon helical folding, and the ability of the cross-links to undergo dynamic covalent exchange. 
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Figure 39. Sequences of peptides 1 and 35-37 and schematic representation of cross-linking. 
(A) Sequences of peptides 1 and 35-37, structures of residues X5 and Z5 and linkers a-d. (B) Peptides 35-
37 were used in combination with linkers a-d to generate a family of cyclized products (35a-35d, 36a, 
36d and 37a-37d). 
3.2 CROSS-LINK FORMATION 
We examined ten different combinations of peptides 35-37 and linkers a-d to prepare cyclic species 35a-
35d, 36a, 36d and 37a-37d (representative examples, Figure 40). Each reaction consisted of peptide in 
pH 7 phosphate buffer with excess linker (4 equiv), and was monitored by HPLC and mass spectrometry. 
It was observed that the intermolecular cross-link formation is considerably slower than observed for the 
intramolecular case, though the reaction goes to completion in 1-2 hours. In most cases, more than one 
peak was observed in the chromatogram with a mass corresponding to the cyclized product. Each new 
oxime bond can form as an E or Z isomer, resulting in cyclic products with four possible stereochemical 
configurations (EE, EZ, ZE, ZZ). As shown in work described in Chapter 2, oxime stereoisomers can be 
separable by HPLC and typically interconvert slowly under neutral buffered aqueous conditions. 
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Peptide 35, which contains two X5 residues at an i→i+4 spacing was efficiently cyclized in 2 
hours or less with each linker, a-d. Not all cyclic products showed separable stereoisomers by HPLC; 
however, it is unclear if this is a result of the thermodynamic stability of particular isomers favoring their 
formation, or a lack of chromatographic resolution. Peptide 36, which contains the same X5 residues but 
at an i→i+11 spacing, was efficiently cyclized by both a small benzene-based core (linker b) and by a 
larger biphenyl linker (d). Changing the identity of the nucleophilic side chain but maintaining the residue 
spacing, as in peptide 37 versus peptide 35, had a minimal effect on peptide cyclization efficiency, except 
in the reaction with biphenyl-based linker d which generated a mixture of linear starting material and 
cyclic products. The observation that the ratio of linear peptide 37 to cyclized product 37d did not change 
considerably over time suggests that an equilibrium was established between the two species. In none of 
the reactions detailed above was a product observed arising from the reaction of two independent peptide 
chains. We attributed this finding to the favorable kinetics of intramolecular ring-closing and cyclization 
following the first side-chain to linker condensation reaction versus the potential competing reaction that 
would cross-link independent peptide chains. 
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Figure 40. Representative HPLC chromatograms of peptides 35-37 reacted with linker b. 
(A) Schematic representation of the cross-linking reactions in HPLC chromatograms. (B) 
Chromatograms of peptide 35 (black) and peptide 35 with 4 equiv linker b two hours after linker addition 
(blue). (C) Chromatograms of peptide 36 (black) and peptide 36 with 4 equiv linker b two hours after 
linker addition (blue). (D) Chromatograms of peptide 37 (black) and peptide 37 with 4 equiv linker b two 
hours after linker addition (blue). 
3.3 INTERMOLECULAR CROSS-LINKS AFFECT FOLDING 
In order to assess the ability of intermolecular cross-links to influence the folded state of the peptide, we 
examined the folding behavior of peptides 35-37 and their cyclized products by CD spectroscopy. Peptide 
1, on which the other sequences are based, is partially helical in neutral aqueous solution. Linear peptides 
35-37 also exhibit helical folding patterns, with a dependence on the side-chain identity. The hydrazide 
side chains in peptide 37 are slightly disruptive to helical folding, while aminooxy-functionalities in 
peptides 35 and 36 had little to no effect on helical folding (Figure 41). 
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Figure 41. Circular dichroism data for peptides 1 and 35-37. 
(A) CD scan of peptide 1. (B) CD scans of peptide 35 and cyclized products 35a-35d. (C) CD 
scans of peptide 36 and cyclized products 36b and 36d. (D) CD scans of peptide 37 and cyclized products 
37a-37d. All CD scans contain 50 µM peptide in 0.1 M phosphate buffer; cyclized samples analyzed 2 
hours after addition of 4 equiv of linker. 
  
  
 Cyclic products based on peptide 35 (peptides 35a-35d) showed differences in helical content 
depending on the identity of the organic linker (Figure 41B). Cyclic peptide 35b, based on the meta-
substituted dialdehyde linker exhibited greatest helicity among the series, while peptides 35a and 35d 
showed diminished helicity compared to the linear parent sequence 35. In contrast, cyclization of 36, 
which has an i→i+11 spacing of X5 residues, showed no significant difference by CD of helical content 
upon cross-link formation with linkers b or d (Figure 41C). The origin of this effect is unclear, although 
we hypothesized that the large, flexible macrocycle formed was incapable of constraining the peptide 
backbone into a helical conformation. However, the observed maintenance of helical folding suggests that 
the cross-links are accommodated into the partially helical fold without disruption. Replacement of the 
aminooxy-functionalized residues (35) with hydrazides (37) led to less apparent influence of linker 
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identity on helical folding, although cyclized product 37a was less helical than the starting linear peptide 
(Figure 41D). Overall, these results show that intermolecular oxime and hydrazone cross-links can 
influence helical folding, though less predictably than observed in intramolecular cross-link formation. In 
particular, both placement of the reactive residues and the dialdehyde linker are important. Some residue 
spacing and linker combinations elicit helical folding, while others do not.  
3.4 CROSS-LINK EXCHANGE WITH A SMALL MOLECULE 
Several experiments were performed to gauge the capacity of the cyclic peptides formed through 
intermolecular cross-links to participate in dynamic covalent equilibria. In previous work, we observed 
that intramolecular cyclization through oxime formation provided only limited dynamic covalent 
exchange (Chapter 2). In order to assess the ability of bis-oxime and bis-hydrazone cross-links to 
exchange, we carried out analogous reactions in which cyclic peptides 35b and 37b were treated with a 
large excess of O-methylhydroxylamine under conditions known to favor exchange (aniline as a catalyst, 
mildly acidic pH).
90
 Product 35b which contains two oxime bonds remains cyclic after several hours 
though the ratio of isomers changes (Figure 42). This finding suggests that the oxime is capable of isomer 
exchange, but is sufficiently thermodynamically stable to remain cyclized. Treatment of cyclic peptide 
37b under the same conditions showed nearly quantitative conversion to the linear precursor, 37, in one 
hour (Figure 42). This result is reasonable given that hydrazones are known to be less hydrolytically 
stable than oximes,
81
 it also provides a potential handle for the generation of peptide-based DCLs. The 
ease of hydrazone exchange may facilitate protein template-mediated selection of cross-linked structures. 
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Figure 42. Small molecule exchange reactions of peptides 35 and 37. 
(A) Schematic representation of the reaction of cyclized product 35b with O-
methylhydroxylamine and aniline at pH 4. The chromatograms show the starting point of the reaction 
(black) and the reaction 5 hours after acidification and addition of O-methylhydroxylamine and aniline 
(blue). (A) Schematic representation of the reaction of cyclized product 37b with O-
methylhydroxylamine and aniline at pH 4. The chromatograms show the starting point of the reaction 
(black) and the reaction 1 hour after acidification and addition of O-methylhydroxylamine and aniline 
(blue). 
 
3.5 LINKER SELECTION IN A HELICAL MODEL SYSTEM 
While the ability to ring open cyclic peptides as described in the previous section is interesting as a proof 
of concept of dynamic covalent exchange, direct selection of linkers in a dynamic covalent equilibrium 
would provide more compelling evidence for the promise of intermolecular bis-oxime or bis-hydrazone 
formation to facilitate discovery of peptide-based inhibitors of protein-protein interactions. In order to 
investigate this issue, we carried out competition experiments in which two different linkers (b and d) 
were added simultaneously in excess to a single linear peptide (35-37). In these experiments, we found 
that peptide 35 strongly favors the formation of product 35b over 35d (Figure 43). Peptide 36, upon 
simultaneous addition of linkers b and d formed a mixture of 36b and 36d, where 36b was favored 
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(Figure 43). Similarly, linear peptide 37 showed favored formation of cyclic product 37b with both 37d 
and 37 (the linear precursor) still present (Figure 43). In the prior two cases, the distribution of products 
remained unchanged after up to 5 hours after linker addition. In the case of simultaneous addition of 
linkers to peptide 35, it was observed that the small amount of product 35d formed after two hours was no 
longer present four hours following linker addition; this serendipitous finding suggested the possibility of 
dynamic covalent exchange being responsible for the selection of a single cross-linked product. 
 
 
Figure 43. Chromatograms of simultaneous addition of linkers b and d to peptides 35-37. 
(A) Schematic representation of the simultaneous addition of two linkers to form cyclic products. 
(B) HPLC chromatogram of peptide 35 at indicated time points after addition of linkers b and d 
simultaneously. (C) HPLC chromatogram of peptide 36 2 hours after simultaneous addition of linkers b 
and d. (D) HPLC chromatogram of peptide 37 2 hours after simultaneous addition of linkers b and d. 
3.6 CROSS-LINK EXCHANGE FROM SEQUENTIAL ADDITION OF TWO LINKERS 
The observation that product 35d may exchange linkers to form product 35b was somewhat surprising, 
given the known tendency for oxime exchange to require acidic pH or nucleophilic catalysis to achieve 
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reasonable rates.
108
 In order to test the hypothesis that peptide 35d exchanges to form cyclic product 35b 
directly, we prepared samples of 35d and then added linker b (Figure 44). In these experiments, a sample 
of peptide 35 was treated with linker d and allowed to proceed until complete cyclization occurred. 
Following this time, linker b was added (4 equiv) and the mixture monitored over time by analytical 
HPLC. Over the course of five hours, the initial product distribution of 35d was found to exchange almost 
quantitatively to form product 35b (Figure 44). This result provided strong support for the possibility that 
the organic linker component can be exchanged in a dynamic covalent manner. The oxime exchange 
reaction between cyclic products 35d and 35b was found to proceed more quickly with aniline as an 
added nucleophilic catalyst (completion in ~2 hours vs. 5 hours). However, the reaction in neutral 
buffered aqueous solution even in the absence of catalyst proceeds on a time scale that may be 
appropriate for dynamic combinatorial selection in systems involving peptide folding and/or binding. 
 An additional experiment in which a sample of peptide 37d was treated with an excess of linker b 
was found to lead to a mixture of products 37b and 37d. Unlike the behavior in the oxime-based system, 
the hydrazone-based system (37b and 37d) shows a different distribution of products when the linkers are 
added simultaneously (Figure 43) versus when they are added sequentially (Figure 44). This may be due 
to the small differences in peptide and linker concentrations when the linkers are added simultaneously 
versus sequentially. Nevertheless, this result demonstrates that the hydrazone cross-links may be able to 
undergo dynamic covalent exchange of the linker component, though the equilibrium established is more 
complex and does not exclusively favor a single product.  
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Figure 44. Linker exchange reactions for peptides 35d and 37d treated with linker b. 
(A) Schematic representation of linker exchange at pH 7. (B) HPLC chromatogram of a mixture 
of peptide 35 and linker d after complete conversion to 35d (black) and the same mixture 5 hours after 
addition of linker b (blue). (C) HPLC chromatogram of a mixture of peptide 37 and linker d after 
establishing an equilibrium of 37 and 37d (black) and the same mixture 5 hours after addition of linker b 
(blue). 
3.7 INTERMOLECULAR CROSS-LINK FORMATION CONCLUSIONS 
An alternative strategy employing the intermolecular formation of cross-links through the reaction of a 
bifunctionalized peptide with a dialdehyde-functionalized small molecule has been explored. 
Intermolecular cross-link formation was found to proceed rapidly (~1-2 hours) to furnish up to four 
chromatographyically resolvable isomers. The cross-links formed under these conditions require no 
reagents other than peptide and linker, and the reactions proceed cleanly under neutral buffered aqueous 
conditions. The divergent and modular nature of this synthetic method can potentially be used for the 
rapid generation of a library of cross-linked compounds for screening against biological targets. 
 Intermolecular cyclization reactions proceed with reasonable rates under neutral buffered aqueous 
conditions to yield cyclic products through either oxime or hydrazone formation. The resulting cyclic 
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oligomers present differences in helical content depending on the identity of the organic linker group, the 
spacing of the nucleophilic residues involved in cross-link formation, and the identity of the cross-link 
bonds (e.g. oxime vs. hydrazone). While in many cases the origins of the differences in helicity are not 
obvious, this cross-linking strategy can furnish more helical oligomers (e.g. 35b vs. 35) provided 
judicious choice of cross-linking residues, their spacing, and the organic linker involved. Residues cross-
linked via oxime formation at an i→i+4 spacing elicit very different helical folding patterns based on the 
linker utilized. However, the same oxime formation at an i→i+11 spacing show little difference in helical 
folding by CD. The same residue spacing (i→i+4) used to form hydrazones show little difference in 
helical folding except in the case of linker a, which diminishes helical folding. 
Examination of the ability of bis-oxime or bis-hydrazone cross-links to undergo exchange via 
reaction with an exogenous aminooxy-functionalized small molecule demonstrated that oxime cross-links 
do not exchange, though hydrazone-based cross-links do. This is not surprising given the known 
chemistry of hydrazones and oximes, but does provide valuable information about the use of hydrazone 
cross-links in the context of dynamic covalent chemistry. 
The ability to select a particular organic linker group from a complex mixture provides  
information about the relative stability of different cyclic products, e.g. 35b vs. 35d. Of note is the fact 
that despite different cross-linking residue spacings (e.g. 35 vs. 36) or cross-link types (e.g. 35 vs. 36) 
products cyclized by linker b were consistently favored. However, the extent differed depending on 
peptide; peptide 35 favored linker b almost exclusively, while peptide 36 led to a mixture or products. 
Bis-hydrazone formation by reaction of peptide 37 with linkers b and d was found to lead to a mixture of 
products, including linear peptide 37, though product 37b was still favored. 
The most direct test of the applicability of intermolecular oxime and hydrazone formation for 
dynamic covalent chemistry applications involves the ability to exchange one organic linker for another. 
Several experiments were performed toward this end, which demonstrated that the oxime cross-linked 
peptide 35d can exchange to form cyclic species 35b in a reasonable time frame for peptide folding 
and/or binding. Interestingly, analogous experiments with peptide 37d and exchange to form peptide 37b 
 100 
did not show an equal preference of organic linker. This may be due to the increased exchange possible 
with hydrazone cross-links. 
In summary, the above data suggest the possibility of using intermolecular oxime and hydrazone 
formation as a strategy to establish dynamic covalent libraries (DCLs) amongst a single peptide sequence 
and multiple dialdehyde functionalized linkers. Consideration must be taken as to the substitution pattern 
of unnatural side chains (e.g. 35 vs 36) to elicit a particular fold, and of the side chain identity; however, 
this strategy is divergent and modular for establishing a library of cyclic peptides based on a single linear 
sequence. In addition, the observation that such cross-linked peptides may be capable of dynamic 
covalent exchange suggests their use as a direct application for protein-templated construction of a DCL. 
3.8 EXPERIMENTAL 
3.8.1  General Information 
Solvents and all other reagents were purchased from Sigma Aldrich, Baker, EMD, Fisher, Acros 
Organics, or TCI and used as received unless otherwise specified. Cbz-Glu-OBn and 2-chlorotrityl 
chloride were purchased from Chem-Impex. 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium hexafluorophosphate (HCTU), (benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyBOP), NovaPEG Rink Amide Resin, 9-fluorenylmethyoxycarbonyl-N-
hydroxysuccinimide (Fmoc-OSu), and Fmoc-protected-amino acids were purchased from 
NovaBiochem and used as received. Fmoc-protected aminooxy-functionalized monomer 12b was 
synthesized as described in Chapter 2, Section 2.4.1. Flash column chromatography was performed using 
SorbTech (60 Å, 40-63 µm) silica gel. Optical rotations were measured on a Perkin-Elmer 241 digital 
polarimeter with a sodium lamp at ambient temperature. NMR spectra were recorded on Bruker Avance-
400 or Bruker Avance-300 spectrometers. MALDI-TOF mass spectrometry was carried out on a Voyager 
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DE Pro instrument. Circular dichroism spectra were recorded on an Olis DSM17 Circular Dichroism 
Spectrometer using quartz cuvettes 0.1 cm path length. Preparative and analytical HPLC were performed 
with Phenomenex Luna C18 columns. 
3.8.2  Hydrazide-Functionalized Monomer Synthesis 
 
Scheme 3.1. Synthesis of hydrazide-functionalized monomer. 
 
Fmoc-protected hydrazide functionalized monomer 40 was prepared by adaptation of previously reported 
procedures as described below.
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tert-Butyl (S)-2-(5-(benzyloxy)-4-(((benzyloxy)carbonyl)amino)-5-
oxopentanoyl)hydrazine-1-carboxylate (38): Cbz-L-Glu-OBn (7b, 3.71 g, 10.0 mmol) 
was dissolved in 50 mL anhydrous DCM under nitrogen. DIEA (5.22 mL, 30.0 mmol) 
was added, followed by tert-butylcarbazate (1.45 g, 11.0 mmol), 1-
hydroxybenzotriazole (HOBt) hydrate (1.68 g, 11.0 mmol), and N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC • HCl) (2.11 g, 11.0 mmol). The reaction was stirred under 
nitrogen at room temperature overnight. The solution was then diluted with 150 mL ethyl acetate and 
washed once each with 50 mL of the following: 1 M HCl, water, saturated sodium carbonate, and brine. 
The organic layer was dried over anhydrous magnesium sulfate and concentrated. Silica gel 
chromatography (33%→66% ethyl acetate in hexanes) afforded product 38 as a white solid (2.34 g, 4.83 
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mmol, 48%). [α]D =  +1.8 (c = 1.0, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ = 8.10 (1H, s), 7.34 (10H, m), 
6.67 (1H, s), 5.88 (1H, d, J = 6.9 Hz), 5.16 (2H, s), 5.09 (2H, s), 4.45 (1H, m), 2.26 (3H, m), 1.99 (1H, 
m), 1.44 (9H, s); 
13
C NMR (100 MHz, CDCl3) δ = 171.69, 156.42, 155.48, 136.06, 135.10, 128.57, 
128.47, 128.26, 128.15, 128.07, 81.67, 67.30, 67,07, 53.37, 29.88, 28.25, 28.05; HRMZ m/z calculated for 
C25H32N3O7 [M+H]
+
: 486.2240; found: 486.2245. 
(S)-Benzyl-2-(((benzyloxy)carbonyl)amino)-5-(2-((2-
chlorophenyl)diphenylmethyl)hydrazinyl)-5-oxopentanoate (39): Compound 38 
(2.19 g, 4.52 mmol) was dissolved in 20 mL DCM. TFA (5 mL) was added and the 
reaction stirred at room temperature for 2.5 hours. The reaction was then diluted with 
50 mL DCM and washed with 30 mL 5% w/v NaHCO3 and 30 mL brine, then dried over anhydrous 
magnesium sulfate and concentrated. The resulting residue was dissolved in 20 mL anhydrous DCM 
under nitrogen and DIEA (1.18 mL, 6.79 mmol) was added. 2-Chlorotrityl chloride (1.41 g, 4.52 mmol) 
was dissolved in 10 mL anhydrous DCM and added to the reaction over 15 minutes. The reaction was 
stirred at room temperature under nitrogen overnight, then diluted with 100 mL ethyl acetate and washed 
with 30 mL 10% w/v citric acid, then twice with 30 mL brine. The organic layer was dried over 
anhydrous magnesium sulfate and concentrated. Silica gel chromatography (33%→50% ethyl acetate in 
hexanes) afforded product 39 as a yellow solid with a small amount of residual ethyl acetate (1.83 g, 2.76 
mmol, 61%). NMR spectra recorded in deuterated chloroform showed two conformers in slow exchange 
on the NMR timescale; 
1
H NMR is reported in DMSO-d6 where only a single set of peaks was observed, 
and 
13
C NMR is reported in CDCl3 with all signals reported. [α]D = −1.2 (c = 1.0, CHCl3). 
1
H NMR (400 
MHz, DMSO-d6): δ = 9.01 (1H, d, J = 8.3 Hz), 7.79 (1H, d, J = 7.4 Hz), 7.65 (1H, d, J = 7.7 Hz), 7.42 
(4H, m), 7.35 (1H, m), 7.28 (8H, m), 7.19 (2H, m), 6.10 (1H, d, J = 8.3 Hz), 5.11 (2H, m), 5.02 (2H, m), 
3.88 (1H, m), 1.88 (2H, t, J = 7.4 Hz), 1.56 (1H, m), 1.44 (1H, m); 
13
C NMR (100 MHz, CDCl3): δ = 
177.24, 171.54, 169.03, 156.19, 155.98, 141.83, 139.60, 138.04, 136.06, 135.03, 134.50, 133.41, 132.44, 
132.04, 131.32, 129.68, 128.90, 128.68, 128.59, 128.52, 128.48, 128.43, 128.35, 128.30, 128.18, 128.14, 
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128.10, 128.04, 127.93, 127.70, 126.90, 126.27, 74.20, 73.68, 67.29, 67.05, 66.83, 53.84, 53.24, 30.42, 
28.70, 26.41; HRMS m/z calculated for C39H37ClN3O5 [M+H]
+
: 662.2422; found: 662.2396. 
 
(S)-2-(((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-(2-((2-
chlorophenyl)diphenylmethyl)hydrazinyl)-5-oxopentanoic acid (40): Compound 
39 (1.71 g, 2.58 mmol) was dissolved in 20 mL anhydrous methanol under nitrogen. 
Palladium on carbon (0.171 g, 10 wt%) was added, the atmosphere was purged, and 
the reaction vessel fit with a hydrogen-filled balloon. The resulting mixture was stirred overnight, then 
filtered through celite, washed with methanol, and concentrated. The resulting white solid was dissolved 
in anhydrous DCM under nitrogen. DIEA (1.79 mL, 10.32 mmol) was added, followed by trimethylsilyl 
chloride (TMS-Cl) (0.655 mL, 5.16 mmol) and stirred for 15 minutes at room temperature. Fmoc-OSu 
(1.04 g, 3.09 mmol) was then added and the reaction stirred at room temperature overnight. The reaction 
was then diluted with 150 mL ethyl acetate and washed twice with 50 mL brine. The organics were then 
dried over anhydrous magnesium sulfate and concentrated. Silica gel chromatography (50%→100% ethyl 
acetate in hexanes) afforded product 40 as a white solid (518.8 mg, 0.79 mmol, 30%). [α]D = +1.9 (c = 
1.0, CHCl3). 
1
H NMR (400MHz, DMSO-d6): δ = 12.58 (1H, s), 9.04 (1H, d, J = 8.2 Hz), 7.89 (2H, d, J = 
7.5 Hz), 7.80 (1H, d, J = 7.8 Hz), 7.70 (2H, d, J = 7.4 Hz), 7.49 (1H, d, J = 7.8 Hz), 7.41 (4H, m), 7.31 
(10H, m), 7.19 (2H, m), 6.11 (1H, m), 5.00 (1H, s), 4.24 (2H, m), 4.20 (1H, m), 3.72 (1H, m), 1.85 (2H, t, 
J = 7.8 Hz), 1.54 (1H, m), 1.42 (1H, m); 
13
C NMR (100 MHz, CDCl3): δ = 170.40, 156.26, 143.77, 
143.56, 141.59, 141.23, 139.39, 134.46, 132.11, 131.25, 129.02, 128.71, 128.32, 128.00, 127.71, 127.03, 
126.38, 125.04, 119.95, 73.70, 66.99, 60.42, 53.54, 53.06, 47.05, 30.47, 28.80, 28.29; HRMS calculated 
for C39H33ClN3O5 [M−H]
−
: 658.2109; found: 658.2137. 
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3.8.3  Peptide Synthesis And Purification 
Peptides 35-37 were prepared by manual Fmoc-solid phase peptide synthesis on NovaPEG Rink Amide 
Resin with microwave heating. Coupling reactions were performed in N-methyl-2-pyrrolidinone (NMP) 
using 4 equiv of amino acid, 4 equiv of activating agent (HCTU for natural Fmoc-protected amino acids; 
PyBOP for unnatural residues 12b and 40) and 6 equiv of DIEA. The microwave coupling program 
consisted of a 2-minute ramp to 70 °C, followed by a 4-minute hold at 70 °C. Removal of the N-terminal 
Fmoc protecting group was achieved by treatment with 20% 4-methylpiperidine in DMF. The microwave 
deprotection program consisted of a 2-minute ramp to 80 °C and a 2 minute hold at 80 °C. The resin was 
washed three times with DMF after each coupling and deprotection reaction. Once the peptide sequence 
was completed on resin, the N-terminus was acetylated by treatment with 8:2:1 v:v:v DMF:DIEA:Ac2O 
for 10-15 minutes at room temperature. The resin was then washed and dried, and the peptide cleaved 
from resin with concomitant side chain deprotection by treatment with 92.5:3:3:1.5 TFA:H2O:EDT:TIS. 
The cleaved peptide was precipitated into cold diethyl ether, centrifuged, and the ether decanted. The 
pelleted crude peptide was dissolved in 0.1% TFA in water for purification by preparative HPLC. 
Peptides were purified by HPLC on a Luna C18 preparative column using gradients between 0.1% TFA 
in water and 0.1% TFA in acetonitrile. Fractions containing the desired peptide were frozen immediately 
and lyophilized. Identities of the purified peptides were confirmed by MALDI-TOF MS, and all peptides 
used in biophysical characterization and cross-linking experiments were ≥ 95% pure by analytical HPLC. 
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Table 7. MALDI-TOF data for peptides 1, 35-37 and cyclized products. 
 [M+H]
+
 (m/z)  [M+H]
+
 (m/z) 
Peptide Calculated Observed Peptide Calculated Observed 
1 1704.9 1704.8 37 1848.9 1849.0 
35 1822.9 1822.7 37a 1951.0 1950.7 
35a 1925.0 1924.7 37b 1951.0 1951.3 
35b 1925.0 1924.8 37c 1951.0 1951.1 
35c 1925.0 1925.1 37d 2027.5 2027.2 
35d 2001.0 2001.2    
36 1822.9 1822.8    
36b 1925.0 1924.8    
36d 2001.0 2000.7    
 
3.8.4  Cross-Link Formation Reactions 
Stock solutions of peptides 35-37 were prepared in water and their concentration determined by UV-Vis 
spectroscopy (Tyr absorbance at 276 nm, ԑ = 1450 M-1 cm-1).102 Stock solutions of organic linkers a-d 
were prepared in water. For solutions of linkers a-c, concentration was determined by UV-Vis 
spectroscopy (a, ԑ300 = 255 M
-1
 cm
-1
 for the corresponding cyclic hydrate; b, ԑ292 = 1120 M
-1
 cm
-1
; c, ԑ296 = 
1950 M
-1
 cm
-1
).
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 ortho-Pthaldialdehyde (a) was allowed to equilibrate in water for at least 30 minutes 
prior to concentration determination to ensure complete conversion to the cyclic hydrate.
110
 The 
concentration of linker d in aqueous stock solution was determined by mass to volume. Cross-linking 
reactions were performed in 0.1 M phosphate buffer, pH 7, with 50 µM peptide and 4 equiv (200 µM) 
linker. The benzene-based dialdehydes (a-c) were well soluble in water and were delivered to reactions 
from aqueous stock solutions of 500-700 µM concentration. Biphenyl-based linker d was less soluble in 
water and consequently was added from a stock solution just below its solubility limit in water (~300 
µM). Following addition of the linker, aliquots were removed from cross-linking reactions and analyzed 
by HPLC and MALDI-TOF MS of collected eluent. Cyclization reactions were performed utilizing 
peptides 35-37 and various combinations of linkers as detailed above to prepare cyclic species 35a-35d, 
36b, 36d, and 37a-d. In all cases, complete consumption of the starting linear peptide was observed in 1-2 
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hours (~2 hour reaction times were required with linker d) with the appearance of one to four separable 
HPLC peaks with masses corresponding to the cyclized product(s). Cross-link formation with peptide 37 
yielded complete cyclization with linkers a-c and a mixture of cyclized product and linear peptide with 
linker d. 
3.8.5  Circular Dichroism Spectroscopy 
Samples of linear peptides 1 and 35-37 were prepared in 0.1 M phosphate buffer, pH 7 at a concentration 
of 50 µM peptide. Samples of cyclized peptides 35a-35d, 36b, 36d, and 37a-37d at 50 µM concentration 
were prepared in 0.1 M phosphate buffer at pH 7 by addition of 4 equiv (200 µM) linker and analyzed 
directly after completion of the reaction as determined by HPLC. CD scans were performed from 200-260 
nm with 5 second integration times, 2 nm bandwidth, and 1 nm step size at 20 °C, Raw CD data were 
smoothed by the Savitsky-Golay method as implemented in GraphPad Prism. 
3.8.6  Cross-Link Exchange With O-Methylhydroxylamine 
A sample of cyclic peptide 35b was prepared in 0.1 M phosphate buffer from peptide 35 (50 µM) and 
linker b (200 µM). Following complete conversion to form cyclic product 35b, the solution was acidified 
to pH 4 with 1 M HCl, then O-methylhydroxylamine (10 µL from a 1 M stock in water) and aniline (10 
µL from a 0.1 M stock in water) were added to yield a sample composed of ~42 µM peptide 35b, residual 
linker b (~160 µM), 1000 equiv of O-methylhydroxylamine and 100 equiv of aniline. The reaction was 
monitored by HPLC at time points from 1 to 5 hours. An identical experiment was carried out by 
preparation of cyclic product 37b and treatment as described above. 
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3.8.7  Linker Mixing Experiments 
3.8.7.1 Simultaneous Addition Of Two Linkers 
A sample of peptide 35, 36, or 37 was prepared and linkers b and d added together to create a solution 
consisting of 50 µM peptide, 150 µM linker b and 150 µM linker d in 0.1 M phosphate buffer at pH 7. 
The reactions were monitored by HPLC and MALDI-TOF MS of collected eluent.  
3.8.7.2 Sequential Addition Of Two Linkers 
A sample of cyclic peptide 35d or 37d was prepared in 0.1 M phosphate buffer at pH 7 from peptide 35 or 
37 (50 µM) and linker d (200 µM). After complete conversion to 35d or the establishment of equilibrium 
between 37 and 37d was confirmed by HPLC, linker b (4 equiv) was added from an aqueous stock 
solution. The sequential addition of linker b diluted the concentration of peptide and linkers slightly 
versus conditions where the linkers were added simultaneously. The reactions were monitored by HPLC 
and MALDI-TOF MS of collected eluent. 
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4.0 CROSS-LINKING PEPTIDE LIGANDS BOUND TO A PROTEIN RECEPTOR 
As noted in Chapter 1, peptide cyclization has proven to be a useful strategy for generating peptide-based 
inhibitors of PPIs. The use of aminooxy-bifunctionalized peptides with dialdehyde linkers, as described in 
Chapter 3, furnishes a possible cross-linking technology amenable to use under conditions involving 
peptide binding to biological receptors. We investigated the use of designed peptide ligands for a protein 
receptor and the effect of cross-link formation on folding and affinity for a protein target. Additionally, 
we tested the ability of the presence of the protein receptor to affect the outcome of the cross-linking 
reactions. We utilized reactions involving a single linker, in which the oxime isomer distribution may be 
affected by the presence of the receptor. Alternatively, we examined reactions involving the use of two 
linkers in which the proportion of each cross-linked product may depend on the presence of the receptor. 
4.1 PROTEIN RECEPTOR SELECTION AND PEPTIDE DESIGN 
We chose to utilize gp41-5, a soluble, single-chain construct derived from the HIV membrane protein 
gp41 as a model protein receptor.
111
 The protein consists of three N-terminal heptad repeat sequences and 
two C-terminal heptad repeat sequences from gp41-5 that are joined by short linker segments (Figure 45). 
The molecule contains five of the six helices found in the gp41 six-helix bundle formed during viral-cell 
fusion (see Section 1.2), and provides an exposed groove for binding molecules with affinity for gp41. 
This construct has previously been used in high-throughput screens to identify small molecule inhibitors 
of HIV fusion
111
 as well as in the development of mixed α/β-peptide backbones with antiviral activity.112  
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Figure 45. Structure and sequence of gp41-5. 
(A) Side view of the gp41-5 helix bundle. (B) Top view of the gp41-5 helix bundle. Structures 
from PDB: 3O3X. (C) Sequence of gp41-5. N-terminal and C-terminal heptad repeat helices are colored 
grey and green, respectively. 
 
 
Based on the C-terminal heptad repeat (CHR) sequence of gp41, we designed potential ligands 
for the gp41-5 helix bundle to have several important characteristics. We sought to decrease any residual 
secondary structure in the unbound ligand, as we reasoned that this may provide additional driving force 
for receptor-mediated selectivity in cross-linking reactions. In this case, stabilizing the helical, bound state 
is uncoupled from stabilizing the helical conformation of the unbound peptide ligand. Peptides based on 
the CHR sequence of gp41 have also been shown to undergo spontaneous oligomerization with changes 
to the sequence;
113
 this oligomerization could potentially interfere with ligand-receptor interactions. 
Therefore, we attempted to minimize any potential oligomerization in our designs. In order to achieve 
these goals, the 36-residue CHR sequence was truncated to 21 residues. We then generated several 
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mutants starting from the wild type CHR sequence based on literature precedent for residue changes 
affecting helicity and/or oligomerization of CHR sequences (Figure 46).
113
 
 
 
Figure 46. Sequences of designed CHR peptides. 
 
Peptide 41 is the native 21 residue sequence from the wild-type CHR domain with a single amino 
acid substitution of Met2 to its hydrocarbon isostere, norleucine (made to avoid any potential oxidation). 
This sequence proved to be insoluble following synthesis and cleavage from the resin. Peptides 42-45 
were then generated with increasing degrees of mutation away from the natural CHR sequence and 
towards the homologous residues of a previously reported helical CHR mimic, T-2635.
113
 Peptide 42 
contains six mutations from the wild-type sequence. Two substitutions (Met2→Glu and Glu20→Arg) were 
made to promote helical structure and solubility. Four lysines were inserted to act as isosteres of the 
aminooxy-functionalized residues to be subsequently included for cross-link formation. These residues 
were placed in solvent-exposed sequence positions based on analysis of crystal structures of the gp41 six-
helix bundle and of a CHR-based peptide bound to gp41-5.
112
 Peptide 43 maintains the Met2→Glu and 
Glu20→Arg mutations of 42, but lacks the lysine mutations and contains additional substitutions from T-
2635: Glu7→Ala, Thr12→Ala, and His16→Ala. Peptide 43 combines the mutations from peptide 42 and 
43 and contains three additional alanine residues found in T-2635; Glu3→Ala, Asn9→Ala, and 
Glu21→Ala. Peptide 45 is simply the 21 residue truncation of T-2635. All peptides include an N-terminal 
acetyl cap to aid in stabilization of the helical fold. With these peptides in hand, we assessed their folding 
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behavior by CD spectroscopy and affinity for gp41-5 through a previously developed competition 
fluorescence polarization assay (Figure 47).
111
 
 
 
Figure 47. CD and competition fluorescence polarization data for peptides 42-45. 
(A) CD spectra of peptides 42, 44, and 45 at 50 µM concentration in 0.1 M phosphate buffer, pH 
7. (B) CD spectra of peptide 43 at 50 µM concentration in 0.1 M phosphate buffer, pH 7. (C) Competition 
fluorescence polarization data for peptides 42, 44, and 45. Peptides were titrated into FP solution 
containing 2 nM gp41-5 and 1 nM Flu-C38. Data points average and standard deviation from triplicate 
measurements. 
 
 
Circular dichroism spectroscopy of peptides 42-45 indicated differing helical content (Figure 
46A, B). Peptide 42 has a CD signature consistent with random coil, as desired in our ligand design. 
Peptide 43 proved to be slightly helical, while peptide 45 showed much stronger helical folding 
characteristics by CD. Interestingly, peptide 43 proved to have a strongly helical CD signature, above that 
expected even for a fully folded monomeric helix of 21 residues (calculated [θ]222 = -31.6 (deg cm
2
 dmol
-1
 
res
-1
) x 10
-3
). This uncharacteristically large CD intensity was found to be independent of concentration. 
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Because of its unusual CD behavior this peptide was not investigated further as a potential ligand for 
gp41-5. 
Peptides 42, 44 and 45 were tested in competition fluorescence polarization assays to determine 
their affinity for gp41-5 (Figure 47C). Fluorescence polarization measures the change in fluorescence 
anisotropy associated with the binding of a fluorescently labeled “tracer” ligand to a protein receptor. In 
the unbound state, the rate of rotation of the ligand is rapid, and causing polarized light to be fluorescently 
emitted as depolarized light (Figure 48). In the bound state, the ligand-protein complex tumbles more 
slowly, leading to retention of polarization in the fluorescence emission (Figure 48). Competitive 
inhibition of the interaction between the fluorescent ligand and the protein receptor by an unlabeled 
competitor leads to emission of depolarized light from the liberated tracer. In the assay used here, the 
fluorescent ligand is the 38-residue CHR domain of gp41 with an N-terminal fluorescein tag, termed Flu-
C38. Serial dilutions of peptides 42, 44, and 45 against protein and fluorescent tracer thus provide a 
measure of fluorescence anisotropy as a function of peptide concentration. This data provides competitive 
inhibition equilibrium constants (Ki). 
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Figure 48. Sequence of Flu-C38 and scheme of competition fluorescence polarization. 
(A) Sequence of Flu-C38 and structure of the fluorescein label. (B) Schematic representation of 
competition fluorescence polarization. Competitive inhibition of the complex formed between the 
fluorescently-labeled ligand and the receptor leads to emission of depolarized light. 
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Peptide 44 showed no competitive inhibition of the Flu-C38−gp41-5 interaction (Figure 47C). 
Peptide 42 was determined to have a Ki of 132 ± 24 nM, and peptide 45 was found to have a Ki of 302 ± 
45 nM (Figure 47C). Taken together with the CD characterization of the peptides, sequence 42 was 
chosen as the starting point for the generation of oligomers containing two aminooxy-functionalized 
residues for cross-link formation. This sequence was selected due to its unstructured nature by CD and 
moderately high affinity for gp41-5. These characteristics allow for either positive or negative changes in 
affinity due to cross-linking to be observed under the conditions of the competition fluorescence 
polarization assay. 
4.2 CROSS-LINKING OF GP41-5 LIGANDS AFFECTS FOLDING AND AFFINITY 
Having chosen peptide 42 as a starting point for the design of oligomers capable of cross-link formation, 
three new sequences (46-48) were generated, each containing two aminooxy residues (Figure 49). Peptide 
46 has two aminooxy-functionalized isosteres of lysine (X5) at positions 13 and 17. The analogous 
sequence, 47, substitutes two aminooxy-functionalized isosteres of ornithine (X4) at the same sequence 
positions in order to gauge the effect of macrocycle size and flexibility on cross-linking and affinity for 
gp41-5. Sequence 48 contains two X5 residues closer to the N-terminus of the sequence, at positions 6 and 
10. Each peptide was reacted with three commercially available dialdehydes (a-c) to furnish cyclic 
products, where the cyclized product is the combination of the peptide and the linker used (e.g. peptide 46 
cyclized with linker a furnishes product 46a) (Figure 49B). 
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Figure 49. Sequences of peptides 46-48 and schematic representation of cross-linking. 
(A) Sequences of peptides 42 and 46-48, with monomers and linkers utilized below. (B) 
Schematic representation of cross-linking reactions performed. 
 
 
We first examined the efficiency of the cross-linking reaction for peptides 46-48 with linkers a-c. 
We performed reactions of each peptide at 10 µM concentration with 40 µM linker in 0.1 M phosphate 
buffer at pH 7. Each peptide was found to react cleanly with linkers a-c; however, the formation of cyclic 
products was considerably slower (~4 hours for the reaction to reach equilibrium) than in the peptides of 
limited sequence diversity utilized in Chapter 3 (Figure 50). Interestingly, this effect was concentration 
independent; when samples of 50 µM peptide 46 were treated with 200 µM of linker, the reaction was not 
found to reach equilibrium at an earlier time point. This result was surprising given that higher 
concentration should lead to a faster intermolecular reaction. However, as found previously in Chapter 3 
and in accordance with literature precedent,
108
 nucleophilic catalysis of the reaction through the use of 
aniline yielded cyclized product more rapidly. In each case, multiple chromatographic peaks were 
observed with masses corresponding to the cyclized species, and were assigned as stereoisomers of the 
desired oxime-cyclized products (Figure 50). Of note is the fact that linker b, in all cases, failed to 
quantitatively yield cyclic product; though the starting peptide is completely consumed after 4 hours, in 
each case a chromatographic peak was observed with a mass corresponding to the formation of a single 
oxime and an acyclic product (termed product #b′, e.g. 46b′).It is unclear why this reaction failed to fully 
cyclize, though the product distribution observed 4 hours following linker addition did not change up to 
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12 hours following linker addition. In no case were products observed resulting from the reaction of two 
independent peptide chains reacting with a single linker. 
 
 
Figure 50. HPLC chromatograms of cross-linking reactions with peptide 43 and linkers a-c. 
All reactions were performed with 10 µM peptide, 40 µM linker in 0.1 M phosphate buffer, pH 7 
and analyzed by HPLC and MALDI-TOF MS of collected eluent 4 hours following linker addition. 
 
 
We next examined the folding behavior of each peptide and its corresponding cross-linked 
products by CD spectroscopy. For peptides 46 and 47, it was found that neither the linear starting peptide 
nor its cyclic products show considerable helical structure (Figure 51). Interestingly, peptide 48, where 
the aminooxy residues are located closer to the N-terminus of the sequence exhibited a CD signature 
indicative of β-sheet folding. Cross-linking this oligomer to generate products 48a-48c affected the 
intensity of the β-sheet minimum at 216 nm, but did not lead to spectra strongly indicative of either 
helical or random coil conformations. Overall, the CD results suggest that the folding behavior of the 
peptides can be perturbed following cross-link formation; in the case of peptides 46 and 47, it is possible 
that multiple conformations are present and equilibrating between random coil, sheet, and helical 
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conformations; in the case of peptide 45, the β-sheet signature observed for the linear peptide can be 
diminished, but not abolished, by cross-link formation. 
 
 
Figure 51. CD Data for peptides 46-48. 
(A) CD scans of peptide 46 and cross-linked products 46a-46c. (B) CD scans of peptide 47 and 
cross-linked products 47a-47c. (C) CD scans of peptide 48 and cross-linked products 48a-48c. All CD 
scans were performed at 50 µM concentration of peptide in 0.1 M phosphate buffer; cross-linking 
reactions contained 200 µM linker and were analyzed four hours after linker addition. 
 
 
We utilized the competition fluorescence polarization assay discussed previously to investigate 
the affinity for the linear peptides bearing unnatural residues, 46-48, and their cyclic products for gp41-5. 
The linear peptides 46-48 were found to have somewhat higher affinity than the sequence upon which 
they are based (42) (Figure 52, Table 8). We hypothesized that this gain in affinity is due to the removal 
of two positively charged lysine residues; in the helical, bound state of the peptide, the lysine side chains 
are displayed on the same face of the helix, potentially leading to destabilizing charge-charge interactions. 
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Removal of this potential destabilizing interaction may correlate to the observed increase in inhibition 
equilibrium constant, Ki, in the competition assay. 
 
 
Figure 52. Competition fluorescence polarization data for peptides 46-48 and linkers a-c. 
(A) Competition fluorescence polarization data for peptide 46 and cyclic products 46a-46c. (B) 
Competition fluorescence polarization data for peptide 47 and cyclic products 47a-47c. (C) Competition 
fluorescence polarization data for peptide 48 and cyclic products 48a-48c. (D) Competition fluorescence 
polarization data for linkers a-c, where no competitive binding is observed.  
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Table 8. Competition fluorescence polarization data for peptides 42 and 46-48. 
Peptide 
FP 
Competition 
Ki (nM) 
Peptide 
FP 
Competition 
Ki (nM) 
42 132 ± 24 47 31 ± 3 
46 35 ± 3 47a 90 ± 13 
46a 111 ± 11 47b 320 ± 31 
46b 246 ± 23 47c 32 ± 5 
46c 32 ± 4 48 37 ± 5 
  48a 162 ± 22 
  48b 2580 ± 430 
  48c 8 ± 2 
 
 
To assess the ability of cross-link formation to affect binding affinity, we prepared samples of 
cross-linked peptide wherein the linker was added 4-5 hours prior to the preparation of the fluorescence 
polarization assay wells to prepare the corresponding cyclized products 46a-46c, 47a-47c, and 48a-48c. 
In order to ensure that the cross-link was maintained during serial dilutions of the cyclized samples, a 
constant concentration (40 µM) of the appropriate linker was maintained (e.g., 46a was serially diluted 
into buffer containing 40 µM linker a). Using this sample treatment, we found that cross-link formation 
affects binding affinity, with linkers a and b making the binding affinity somewhat worse, while linker c 
maintains, but does not necessarily improve, the binding affinity compared to the linear starting peptide 
(Figure 52, Table 8). In only one case was a cross-linked oligomer obtained with a higher affinity for 
gp41-5 than its linear starting point, cross-linked product 48c. This is interesting given that peptide 48, 
even when cyclized with linker c, exhibits β-sheet like character by CD in the absence of the receptor. 
This indicates either that the cross-linked product is capable of undergoing a conformational change to a 
helical folding pattern in order to bind to gp41-5, or that it is capable of binding to gp41-5 as a β-sheet. In 
no case were the linkers alone responsible for competitive binding to gp41-5, as determined by 
competition assays of linker samples lacking peptide (Figure 52D). 
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4.3 EFFECT OF RECEPTOR PRESENCE ON CROSS-LINKING REACTIONS 
Two types of experiments were designed to determine if the presence of gp41-5 affects the outcome of 
the cross-linking reaction. In the first, a peptide is treated with one or more linkers while bound to the 
receptor; in this case, the presence of the receptor can affect either the kinetic or thermodynamic outcome 
of the reaction (e.g. change the kinetics of the peptide-linker reaction and/or the equilibrium position of 
the reaction). In the second, a peptide is treated with one or more linkers, followed by the addition of the 
protein receptor to this mixture; in this case, any changes to the equilibrium position of the reaction would 
result in observed changes in the distribution of products of the reaction over time, as determined by 
HPLC. In the latter case, the observation of no change in the equilibrium position of the reaction may 
indicate either that the receptor is not changing the energetic landscape of the reaction mixture, that the 
changes to the energetic landscape are too small to lead to distinguishable changes by the analytical 
method employed, or that the reaction is kinetically trapped at a non-equilibrium position. In the case of 
kinetic control, prior studies have demonstrated that nucleophilic catalysis and/or mildly acidic pH can 
surmount the kinetic trapping effect.
90
 
4.3.1  Reactions Utilizing A Single Organic Linker 
The simplest possible test of the effect of the presence of protein receptor on the cross-linking reactions 
used here is the use of a single peptide and a single linker in the presence or absence of the receptor. In 
order to test this directly, we utilized peptide 46 with each linker, a-c, in the absence or in the presence of 
1 equivalent of gp41-5 relative to peptide (Figure 53). It is important to note that in this case any observed 
changes in the reaction outcome due to the presence of the receptor do not necessarily result from 
exchange between the possible products, but could also result from kinetic differences in the reaction 
outcome due to the presence of the receptor. In preparing reactions of peptide 46 with linkers a-c, it was 
observed that the presence of the receptor can affect the outcome of the cross-linking reactions to 
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differing extents based on the linker utilized. In the case of linker c, almost no differences are observed in 
HPLC chromatograms whether or not the receptor is present. In the case of peptide 46 reacted with linker 
a, only small changes are observed in the HPLC chromatogram, where the proportion of the cross-linked 
isomer eluting last in the chromatogram is slightly smaller than in the untemplated reaction. In the case of 
the reaction of peptide 46 with linker b, significant qualitative changes are observed by HPLC in the 
template reaction versus the untemplated reaction wherein gp41-5 is not present. Of note is that the 
product resulting from single oxime formation (product 46b′) is no longer present when the reaction is 
performed in the presence of the receptor, and the distribution of isomers of product 46b observed in the 
untemplated reaction is markedly different. 
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Figure 53. Receptor-templated reactions of peptide 46 with linkers a-c. 
(A) Schematic representation of the experimental set-up. (B) HPLC chromatograms of cross-
linking reactions with peptide 46 and linker a in the absence (black) and presence (blue) of 1 equiv gp41-
5 relative to peptide. (C) HPLC chromatograms of cross-linking reactions with peptide 46 and linker b in 
the absence (black) and presence (blue) of 1 equiv gp41-5 relative to peptide. (D) HPLC chromatograms 
of cross-linking reactions with peptide 46 and linker c in the absence (black) and presence (blue) of 1 
equiv gp41-5 relative to peptide. All chromatograms shown are 8 hours following linker addition. Peaks 
which qualitatively change in proportion in the chromatogram are denoted with an asterisk. 
 
 
These experiments show that the presence of the receptor does not affect the efficiency of the 
cross-linking reaction, as the timescale of the reaction remained unchanged. The presence of the receptor 
was found to be capable of influencing the outcome of the reaction in some cases, but not all. Taken 
together with the fluorescence polarization data, these experiments suggest that in some cases the product 
mixture formed (as in the case of 46b) may contain products which have poor affinity for gp41-5. The 
differences observed in reactions where the protein “template,” is present may indicate discrimination 
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between cross-linked products. The bound state of the peptide leads to differences in product distribution 
in some cases, particularly peptide 46 reacted with linker b. From these experiments it is unclear if the 
resulting differences in cross-linking reaction outcome arise from kinetic effects due to the presence of 
the template or from differences in the equilibrium position of the reaction (e.g., changes in the 
thermodynamics). However, these results encouraged further exploration of the ability of the protein 
receptor to affect cross-linking reaction outcomes, as discussed below. 
4.3.2  Reactions Utilizing Two Organic Linkers Simultaneously 
Encouraged by the observed changes in isomer distribution based on the presence of the receptor for 
peptide 46 in a linker-dependent fashion, we undertook a series of experiments involving the 
simultaneous addition of two linkers (e.g., a and b) to peptide 46 in the presence or absence of gp41-5. In 
these experiments, any observed changes in the composition of the reaction mixture based on the presence 
of the receptor could indicate receptor-templated selection of a particular cross-linked product at the 
expense of other cross-linked products. Given this outcome, the possibility would exist of using this 
cross-linking method to directly screen for the most effective cross-linked oligomers for protein binding 
out of a complex mixture of possible products. 
Experimental tests of this hypothesis utilized two parallel reactions: one in which peptide 46 was 
cross-linked by the simultaneous addition of two linkers in the absence of protein receptor and a second in 
which peptide 46 is cross-linked by the addition of two linkers in the presence of gp41-5. In these 
experiments, the analysis of the HPLC chromatograms is complicated by the considerable overlap 
amongst the various isomers of each cross-linked product. Nevertheless, some chromatographic peaks 
could be unambiguously assigned based on their retention time and/or observed mass by MALDI-TOF 
MS following collection of the HPLC eluent. In the case of the mixture of linkers a and b, the cross-
linked products are mass degenerate, further complicating analysis of the reaction mixture. 
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Figure 54. Scheme and chromatograms for reactions involving addition of two linkers. 
(A) Schematic representation of the cross-linking reactions utilized; peptide bound to gp41-5 is 
treated simultaneously with two linkers (R1 and R2). (B) HPLC chromatograms of the reactions between 
peptide 46 and linkers a and b either with (blue) or without (black) gp41-5 present. (C) HPLC 
chromatograms of the reactions between peptide 46 and linkers a and c either with (blue) or without 
(black) gp41-5 present. (D) HPLC chromatograms of the reactions between peptide 46 and linkers b and c 
either with (blue) or without (black) gp41-5 present. Peaks which show considerable change in the 
template versus untemplated reaction are highlighted with an asterisk. 
 
 
It was found that the qualitative outcome of a reaction involving linker mixtures can depend on 
the presence of the receptor, particularly for reactions involving the use of linker b (Figure 54). However, 
in the binary combination of linkers a and c, there is little difference observed between template and 
untemplated reactions. We hypothesized that this may be due to the larger differences in binding affinity 
observed by fluorescence polarization for cross-linked products a or c versus b (e.g. in the case of linker b 
and c, an order of magnitude difference in observed Ki). In the case of linkers a and c, the magnitude of 
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the difference in Ki is more modest, which may be responsible for the lack of protein-templated selection 
of a particular cross-linked product. However, an alternative hypothesis also exists: that the resulting 
differences in the templated versus untemplated reactions result not from the selection of a particular 
cross-linked product but from the observed effect of the protein template on individual cross-linking 
reactions. Prior observations suggested that there were considerable differences in the cross-linking 
reaction outcome for peptide 46 treated with linker b in the presence of the receptor versus in its absence; 
no differences were observed for peptide 46 treated with linker c, and considerably more modest 
differences were observed with linker a. The qualitative observation above that the binary mixture of two 
linkers only show differences by analytical HPLC when linker b is involved suggested the possibility that 
the protein template is not discriminating between different cross-linked macrocycles. Rather, the cross-
linking reactions result in mixtures which are comprised of the sum of two individual cross-linking 
reactions in the presence of the protein receptor. 
In order to test the hypothesis that the protein receptor is not discriminating between different 
cross-linked products we set up an experiment where two parallel reactions were prepared. In the first 
reaction, peptide 46 was treated with linker b in the presence of gp41-5; in the second, peptide 46 was 
treated with linker c in the presence of gp41-5. The two reactions were allowed to go to completion, then 
mixed in a 1:1 v:v ratio. The outcome of this experiment suggested that the observed differences in the 
protein-templated reaction involving linkers b and c above was due to the sum of the individual cross-
linking reactions, as determined by qualitative comparison of the two samples (Figure 55). The 
observation that there is little or no difference between the two reactions (one where linkers are added 
simultaneously vs. one where independent reactions are mixed) shows that the protein template is not 
selecting for a given cross-linked product (e.g. 46c versus 46b), but that the outcome of the individual 
reactions of peptide 46 with either linker leads to the observed distribution of products. 
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Figure 55. HPLC chromatograms of 46 with b and c treated simultaneously or independently. 
(A) Chromatogram of peptide 46 in the presence of gp41-5 treated with linkers b and c 
simultaneously. (B) Chromatogram of peptide 46 in the presence of gp41-5 treated with linker b or c in 
independent reactions, then mixed. 
 
Despite the observation that gp41-5 is unable to selectively template the formation of a particular 
cross-linked product in the reactions with mixtures of linkers, the possibility remained that the lack of 
observed templating was due to the reaction mixture being kinetically trapped at a non-equilibrium 
position. In this case, the kinetic outcome of the reaction (a roughly statistical mixture of the two possible 
cross-linked products) would remain unchanged due to the inability of the system to undergo dynamic 
covalent exchange. An alternative hypothesis is that the reaction mixture observed represents the true 
equilibrium position of the reaction outcome, and that the system is at its thermodynamic minimum. It 
was observed that the product distribution of the reactions remained unchanged up to 24 hours following 
linker addition under the conditions utilized (pH 7 phosphate buffer, no nucleophilic catalyst). 
We next undertook a series of experiments designed to test the possibility of the system to 
undergo dynamic covalent exchange. In these experiments, the objective is to first trap the system at a 
non-equilibrium position, then perturb the equilibrium by addition of a second linker or by addition of 
gp41-5. 
In the first set of reactions, we utilized peptide 46 treated with linker b in the presence of aniline 
at pH 7 to form the product distribution of 46b and 46b′ observed previously. A second linker, c, was 
then added and the reaction mixture monitored by HPLC for up to 24 hours (Figure 56). Nucleophilic 
catalysis of oxime or hydrazone ligation and/or exchange has previously been used in the context of 
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peptide or protein conjugation
81, 108
 and in the construction of protein-templated DCLs.
14
 In this case, 
there was found to be no change in the product distribution even after 24 hours, suggesting that the 
system is kinetically trapped at a non-equilibrium position. This is demonstrated by the difference in 
equilibrium position of the reaction for the simultaneous addition of linkers b and c than that observed for 
this sequential addition experiment. An additional experiment carried out under the same reaction 
conditions, except that the pH was decreased from 7 to 5, as mildly acidic pH has been found to facilitate 
exchange.
90
 Even under these conditions, which should provide the most favorable possible conditions to 
facilitate exchange, the product distribution of the reaction was found to remain unchanged for up to 24 
hours (Figure 56). 
 
 
Figure 56. Attempted exchange reactions of peptide 46 with linkers b and c. 
(A) Schematic representation of the possible exchange reaction of cross-linked product 46b to 
form product 46c. (B) HPLC chromatograms of the addition of linker b to peptide 46 in the presence of 
1.25 mM aniline, 2 hours following linker addition (black), and 24 hours after the addition of linker c in 
the presence of 1 mM aniline. (C) HPLC chromatograms of the addition of linker b to peptide 46 in the 
presence of 1.25 mM aniline at pH 5, 2 hours following linker addition (black), and 24 hours after the 
addition of linker c in the presence of 1 mM aniline at pH 5. 
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Parallel experiments were performed where peptide 46 was treated simultaneously with linker b 
and c at pH 7 (Figure 57). Following completion of the reaction to yield the previously observed 
distribution of products for an untemplated reaction, gp41-5 was added and the product distribution 
monitored by HPLC for up to 24 hours. Under these conditions it was again found that the product 
distribution does not change. This result was somewhat surprising given the previous observations that 
oxime stereoisomers can interconvert easily; the observation that even the isomer distribution does not 
change in this case indicates significant kinetic trapping of the system at non-equilibrium positions. 
 
 
Figure 57. Attempted protein-templated selection of a binary mixture of linkers with peptide 46. 
(A) Schematic representation of the reaction performed, where the selection of one cross-linked 
product is possible upon addition of protein template. (B) HPLC chromatograms of the reaction of 
peptide 46 with simultaneous addition of linkers b and c before (black) and 24 hours after (blue) addition 
of gp41-5 as a protein template. 
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4.4 CONCLUSIONS AND PROSPECTIVE 
Oxime formation to generate side-chain to side-chain cross-links between aminooxy-bifunctionalized 
peptides and dialdehyde based linkers is uniquely capable of being utilized under conditions compatible 
with peptide ligand-protein interactions. A series of peptides based on the gp41-5 C-terminal heptad 
repeat sequence bearing two aminooxy-functionalized residues were designed to have low inherent helical 
folding in the absence of receptor. Of this peptide series, peptides 46 and 47 are principally unstructured 
in the absence of receptor, and the addition of organic linkers does not lead to significant helical folding 
as determined by circular dichroism spectroscopy. Peptide 48 displays CD spectra characteristic of β-
sheet folding both prior to and following the formation of side chain cross-links. These peptides cross-
linked in the absence of receptor exhibit differing affinities for gp41-5 as determined by competition 
fluorescence polarization assays, with the general order of affinity being dependent upon the linker 
utilized (c > a > b). In one case (product 48c) the affinity by competition fluorescence polarization of the 
cross-linked product was higher than that of the starting linear peptide. 
With the ultimate goal of utilizing this method as a way to generate complex mixtures of cross-
linked peptides which would then be subjected to a protein receptor mediated selection process, we 
undertook a series of experiments to determine if the protein receptor, gp41-5, was capable of influencing 
the outcome of cross-linking reactions. In the case of the addition of a single linker to peptide 46 either 
bound or unbound to the protein receptor, differences are observed in the outcome of cross-linking 
reactions in some cases, principally in the distribution of products in cross-linking reactions involving 
linker b. However, the use of binary mixtures (e.g. simultaneous addition of linkers b and c) in analogous 
experiments demonstrate little to no selectivity for a given collection of cross-linked isomers due to the 
presence of the protein receptor. Stereoisomers of 46c are not selectively formed over stereoisomers of 
46b in these reactions. This is contrary to the expectation that the cross-linked products more compatible 
with receptor binding should be selectively formed under the reaction conditions. Instead, the collective 
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outcome of the experiments suggests that the reaction outcome is determined kinetically and leads to a 
roughly statistical mixture of cross-linked products of 46b and 46c. 
A series of experiments performed to gauge (1) whether or not the system is capable of dynamic 
covalent exchange and (2) whether or not addition of the protein receptor gp41-5 changes the distribution 
of products were unsuccessful. In the prior case, it was found that even under conditions which should be 
optimal for oxime exchange (mildly acidic pH, nucleophilic catalyst present) the product distribution 
remains unchanged following addition of a second linker even after 24 hours. The most likely explanation 
for this outcome is kinetic trapping of the system in a non-equilibrium position, given that the outcome of 
the reaction of sequential addition of linkers is markedly different than the outcome of the same linkers 
added simultaneously. In the case of attempted template-mediated amplification of products from a pre-
equilibrated mixture, the lack of any observed selectivity (even to yield previously observed changes in 
product distribution based on the presence of the receptor) again suggests significant kinetic trapping, 
even amongst oxime stereoisomers. This kinetic trapping effect is unique to this system amongst the 
oxime cross-linking systems described in earlier chapters; in prior cases, even in the absence of 
significant dynamic covalent exchange of oximes, the distribution of oxime isomers formed were found to 
interconvert readily, which does not occur in this case. 
Addressing the limitations of this system presents a challenge; it is possible that the use of 
additional dialdehyde based linkers and/or peptide sequences with different aminooxy-functionalized 
residue spacing may yield oligomers with improved affinity for gp41-5. However, given the lack of 
receptor-templated selectivity beyond a change in the distribution of cross-linked products for single 
linker additions to bound versus unbound peptide, and the proposed significant kinetic trapping of the 
system, it is unlikely that the use of additional linkers and/or peptides will yield the desired selectivity. It 
is important to note that under the conditions of the experiments performed and described above, the 
receptor is present in equal concentration as the peptide ligand; thus, under the experimental conditions, 
all of the linear peptide is presumed to be bound to the protein receptor. This experimental design is 
commonly used in protein-templated selection experiments involving small molecule DCLs,
14, 15
 but may 
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not be ideal in this case. An experimental design wherein the ligand and protein concentration are 
significantly lower (e.g. nanomolar concentrations) such that one cross-linked product may more 
efficiently bind to the protein receptor at the expense of another cross-linked product is more likely to 
yield the desired selectivity. However, this design poses significant analytical challenges, as the 
sensitivity of the analytical methods used here is insufficient. Further development of this method may 
require either the development of new analytical techniques and/or the generation of peptide ligands 
which have decreased affinity for the protein receptor and thus can be analyzed at concentrations relevant 
to protein-mediated amplification. 
4.5 EXPERIMENTAL 
4.5.1  Peptide Synthesis And Purification 
Protected Fmoc-α-amino acids and NovaPEG Rink Amide Resin were purchased from NovaBioChem. 
Fmoc-protected versions of aminooxy residues X5 and X4 were prepared by previously used protocols 
(Chapter 2.4.2). Peptides 41-48 were prepared by manual Fmoc-solid phase peptide synthesis with 
microwave heating (CEM Mars microwave reactor). Coupling reactions were performed in N-methyl-2-
pyrrolidinone (NMP) using 5 equiv of amino acid, 5 equiv of activating agent (HCTU for natural α-amino 
acids, PyBOP for unnatural X residues) and 7.5 equiv of DIEA. The microwave coupling program 
consisted of a 2 minute ramp to 70 °C followed by a 4 minute hold at 70 °C. Removal of the N-terminal 
Fmoc-protecting group was achieved by treatment with 20% 4-methylpiperidine in DMF. The microwave 
deprotection program consisted of a 2 minute ramp to 80 °C followed by a 2 minute hold at 80 °C. The 
resin was washed three times with DMF after each coupling and deprotection reaction. Following 
completion of the peptide sequence on resin and removal of the N-terminal Fmoc group, the N-terminus 
was acetylated by treatment with 8:2:1 v:v:v DMF:DIEA:Ac2O at room temperature for 15 minutes. The 
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resin was then washed with DMF, DCM, and methanol and dried under vacuum. Cleavage of the peptide 
from resin and concomitant side chain deprotection were performed by treatment with 92.5:3:3:1.5 
TFA:H2O:EDT:TIS for 2.5-3 hours. The cleaved peptide was then precipitated into chilled diethyl ether, 
centrifuged, and the ether decanted. The pelleted crude peptide was dissolved in 30% by volume 0.1% 
TFA in acetonitrile and 70% by volume 0.1% TFA in water for purification by preparative HPLC. 
Preparative HPLC was performed using a Phenomenex Luna-C18 column and gradients between 0.1% 
TFA in water and 0.1% TFA in acetonitrile. Fractions containing the desired peptide were frozen 
immediately for lyophilization due to previous observations of unknown byproducts resulting from 
prolonged exposure of aminooxy-functionalized peptides to acetonitrile containing solution. All peptide 
samples used for biophysical characterization and cross-linking reactions were ≥95% pure as determined 
by analytical HPLC. 
 
Table 9. MALDI-TOF Data for peptides 42-48, their cyclic products, protein gp41-5 and Flu-C38. 
 [M+H]
+
 (m/z)  M+H]
+
 (m/z) 
Peptide Calculated Observed Peptide Calculated Observed 
42 2812.5 2812.3 47 2788.4 2788.3 
43 2706.3 2706.3 47a 2886.4 2886.3 
44 2600.5 2600.4 47b 2886.4 2886.6 
45 2515.3 2515.4 47b′ 2904.5 2904.7* 
46 2816.5 2816.5 47c 2892.4 2982.4 
46a 2914.5 2914.6 48 2816.5 2816.3 
46b 2914.5 2914.7 48a 2914.5 2914.8 
46b′ 2932.5 2932.7* 48b 2914.5 2914.2 
46c 2920.4 2920.2 48b′ 2932.5 2932.8* 
   48c 2920.4 2920.5 
gp41-5 22228.7
†
 22232.1
†
    
Flu-C38 5089.3 5089.5    
*Mass also observed corresponding to the acyclic hydrate, 2949.5 (46b′, 48b′) or 2921.5 (47b′) 
†
Calculated and observed average [M+H]
+
 masses
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4.5.2  Expression And Purification Of gp41-5 
The DNA fragment encoding for gp41-5 subcloned into the expression vector pRSET (Invitrogen) and 
previously utilized for expression of gp41-5
112
 was transformed into Eschericia coli BL21 DE3 cells. The 
transformed E. coli cells were grown in an overnight culture at 37 °C in 2xYT with ampicillin (100 
mg/mL) and chloramphenicol (5 mg/mL). Following overnight culture, 2xYT growth medium was 
inoculated with media containing E. coli cells and allowed to grow at 37 °C to OD600 = 0.5-0.6. IPTG 
(500 µM final concentration) was then added and the culture incubated 4.5-5 hours at 37 °C. Following 
this time, the cells were pelleted by centrifugation for 10 minutes at 2000 rpm at 4 °C. The cell pellet was 
then dissolved in cold glacial acetic acid and incubated on ice for 30 minutes. Cell debris was then 
removed by ultracentrifugation (20,000 rpm, 30 min), and the supernatant diluted to 10% acetic acid with 
deionized water, frozen, and lyophilized. Following lyophilization, the crude protein was dissolved in 
0.1% TFA in acetonitrile (35% by volume) and 0.1% TFA in water (65% by volume) and purified by 
preparative HPLC on a Phenomenex Jupiter-C18 column using gradients between 0.1% TFA in water and 
0.1% TFA in acetonitrile. Fractions containing the desired protein were frozen and lyophilized. Purity of 
the protein was assessed by analytical HPLC using a Phenomenex Jupiter-C18 column. 
 
 
Figure 58. Analytical HPLC chromatogram of purified gp41-5. 
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4.5.3  Refolding Of gp41-5 
Purified and lyophilized gp41-5 was dissolved in 6M guanidinium hydrochloride (0.1-0.3 mg/mL protein) 
and dialyzed against 100 mM glycine at pH 3.5 overnight, then dialyzed against phosphate buffered saline 
(pH 7.2) over the course of 3 days with the dialysis buffer changed daily. Following refolding, the protein 
solution was concentrated by centrifugation through a 3 kDa cutoff filter (Amicon Ultra). Purity of the 
refolded material was determined by gel permeation chromatography (GPC) on an AKTA purifier FPLC 
system equipped with Superdex 75 column (GE Healthcare). GPC was performed using an isocratic 
elution gradient consisting of 140 mM NaCl, 3 mM KCl and 10 mM phosphate buffer pH 7.4. A 
molecular weight calibration curve for the column was obtained by analyzing a solution of 0.2 mg/mL 
each of bovine serum albumin, myoglobin, cytochrome C, and insulin. 
 
 
Figure 59. Analytical GPC chromatogram of refolded gp41-5. 
4.5.4  Cross-Linking Reactions 
Stock solutions of peptides 46-48  were prepared in water and their concentration determined by UV-Vis 
spectroscopy based on Trp and Tyr absorbance at 280 nm (ԑ280 = 12660 M
-1
 cm
-1
)
102
 following 5x dilution 
of the peptide stock into 8M guanidinium hydrochloride. The concentration of refolded gp41-5 in 
phosphate buffered saline (ԑ280 = 42390 M
-1
 cm
-1
)
102
 was determined identically. Stock solutions of linkers 
a-c were prepared in water. The concentration of linkers a and b were determined by UV-Vis (a, ԑ292 = 
 135 
1120 M
-1
 cm
-1
; b, ԑ296 = 1950 M
-1
 cm
-1
).
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 The concentration of linker c was determined by mass to 
volume. Linkers a-c were well soluble in water and were delivered to the reactions from stock solutions 
containing 400-700 µM linker in water. All cross-linking reactions were performed in 0.1 M phosphate 
buffer pH 7 with 10 µM peptide and 4 equiv (40 µM) of the appropriate linker(s) with or without 10 µM 
gp41-5. For samples containing gp41-5, the sample was prepared containing peptide and gp41-5 in pH 7 
phosphate buffer and equilibrated for 40 minutes at room temperature prior to dilution by addition of 
linker(s) to furnish the reaction solutions described above.  Reactions were analyzed by analytical HPLC 
on a Phenomenex Luna-C18 column and by MALDI-TOF MS following collection of the eluent. 
 For attempted linker exchange reactions, a sample of cyclic peptide 46b or was prepared in 0.1 M 
phosphate buffer at pH 7 or 0.1 M phosphate buffer at pH 5 from peptide 46 (12.5 µM) and linker b (50 
µM) in the presence of 1.25 mM aniline. After complete conversion to 46b as determined by analytical 
HPLC and MALDI-TOF MS (after 2 hours) linker c (4 equiv) was added from an aqueous stock solution 
to yield a final composition of 10 µM peptide, 40 µM each of linkers b and c in 0.1 M phosphate buffer at 
pH 7 or pH 5 and 1 mM aniline. The resulting reaction mixtures were monitored by HPLC for any 
changes in the distribution of products for up to 24 hours. 
 For attempted receptor-mediated selection of cross-linked products, peptide 46 at 15 µM 
concentration in 0.1 M phosphate buffer at pH 7 was reacted with linkers b and c added simultaneously. 
Following completion of the reaction as determined by analytical HPLC (4 hours), gp41-5 was added 
from an aqueous stock solution to yield a final reaction composition of 10 µM peptide 46, 10 µM gp41-5, 
and 40 µM each of linkers b and c and the reaction mixture was monitored by analytical HPLC for a 
change in reaction composition over the course of 24 hours. 
4.5.5  Circular Dichroism Spectroscopy 
Samples of linear peptides 42, 44, and 45 as well as 46-48 were prepared in 0.1 M phosphate 
buffer pH 7 at a concentration of 50 µM. Samples of cyclized peptides 46a-46c, 47a-47c, and 48a-48c 
 136 
were prepared in 0.1 M phosphate buffer at pH 7 containing 50 µM peptide and 4 equiv (200 µM) linker 
and allowed to react 4 hours at room temperature. Following completion of the cross-linking reaction as 
determined by HPLC and MALDI-TOF MS, CD scans were performed on an Olis DSM17 circular 
dichroism spectrophotometer. Scans were performed from 200 to 260 nm with 1-nm step size, 2-nm 
bandwidth and 5 second integration time at 20 °C in 1 mm cuvettes. Raw CD data were smoothed by the 
Savitsky-Golay method as implemented in GraphPad Prism. 
4.5.6  Fluorescence Polarization Assays 
Fluorescence polarization assays were conducted at room temperature in non-treated 96-well black 
polystyrene plates (Costar) on an Envision 2100 plate reader. All measurements were performed in 
triplicate wells containing 100 µL total volume. The assay buffer was composed of 20 mM phosphate 
buffer pH 7.4, 50 mM NaCl, 1 mM EDTA, 0.2 mM NaN3 and 0.5 mg/mL Pluronic-F68. All assay plates 
contained four wells of each of the following: (1) assay buffer (90 µL + 10 µL H2O), (2) Flu-C38 (90 µL 
at 1.1 nM concentration diluted with 10 µL H2O to a final concentration of 1.0 nM) and (3) Flu-C38 and 
gp41-5 (1.1 nM and 2.2 nM, respectively), in 90 µL of assay buffer diluted with 10 µL water to a final 
concentration of 1.0 nM Flu-C38 and 2.0 nM gp41-5. Direct binding experiments to determine the 
affinity of Flu-C38 for gp41-5 were performed by serial dilutions of gp41-5 against a solution containing 
2 nM Flu-C38, and the Kd determined to be ≤ 1 nM, in agreement with literature values.
112
 Competition 
fluorescence polarization assays for linear peptides 42, 44, 45 and 46-48 were conducted by addition of 
10 µL of serial dilutions from peptide stocks in water to the assay buffer described above, 90 µL 
containing 1.1 nM Flu-C38 and 2.2 nM gp41-5 to assay wells containing final concentrations of 1.0 nM 
Flu-C38 and 2.0 nM gp41-5. 
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Figure 60. Direct binding fluorescence polarization assay of gp41-5 and Flu-C38. 
 
Competition fluorescence polarization assays for cyclized peptides 46a-46c, 47a-47c, and 48a-
48c were prepared similarly. Cross-linking reactions of each peptide were prepared as described above 
and allowed to rest for 4-5 hours, until completion of the reaction was determined by MALDI-TOF MS. 
The cyclized peptide was then serially diluted into appropriate linker stocks containing 40 µM linker in 
assay buffer. The serial dilutions were then added (10 µL) into 90 µL assay buffer to a final composition 
of cross-linked product with 1.0 nM Flu-C38 and 2.0 nM gp41-5.  
All assay plates were allowed to equilibrate for 30 minutes to 1 hour at room temperature prior to 
analysis. Fluorescence polarization direct binding data were analyzed in GraphPad prism using published 
methods.
114
 The concentration of ligand was constrained to 2.0 nM in the fit and the molar emissivity 
ratio of the bound ligand to that of the unbound ligand was taken as the ratio of the total fluorescence of 
the control wells lacking receptor and control wells of fluorescent tracer bound to the protein in the assay 
plate.  Competition fluorescence polarization data were analyzed in GraphPad Prism using published 
methods
115
 where Kd of the tracer was set to 0.4 nM based on literature precedent.
112
 In the fit of 
competition fluorescence polarization data, the parameters describing the top, Ki, and slope of each curve 
were allowed to float. Not all compounds exhibited complete inhibition at the highest peptide 
concentration; the parameter for the bottom of each curve was set as a shared value (the mP of the 
unbound tracer from the control wells described above) for each assay plate.
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APPENDIX A. INVESTIGATION OF THE THERMODYNAMICS OF CROSS-LINKING 
A.1.  INTRODUCTION 
The use of side-chain to side-chain cylization (referred to as “cross-linking,” or “stapling,”) of peptides 
has developed considerably over the course of the last decade with an eye towards generating peptide 
scaffolds with improved biophysical and therapeutic characteristics.
40
 Several successful strategies have 
been implemented in developing peptide-based inhibitors of protein-protein interactions. The leading 
hypothesis for the success of side-chain to side-chain cyclization in nucleating and stabilizing helical 
structures is that the side chain cross-links lead to preorganization of the peptide backbone into a helical 
conformation.
39
 This implies an entropic stabilization of the helical fold through constraint of backbone 
conformations. Prior study has shown how cross-linked oligomers change the folding free energy 
associated with protein-protein interactions.
116, 117
 Additional work has examined the relative ability of 
different cross-linking strategies to nucleate helical folding patterns.
118
 However, there has yet to be a 
direct test of the hypothesis that side chain cross-linking influences helical folding through entropic 
stabilization. In order to directly test the hypothesis that side chain cross-links are entropically stabilizing 
to helical folds, we utilized a folded monomeric protein containing an α-helical region into which were 
inserted three different types of cross-links. Subsequent global analysis of the folding free energy 
landscape of the resulting oligomers in their linear and cyclic forms through circular dichroism thermal-
chemical denaturation
119, 120, 121
 allows for direct comparison of different cross-linking strategies in their 
ability to stabilize a monomeric helical fold. This strategy also allows for determination if any resulting 
gain in stability of the folded peptide is due to changes in the enthalpy or entropy of folding. 
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A.2.  MODEL SYSTEM SELECTION AND DESIGN 
As noted above, previous studies have investigated thermodynamic changes associated with peptide 
cross-linking in the context of protein-protein interactions.
116, 117
 However, in these analyses the process 
of quaternary structure formation and monomeric folding are inextricably entwined, which complicates 
analysis. In order to answer the open questions regarding the thermodynamic consequences of cross-link 
formation, a peptide model system is needed with particular characteristics: (1) a well-folded, monomeric 
and stable tertiary structure in aqueous solution, (2) one or more α-helical regions in which to insert cross-
linking residues, and (3) a length and sequence amenable to solid-phase peptide synthesis and post-
synthetic manipulations associated with cross-link formation. 
We chose to utilize the villin headpiece domain (VHP) as a model system for our studies (Figure 
A1).
122
 This domain has previously been utilized to investigate the kinetics and thermodynamics of 
folding for short, fast-folding polypeptide sequences, and is comprised of 36-residues found in three short 
helical regions.
123, 124, 125
 The folding of the VHP domain results from the formation of hydrophobic 
packing interactions between residues found on one face of each helix.
126
 The wild-type VHP domain was 
altered by replacement of methionine residues with norleucine, in order to avoid potential oxidation of 
methionine during synthesis or analysis of cross-linked oligomers requiring oxidative conditions. 
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Figure A1. Sequence of VHP and peptide A1, wild-type structure, and CD spectrum of A1. 
(A) Sequence of VHP and analogue A1 where methionine has been replaced with norleucine. (B) 
Structure of the wild-type VHP domain from PDB: 1VII. (C) CD scan of peptide A1. 
Having generated a suitable analogue of the VHP domain, peptide A1, we investigated its folding 
by circular dichroism spectroscopy. Peptide A1 was found to have a CD spectrum consistent with that of 
the wild-type VHP domain.
126
 Temperature-dependent CD spectroscopy was used to ascertain the thermal 
stability of peptide A1. The mutation of methionine to norleucine was found to have a small impact on the 
thermal stability of the fold (Tm = 64 °C) as compared to the wild-type VHP domain (Tm = 70 °C).
126
 We
used thermal-chemical denaturation circular dichroism experiments to investigate the thermodynamics of 
unfolding in VHP analogue A1. Thermal-chemical denaturation circular dichroism spectroscopy has 
previously been used to evaluate the folding free energy of the Arabidopsis N-terminal ribosomal 
transcription factor, NTL9,
119
 the thermodynamic changes associated with side-chain fluorination in well-
folded peptides,
120
 and the consequences of insertion of β-residues into α-peptide backbones in a well
folded tertiary structure.
121
 Thermal denaturation experiments were performed in 50 µM solutions of 
peptide in the presence of guanidinium hydrochloride in 0.5 M increments between 0 and 5.5 M (Figure 
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A2). Analysis of the thermal-chemical denaturation data provides the thermodynamic parameters 
associated with unfolding of the peptide backbone (Table A1). 
Figure A2. CD thermal and thermal-chemical denaturation experiments of A1. 
(A) CD melt of peptide A1 where molar elipticity at 222 nm is monitored as a function of 
temperature. (B) Thermal-chemical CD denaturation of peptide A1. Molar elipticity at 222 nm is 
monitored as a function of temperature and chemical denaturant. Raw data (points) are fit (surface) to 
extract thermodynamic parameters of the unfolding equilibrium. 
Having validated the use of the VHP domain A1 as a suitable model system, we designed 
oligomers (A2-4) containing residues appropriate for the introduction of side chain to side chain cross-
links (Figure A3). In each peptide A2-A4 lysine or a close analogue of lysine (azidolysine in A3, X in 
A4) is substituted at position 31. These substitutions are conservative or nearly so for the lysine at that 
position in the natural sequence. A complementary amino acid for the cross-linking type employed is 
placed at position 27 in the sequence, for an i→i+4 spacing of the residues. Peptide A2 contains 
orthogonally protected lysine and aspartic acid residues which can be deprotected by treatment with mild 
acidic conditions on resin and cyclized to form a lactam cross-link. Peptide A3 contains D-
propargylglycine at position 27 and azidolysine at position 31 to be used in the formation of a triazole 
cross-link. Peptide A4 contains an aminooxy-functionalized residue at position 31 and a serine-acylated 
residue at position 27 in order to generate an oxime cross-link. 
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Figure A3. Sequences of peptides A1-A4, residue and cross-link chemical structures. 
(A) Sequences of peptides A1 and variants A2-A4 in which residues are inserted to form cross-
links. (B) Chemical structures of the monomers used in cross-linking and the cyclic products of cross-
linking reactions. 
Orthogonally protected Fmoc-Lys(Mtt)-OH and Fmoc-Asp(OPip)-OH residues in peptide A2 and 
Fmoc-D-propargylglycine used in peptide A3 were purchased from commercial suppliers. Fmoc-L-
azidolysine was synthesized according to literature procedures (Scheme A1). Triflic azide was prepared 
by reaction of triflic anhydride with sodium azide. The crude triflic azide was directly reacted with Fmoc- 
-Lys-OH to form Fmoc-azidolysine. Fmoc-protected aminooxy monomer X and serine-acylated monomer 
U were prepared as described in section 2.4.2. 
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Scheme A.1. Synthesis of Fmoc-L-azidolysine 
Peptides A2-A4 were synthesized by standard Fmoc-based SPPS. Peptide A2 was then subjected 
to mild acid treatment to deprotect orthogonally protected lysine and aspartic acid residues. The peptide 
was then subjected to on-resin cyclization by reaction with PyBOP and DIEA under microwave 
irradiation to form peptide A2Cyc. Peptides A3 and A4 were synthesized, cleaved, and purified by 
HPLC. Peptide A3Cyc was prepared by copper(I)-mediated azide-alkyne cycloaddition. Peptide A4Cyc 
was generated by treatment of A4 with aqueous sodium periodate and subsequent formation of oxime-
cyclized product A4Cyc. Cyclic products A3Cyc and A4Cyc were purified by HPLC prior to biophysical 
analysis. 
A.3.  CROSS-LINK EFFECT ON FOLDING AND STABILITY 
With peptides A2-A4 and in hand, we examined their folding behavior by CD spectroscopy. In each case, 
the CD spectrum is indicative of α-helical folding (Figure A4). Products A2Cyc, A3Cyc, and A4Cyc 
were found to have similar CD spectra as compared to their linear counterparts. Cumulatively, CD scans 
show that side chain cross-linking in these peptides has a minimal impact on the helical fold. 
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Figure A4. CD scans of peptides A1-A4 and cyclic products A2Cyc, A3Cyc and A4Cyc. 
(A) CD scans of peptide A1, A2, and A2Cyc at 50 µM concentration in 50 mM phosphate buffer, 
pH 7. (B) CD scans of peptide A1, A3, and A3Cyc at 50 µM concentration in 50 mM phosphate buffer, 
pH 7. (C) CD scans of peptide A1, A4, and A4Cyc at 50 µM concentration in 50 mM phosphate buffer, 
pH 7. 
CD thermal denaturation experiments were used to compare the thermal stability of A2-A4 and 
their cyclized products (Figure A5). Peptides A2 and A4 showed two-state thermal transitions and had 
thermal melting temperatures similar to control peptide A1. Peptide A3 showed a two-state thermal 
transition but was significantly destabilized as compared to A1. We attribute this destabilization to the 
insertion of D-propargylglycine into the sequence. While D-propargylglycine was found to be most 
effective in stabilization of helical folding in a short helical peptide,
76
 the insertion of D-amino acids can 
be destabilizing to helical folds. CD thermal denaturation experiments with peptide A3Cyc showed a 
nearly identical thermal transition as compared to its linear counterpart A3. In contrast, the thermal 
denaturation of peptides A2Cyc and A4Cyc led to shallower thermal transitions over the temperature 
range of the experiment. Fitting to a two-state thermal denaturation model failed for A2Cyc and A4Cyc 
due to the nearly linear nature of the thermal transition. 
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Figure A5. CD melts of peptides A1-A4 and cyclized products A2Cyc, A3Cyc, and A4Cyc. 
(A) CD melts of peptides A1, A2, and A2Cyc. (B) CD melts of peptides A1, A3 and A3Cyc. (C) 
CD melts of peptides A1, A4, and A4Cyc. 
A.4.  THERMODYNAMICS OF UNFOLDING BY THERMAL-CHEMICAL 
DENATURATION 
Thermal-chemical denaturation CD experiments were performed to analyze the thermodynamic 
equilibrium of unfolding for peptides A2-A4 and their cyclized products. Despite ambiguous fitting of 
peptides A2Cyc and A4Cyc in simple thermal denaturation experiments, all peptides were successfully fit 
to two-state folding model (Figure A6). Peptide A3Cyc was found to have almost identical 
thermodynamic parameters to its linear counterpart A3 (Table A1). In contrast, peptides A2Cyc and 
A4Cyc were found to have significantly different thermodynamic parameters of unfolding (Table A1). 
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Table A1. Thermodynamic parameters of unfolding for A1-A4, A2Cyc, A3Cyc, and A4Cyc. 
Peptide ΔHunfold (kcal mol
-1
) ΔSunfold (cal mol
-1
) ΔCp,unfold (kcal mol
-1
 K
-1
) m (kcal mol
-1
 M
-1
)
A1 7.4 ± 0.5 19.3 ± 1.3 0.30 ± 0.04 0.55 ± 0.04 
A2 10.8 ± 0.1 28.3 ± 1.5 0.44 ± 0.04 0.81 ± 0.04 
A2Cyc 3.6 ± 0.5 10.7 ± 2.6 0.16 ± 0.05 0.32 ± 0.06 
A3 9.0 ± 0.4 24.8 ± 1.1 0.35 ± 0.03 0.73 ± 0.03 
A3Cyc 8.9 ± 0.5 24.3 ± 1.6 0.37 ± 0.04 0.68 ± 0.04 
A4 9.2 ± 0.5 24.0 ± 1.2 0.34 ± 0.03 0.70 ± 0.04 
A4Cyc 5.6 ± 0.3 13.2 ± 1.1 0.26 ± 0.04 0.48 ± 0.04 
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Figure A6. 3D melts of peptides A2-A4 and cyclic products A2Cyc, A3Cyc, and A4Cyc. 
CD signature at 222 nm is monitored as a function of temperature and chemical denaturant. Raw 
data (points) are fit (surface) to extract thermodynamic parameters of the folding equilibrium. (A) 3D CD 
melt of peptide A2. (B) 3D CD melt of peptide A2Cyc. (C) 3D CD melt of peptide A3. (D) 3D CD melt 
of peptide A3Cyc. (E) 3D CD melt of peptide A4. (B) 3D CD melt of peptide A4Cyc. 
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The enthalpy change associated with unfolding is considerably smaller in A2Cyc versus A2; this 
is also true of A4Cyc versus A4 (Figure A7). One possible origin of the unfavorable change of ΔHunfold
accompanying side-chain cyclization is a change in backbone interactions with solvent. Cross-linking 
may limit solvent accessibility for hydrogen bonding interactions with backbone amides. This would 
cause significant changes to the enthalpy associated with hydrogen bonding interactions between the 
folded and unfolded states of the peptide. An alternative explanation is the removal of stabilizing 
intramolecular polar interactions in the cyclized peptides. Sequestration of the residues utilized in cross-
link formation (Asp, Lys in A2, U and X in A4) may remove enthalpically favorable interactions. Of note 
is that the enthalpy of unfolding for peptides A3 and A3Cyc are the same within the error associated with 
the fitting analysis (Figure A7). This suggests that there are few changes to enthalpic solvent-peptide 
interactions and/or intrapeptide interactions involved in the cyclization reaction between D-
propargylglycine and azidolysine. 
Figure A7. Enthalpy change of unfolding for peptides A2-A4 and cyclic products. Each 
bar represents the ΔHunfold from fitting of raw 3D melt data. Error bars represent the 
uncertainty of the fit. 
The entropy change associated with unfolding is significantly smaller in peptide A2Cyc versus 
A2; a similar difference is observed for A4Cyc versus A4. Taken in concert with the above observations 
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about the change in enthalpy associated with unfolding for peptide pairs A2, A2Cyc and A4, A4Cyc, this 
suggests significant entropy-enthalpy compensation is occurring. This effect has been noted for the 
thermal denaturation of other proteins.
127
 As is the case for the enthalpy change of unfolding for peptide 
pair A3 and A3Cyc, the entropy change of unfolding is unchanged upon cyclization. The observation that 
the entropy of unfolding does not change in all cases is somewhat surprising. It is expected that side chain 
cross-linking should introduce conformational constraints on the unfolding process. This should lead to a 
decrease in the entropy change associated with the unfolding of the peptide backbone. However, in the 
case of A3Cyc versus A3, this is not the case. One possible explanation is that the macrocycle present in 
A3Cyc is too flexible to effectively constrain the backbone. However, the macrocycle of A3Cyc is nearly 
isosteric with that in A2Cyc, where a change in the entropy of unfolding is associated with cyclization. 
Figure A8. Entropy change of unfolding for peptides A2-A4 and cyclic products. 
Each bar represents the ΔSunfold from fitting of raw 3D melt data. Error bars represent 
the uncertainty of the fit. 
Protein folding is often accompanied by positive changes in heat capacity, which result from 
differences in the interaction of water with the folded versus unfolded state.
128
 The magnitude of the 
change in heat capacity depends on a number of factors, which include residual structure in the denatured 
ensemble. The constraint of backbone atoms introduced by side chain to side chain cross-links would thus 
be expected to have an impact on the change in heat capacity associated with unfolding. As observed 
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previously, this is not the case for peptide A3Cyc versus A3. However, this hypothesis is supported by 
the heat capacity changes associated with peptide A2Cyc versus A2 and A4Cyc versus A4. The 
observations from A2 and A4 and their cyclized counterparts are consistent with changes to the denatured 
conformational ensemble to favor more compact structures. This is further supported by observations in 
the change in m between the cyclized and linear sets of A2 and A4. The parameter m is a measure of the 
dependence of the folding free energy on denaturant concentration.
129
 This dependence of free energy of 
unfolding on denaturant concentration, combined with changes to heat capacity, are correlated to the 
change in solvent accessible surface area that accompanies unfolding. That the dependence of free energy 
on denaturant concentration, m, decreases for A2Cyc versus A2 and for A4Cyc versus A4, but not for 
A3Cyc versus A3 correlates well to prior observations. 
Figure A9. Heat capacity and m for peptides A1-A4 and cyclic products. 
(A) Change in heat capacity (ΔCp) of unfolding for peptides A1-A4 and cyclic products. Each bar 
represents the ΔCp from fitting of raw 3D melt data. Error bars represent the uncertainty of the fit. (B) 
Dependence of folding free energy on denaturant concentration (m) for peptides A1-A4 and cyclic 
products. Each bar represents the m value from fitting of raw 3D melt data. Error bars represent the 
uncertainty of the fit. 
Overall, the thermodynamic parameters of unfolding associated with unfolding of cyclized 
peptides versus their linear counterparts supports the hypothesis that cross-linking constrains the 
backbone and decreases the entropy associated with unfolding. This decrease in the entropy of unfolding 
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is further supported by changes to heat capacity and m, which follow the same general trend. Of note is 
that one cyclic and linear pair (A3Cyc and A3) do not vary considerably in any of the thermodynamic 
parameters associated with unfolding. This is likely due to inappropriate design of the substitution pattern 
for cross-linking residues. Prior study of triazole cross-linked helical peptides noted that the monomer 
pairing of D-propargylglycine and azidolysine led to significant stabilization of a helical fold.
76
 However, 
in that study the alkyne-functionalized side chain utilized in cross-link formation was C-terminal to the 
corresponding azide-functionalized side chain. It is likely that reversal of the residue positions, as 
implemented in A3 and A3Cyc is destabilizing to the helical fold due to insertion of D-propargylglycine. 
However, it is still surprising that cyclization of peptide A3 does not change the thermodynamic 
parameters associated with unfolding. Even if the helical fold is destabilized, it is expected that cross-link 
formation would change the thermodynamics of unfolding; this outcome is not observed. 
A.5.  CONCLUSIONS 
The use of VHP as a model sequence has provided valuable data which largely supports the hypothesis 
that cross-linking conformationally restricts the peptide backbone thus stabilizing helical folds. However, 
the inability to fit the thermal denaturation experiments of A2Cyc and A4Cyc to a simple two-state 
unfolding model argues that this model system is not ideal. It was previously observed (see section 2.2) 
that oxime cross-links can significantly decrease the sigmoidal nature of the two-state thermal 
denaturation of a peptide quaternary structure. In extreme cases, this change results in a nearly linear 
dependence of helical folding on temperature. It is likely that in the VHP system similar changes to the 
sigmoidal nature of the thermal denaturation curve are responsible for the ambiguity in two-state thermal 
denaturation model fitting. It is unclear if this results from significant changes to the overall folding 
pathway of the peptide, or if it is due to changes in the thermodynamic parameters of unfolding along the 
same unfolding pathway. A potential avenue to explore this phenomenon further is to utilize a system 
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which has a greater change in the magnitude of the CD minima monitored during thermal-chemical 
denaturation experiments. The Streptococcal protein GB1 has proven to be a valuable model system in 
our lab for this type of analysis.
121
 While its 56-residue length makes its synthesis non-trivial, a series of 
variants of GB1 bearing cross-linking residues may be synthesized by semisynthetic procedures adapted 
from larger proteins. GB1 has a much sharper thermal denaturation transition than is observed for VHP. 
Utilizing a different model system would allow for confidence in the global analysis of thermodynamic 
parameters even if the sigmoidal transition is broaded due to the presence of cross-links. 
A.6.  EXPERIMENTAL 
A.6.1. General Information 
Solvents and other reagents were purchased from Sigma Aldrich, Baker, EMD, Fisher, or Acros Organics 
and used as received unless otherwise specified. Cbz-Asp-OBn, Cbz-Glu-OBn, and Fmoc-Lys-OH were 
purchased from Chem-Impex. 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
hexafluorophosphate (HCTU), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate 
(PyBOP), Nova-Peg Rink Amide Resin, 9-fluorenylmethoxycarbonyl-N-hydroxysuccinamide and Fmoc-
protected α-amino acids were purchased from NovaBiochem. Flash column chromatography was 
performed using SorbTech (60 Å, 40-63 µm) silica gel. NMR spectra were recorded on a Bruker Avance-
400 spectrometer. MALDI-TOF mass spectrometry was performed on a Voyager DE Pro instrument. 
Circular dichroism spectra were recorded on an Olis DSM17 Circular Dichroism Spectrometer using 
quartz cuvettes of 0.1 cm path length. Preparative and analytical HPLC were performed with Phenomenex 
Luna C18 columns. 
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A.6.2. Monomer Synthesis 
Fmoc-protected aminooxy-functionalized residue 12a and serine-acylated residue 16b were synthesized 
as described in section 2.4.2. Fmoc-L-azidolysine was synthesized by a previously reported procedure.
130
 
Scheme A.2. Synthesis of Fmoc-L-azidolysine (A7). 
N-(9-Fluorenylmethoxycarbonyl)-2-(S)-amino-6-azidohexanoic acid (Fmoc-Lys(N3)-
OH; A7):
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 Sodium azide (5.75 g, 88.6 mmol, 5.0 equiv) was dissolved in 15 mL water 
and cooled to 0 °C under nitrogen. Trifluoromethanesulfonic anhydride (5.0 g, 17.7 
mmol, 1.0 equiv) was dissolved in 12 mL dichloromethane and added to the reaction vessel dropwise. 
The resulting mixture was stirred for 2 hours under nitrogen at 0 °C. Following this time the reaction 
mixture was poured into a separatory funnel and the organic layer separated. The aqueous layer was 
extracted twice with 8 mL dichloromethane, the organic layers combined, and washed once with 10 mL 
saturated aqueous Na2CO3. The organic layer containing trifluoromethanesulfonyl azide (A5) was used 
directly in the next step without concentration or further purification. Trifluoromethanesulfonyl azide is 
explosive and should not be isolated. Following preparation of compound A5, Fmoc-Lys-OH (3.26 g, 
8.86 mmol, 1.0 equiv), CuSO4•5H2O (22.1 mg, 0.089 mmol, 0.01 equiv) and K2CO3 (2.57 g, 18.61 mmol, 
2.1 equiv) were suspended in 80 mL anhydrous methanol under nitrogen. Water (10 mL) was added to aid 
dissolution. The dichloromethane containing trifluoromethanesulfonyl azide from the previous step 
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(assumed to be 17.72 mmol, 2.0 equiv) was added slowly to the reaction vessel. The reaction was stirred 
overnight at room temperature, then concentrated by rotary evaporation. The resulting aqueous solution 
was diluted with 30 mL 5% w/v NaHCO3 and extracted twice with 50 mL ethyl acetate. The aqueous 
layer was then acidified to pH 1with 1 M HCl and extracted four times with 40 mL ethyl acetate. The 
organic layers were combined and washed with 40 mL brine, then dried over anhydrous magnesium 
sulfate and concentrated. The resulting oil was purified by flash column chromatography (50%→100% 
ethyl acetate in hexanes) to afford product A7 as a viscous yellow oil (4.16 mmol, 46%). Spectra agreed 
with previously reported data.
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A.6.3. Peptide Synthesis And Cyclization 
Peptides A1-A4 and cyclized products A2Cyc, A3Cyc, and A4Cyc were synthesized on NovaPEG Rink 
Amide Resin with microwave heating (MARS microwave reactor, CEM). Amino acid couplings were 
performed with 5.0 equiv of amino acid to resin. Natural α-amino acids were preactivated with HCTU 
(5.0 equiv to resin) and DIEA (7.5 equiv to resin) for in NMP for 2-3 minutes. Unnatural residues Fmoc-
D-propargylglycine, Fmoc-L-azidolysine, serine-acylated monomer 16a and aminooxy-functionalized 
monomer 12b were preactivated with PyBOP (5.0 equiv to resin) and DIEA (7.5 equiv to resin). The 
preactivated amino acid was then added to the resin in a reaction vessel equipped with a stir bar, and a 
microwave program consisting of a 2 minute ramp to 70 °C followed by a 4 minute hold at 70 °C was 
run. Following the coupling program, the resin was washed three times with DMF. After washing, the 
resin was treated with 20% 4-methylpiperidine in DMF with a microwave deprotection program 
consisting of a 2 minute ramp to 80 °C followed by a 2 minute hold at 80 °C. Following Fmoc 
deprotection, the resin was washed with DMF, and the couple-wash-deprotect cycle repeated until the 
desired peptide chain was obtained on resin. Subsequent N-terminal deprotection and cleavage using 
92.5% trifluoroacetic acid, 3% water, 3% ethanedithiol, and 1.5% triisopropylsilane afforded crude 
peptides A1-A4. 
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Peptide A2Cyc was prepared by on-resin cyclization procedures.
44
 Following assembly of the 
desired peptide chain on resin, but prior to N-terminal Fmoc deprotection, the resin was washed five times 
with dichloromethane. Following this washing procedure, the resin was subjected to treatment with 3% 
trifluoroacetic acid and 5% triisopropylsilane in dichloromethane for five minutes. This treatment with 
dilute trifluoracetic acid is precedented for the removal of the 4-methyltrityl (Mtt) protecting group on 
lysine and the phenylisopropyl ester (OPip) protecting group on aspartic acid.
44
 The deprotection and 
washing procedure was repeated three times total to achieve deprotection of the desired residues. 
Following side chain deprotection, the resin was washed three times with DMF, then subjected to 
treatment with PyBOP (1 equiv to resin) and DIEA (1.5 equiv to resin) under the microwave coupling 
program described above. This procedure was repeated twice to form the desired lactam cross-link 
between Asp27 and Lys31. Following on-resin cyclization, the N-terminus was deprotected under the 
standard microwave deprotection procedure and the peptide cleaved and purified under identical 
conditions to those used for the linear peptides A1-A4. 
Following cleavage of peptides A1-A4 and A3Cyc from resin, the crude peptide was precipitated 
in cold diethyl ether and centrifuged. The ether was decanted and the resulting crude material was 
dissolved in 0.1% TFA in water and 0.1% TFA in acetonitrile and sonicated for 30-40 minutes prior to 
purification. Purification by HPLC was performed in a Luna C18 preparative column using gradients 
between 0.1% TFA in water and 0.1% TFA in acetonitrile. Identities of the purified peptides were 
confirmed by MALDI-TOF MS. All peptides used in subsequent biophysical characterization or 
cyclization were judged to be ≥ 95% pure by analytical HPLC. 
Cyclized product A3Cyc was prepared from peptide A3 by copper(I)-mediated azide-alkyne 
cycloaddition in solution. Pure, lyophilized A3 and CuSO4•5H2O (4.4 equiv) were dissolved in 2:1 v:v 
water:tert-butanol to give a final peptide concentration of 1 mg/mL. Sodium L-ascorbate (4.4 equiv) 
dissolved in water was added in 4 portions over the course of 1 hour. The reaction was placed on a shaker 
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at room temperature for 2 hours following completion of sodium ascorbate addition. The reaction was 
then purified by preparative HPLC. 
Cyclized product A4Cyc was prepared from peptide A4 by treatment with aqueous sodium 
periodate. Pure lyophilized A4 was dissolved in water and its concentration determined by UV-Vis 
spectroscopy (ԑ280 = 5690 M
-1
 cm
-1
 based on Trp absorbance).
102
 A stock of sodium periodate prepared in
water and the concentration of periodate determined by UV-Vis spectroscopy (ԑ280 = 317 M
-1
 cm
-1
).
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Oxidation ad cross-linking was performed by dilution of the peptide stock with water, buffer, and 
periodate to a final concentration of 100 µM peptide in 100 mM phosphate buffer with 1 equiv (100 µM) 
sodium periodate in a total volume of 2 mL. The reaction as allowed to rest for 15 minutes, then product 
A4Cyc was purified by preparative HPLC. The above procedure was repeated to obtain sufficient purified 
A4Cyc for subsequent biophysical characterization. 
Table A2. MALDI-TOF data for peptides A2-A4, A2Cyc, A3Cyc, and A4Cyc. 
[M+H]
+
 (m/z) 
Peptide Calculated Observed 
A1 4151.3 4151.1 
A2 4138.2 4138.0 
A2Cyc 4120.2 4120.3 
A3 4144.2 4144.1 
A3Cyc 4144.2 4144.3 
A4 4212.3 4212.3 
A4Cyc 4163.2 4163.0 
A.6.4. Circular Dichroism Spectroscopy And Data Analysis 
Stock solutions of peptides A1-A4, A2Cyc, A3Cyc, and A4Cyc were prepared in water and the 
concentration of peptide determined by UV-Vis spectroscopy based on Trp absorbance (ԑ280 = 5690 M
-1
cm
-1
).
102
 Sampled for CD spectroscopy were prepared by dilution of the peptide stock with water and 
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buffer to yield samples consisting of 50 µM peptide in 50 mM phosphate buffer, pH 7. Additional 
samples containing varying concentrations of guanidinium hydrochloride were prepared identically 
excepting addition of guanidinium hydrochloride from an 8 M aqueous stock solution. CD scans were 
performed from 200-260 nM with 1 nM step size, 2 nM bandwidth, and 5 second integration times. CD 
melts were performed by monitoring molar elipticity at 222 nm over the range of 2 °C to 95 °C in 3 °C 
increments, a dead band of 0.5 °C and a 2 minute equilibration time at each temperature. All 
measurements were baseline corrected for buffer. Circular dichroism scans were smoothed by the 
Savitsky-Golay method as implemented in GraphPad Prism. Thermal melts of samples lacking 
guanidinium hydrochloride were processed using GraphPad prism and fit to a two-state thermal 
denaturation model.
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Raw data from thermal-chemical denaturation experiments were fit using Mathematica 8 
(Wolfram) and equations reported previously
119
 and summarized below. The protein folding free energy 
(ΔG) at a given temperature (T) and concentration of guanidinium ([Gdm]) is given by the modified 
Gibbs-Helmholtz equation (8): 
Equation 8 
][)ln(( Gdmm
T
T
TTTCSTHG p 
  
In the above equation, ΔH° and ΔS° are the folding enthalpy and entropy at a reference temperature, T° 
(293 K). ΔCp is the changei n heat capacity and m is the dependence of folding free energy on denaturant 
concentration, [Gdm]. The observed elipticity at 222 nm (θobs) at a particular temperature, T, and [Gdm] is 
given by equation 9: 
Equation 9 
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In the above equation, θn and θu are the elipticity of the folded and unfolded states, respectively. Based on 
literature precedent
119
 and inspection of the thermal-chemical denaturation data, θn was assumed to vary
linearly with T. The elipticity of the folded protein as a function of T and [Gdm] is given by equation 10: 
Equation 10 
][])[,( GdmcTbaGdmTn   
The elipticity of the unfolded state, θu, showed curvature in elipticity as a function of temperature and 
therefore the quadratic term f x T
2
 was added to equation 11. 
Equation 11 
][])[,( 2 GdmgTfTedGdmTu   
Combining equations 1-4 provides the equation 12 used to fit the two-dimensional surface (Figures A2, 
A6): 
Equation 12 
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APPENDIX B. HPLC CHROMATOGRAMS 
Figure B1. Chromatograms of peptides 1, 6, and 6a. 
Figure B2. Chromatograms of peptides 18-26 before (solid) and after (dashed) addition of NaIO4. 
160 
Figure B3. Chromatograms of peptides 27-33 before (solid) and after (dashed) addition of NaIO4. 
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Figure B4. Chromatograms of peptides 35-37 and cyclized products. 
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Figure B5. Chromatograms of peptides 42-45. 
Figure B6. Chromatograms of peptides 47-48 and cyclized products. 
163 
Figure B7. Chromatograms of peptides A1-A4 and cyclic products A2Cyc, A3Cyc, and A4Cyc. 
164 
APPENDIX C. NMR SPECTRA 
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